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 FREQUENTLY USED ABBREVIATIONS: 
 
 
BM   bone marrow 
HSC  hematopoietic stem cell 
MSC/BMSC mesenchymal stem cell (used as a synonym for bone   
   marrow derived stem cell or bone marrow derived    
   stromal cell) 
GFP  green fluorescent protein 
GCSF  granulocyte colony stimulatory factor 
SCF   Stem cell factor   
GPCR  G protein coupled receptor   
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I.) Introduction 
  
 This thesis summarizes my work of the last 15 years on the role of bone 
marrow derived cells in the maintainance of the healthy environment in the body.  
My interest in these cells stemmed from the observation that they are able to move 
from the blood into the brain.  This observation stood against a longstanding dogma 
that all the cells that constitute the CNS we are either born with or they derive from 
neural stem cells that seed the brain during embryonal development.  The sig-
nificance of the observation was that - if held true for humans - it would constitute 
new means to get pharmaceutical agents into or replace missing natural agents in the 
central nervous system.  My first experiments showed that stem cells in the blood 
could indeed give rise to microglia and astrocytes in the rat brain.  Subsequently, we 
showed that cells from gender-mismatched transplanted bone marrow make their 
way into the brain and differentiate into all neural linages in the mouse.  These 
results were confirmed independently by other groups before we also demonstrated 
the same phenomenon in humans.  In human transplant recipients, we found that 
bone marrow derived cells  also colonize the oral mucosa and salivary glands.  
In addition to their regenerative capacity, in the last years new evidence emerged 
that non-hematopoietic cells in the bone marrow might modulate the function of the 
immune system and these data prompted us to study this new phenomenon as well.  
Our published data indicate that administration of bone marrow stromal cells to 
animals corrects imbalances in the immune system.  Based on our work and studies 
by other groups, a number of clinical trials are underway to determine whether these 
immunomodulatory effects of BMSCs can be exploited to treat diseases.   
 
I have separated the description of my work into two parts: First I have described 
our studies demonstrating the role of circulating BM cells in tissue regeneration.  
Then I have summarized our work on the immuno-regulatory properties of bone 
marrow derived stromal cells. 
 
               dc_219_11
 5 
 
II.)   Contribution of circulating cells to tissue regeneration 
 
 The first attempt in medical history to use BM for tissue regeneration was to 
renew the BM itself. Around the middle of the 20th century scientists realized that 
certain organs might be transplanted from one person into another - but problems 
associated with transplantation quickly surfaced.  Sir Peter Brian Medawar’s work 
shed light on graft rejection and this eventually allowed clinicians to use matched 
donated organs to recipients and/or use immune-suppression to prevent rejection. 
However, there were way too few organs to meet the demand, and the need to 
manufacture organs in vitro arose. To imagine making organs we need to understand 
how they develop in the embryo and how tissues are maintained throughout life 
physiologically. A logical choice of cells that contribute to tissue regeneration is 
those that circulate and thus can easily access all organs of the body, such as blood 
cells. These cells arise in the BM known to have two populations of stem cells: the 
hematopoietic (HSC) and the stromal (BMSC) stem cells. HSCs are generally 
accepted to give rise to the different classes of blood cells (myeloid, erythroid, 
lymphoid, platelets, and mast cells), while BMSCs give rise to the structural 
elements of the skeleton, such as bone, cartilage, and marrow fat.   
 
1.) CNS  
1a)Rodents 
 
a(1) Uninjured brain 
 
  Our first sets of experiments was aimed at determining whether 
circulating blood cells can enter the CNS and differentiate into cells of the neural 
lineage, e.g., microglia, microglia, neurons, or vascular endothelial cells.  We 
worked out a technique to detect the Y chromosome in cells and to colocalize it 
with a variety of protein markers that confirm the identity of differentiated cells. 
Once the technique was working reliably, we irradiated female rats to destroy their 
BM and then injected them with genetically identical male bone marrow. 
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Subsequently, we examined the rats’ brains for the presence of Y chromosome 
positive (i.e., male donor) cells.  We found both macroglia and microglia that 
contained the Y chromosome, suggesting that these cells derived from the donor 
BM and entered the brain through the general circulation.  After we published these 
results in 1997 (1), we wondered whether bone marrow cells could contribute to the 
neuronal population of the brain as well as the glial populations.  Since radiation 
might injure the blood-brain barrier and make it leaky, we designed a new 
experiment that circumvented this problem.  To achieve this, we collaborated with a 
group of scientists who developed a special transgenic mouse that lacks a gene 
(PU1) vital for the development of the white cell lineage.  PU1-/- mice have to be 
given BM transplants at birth in order to survive, and we transplanted them with 
gender mismatched BM within 48 hours of their births (2).  At different time points 
following these transplantations we perfused the mice and used Y chromosome in 
situ hybridization histochemistry (ISHH) to colocalize the Y chromosome and 
NeuN, a specific marker of neurons (Fig.1).  We found that 0.3-2.3% of all neurons 
were positive for both markers.  The shortest survival time following BM transplant 
was 1 month, the longest was 4 months. We did not find a correlation between the 
elapsed time post-transplant and the number of double-positive cells.  We also did 
not find any specific regional localization; the double-positive cells could be found 
in all brain regions examined in a seemingly random distribution. 
Fig.1. 
Y chromosome staining in the CNS. Coronal sections from 4-month-old nontrans- 
planted (A) female and (B) male brains were mounted and processed together. The 
panels show the over- lay of the NeuN (red) immunostaining, Y chromosome 
nonradioactive ISH [visualized with tyramide-FITC conjugate (green)], and DAPI 
stain- ing of cell nuclei (blue). The Y chromosome was restricted to the male brain, 
demonstrating hybridization specifici- ty. (C) Confocal image of coronal sections 
from a 4-month-old recipient female striatum that was double-immunostained for 
the neuron-specific antigens NeuN and NSE (neuron specific enolase). All NeuN-
expressing cells (red) were also immunoreactive for NSE (green). (D) Sagittal 
section from a 1-month-old female PU.1 knockout mouse brain transplanted at birth 
with male bone marrow. The Y chromosome was visualized with BCIP/NBT (dark 
purple dots) to identify anatomical landmarks. cc, corpus callosum; cx, cerebral 
cortex; CPu, caudate putamen; fi, fimbria hippocampi; hi, hippocampus; LV, lateral 
ventricle. (E to G) Identical fields showing NeuN, Y chromosome, and DAPI 
nuclear triple staining in the hypothalamic dorsomedial nucleus of a 3-month-old 
female recipient. Colocalization of the Y chromosome [visualized with tyramide-
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FITC conjugate (green)] to a NeuN immunopositive (red) nucleus is shown in (E). 
In (F), DAPI staining identifies all cell nuclei (blue). Overlays of the NeuN, Y 
chromosome, and DAPI fluorescence are shown in (G). The arrow identifies a cell 
nucleus that contained both the Y chromosome (indicating the bone marrow origin) 
and NeuN. Scale bar in (G) represents the following sizes: 30 µm, (A) and (B); 10 
µm, (C); 250 µm (D); and 12 µm, (E) to (G).  
 
 
 
a(2) Injured brain 
 After we established that circulating cells can enter the CNS and differentiate 
into neural cells, we asked whether this process might be used physiologically for repair 
following brain injury. A month after transplanting PU1-/- mice with GFP expressing, 
gender mismatched bone marrow, we induced hypoxic brain injury using a permanent 
ligation of the middle cerebral artery (MCAO) and examined the brains 1-6 months later 
(3).  We used both the GFP and the Y chromosome as markers of donor cells. We 
observed that few neurons, but numerous astrocytes and many new vessels were derived 
from cells of the transplanted BM. 
 Mobilizing BM cells with a combination of GCSF/SCF induced the formation 
of many new vessels and significantly decreased the infarct volume (Fig.2) in the mice.   
These results suggested that mobilized circulating cells might contribute to brain healing  
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Fig.2. 
 
 
in a variety of ways, e.g., by stimulating neovascularization and also generating new 
cells.  
 
1b) Human Brains 
 Following our rodent studies we wanted to know whether BM cells could 
colonize the brains of humans. In a collaboration with scientists at the Johns Hopkins 
School of Medicine, we collected samples from brains of four female patients who died 
after receiving bone marrow transplants from male donor relatives (4).  The brains were 
immersion fixed in formaldehyde and paraffin embedded, which made it difficult to use 
the staining methods that we had employed earlier. However, once again, we worked 
out a suitable method to colocalize the human Y chromosome with specific nuclear 
(NeuN) and cytoplasmic (Kv2.1) neuronal markers.  Using the new techniques we found 
that, indeed, cells that derived from the transplanted male donor blood entered the brains 
and did bear neuronal markers in all four patients.   We found the greatest number of 
donor-derived neurons (7 in 10,000) in the youngest patient, a 2 year old child, who also 
lived the longest time after transplantation. The distribution of the labeled cells in the 
brains was not homogeneous. There were clusters of Y-positive cells, suggesting that 
single progenitor cells underwent clonal expansion and differentiation. 
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Fig.3. Neuronal markers colocalized with the Y chromosome in human 
postmortem brain samples. Fluorescent microscopic images of neocortex from 
patients 2 (A–C) and 1 (E) and hippocampus from patients 1 (D) and 3 (F) are 
shown. The green color represents the immunostaining for neuronal markers 
Kv2.1 (A–D) and NeuN (E and F), and the Y chromosome is represented by 
the red fluorescent dots. All cell nuclei are stained with 4!,6-diamidino-2-
phenylindole, a chromosomal marker that shows up as blue fluorescence. All 
images are overlays of the images seen through the three separate filters to 
show all colors. Arrows point to cells that are labeled with neuronal markers 
and are also Y chromosome-positive. In the Kv2.1 immunostaining the initial 
axons of some neurons can also be visualized. (Scale bars, 10 µm.) 
 
2) Epithelial tissues 
  
2a) Mouse uterus 
 Since the uterine epithelium needs to regenerate after every cycle (in the 
mouse every 4 days), we decided that this tissue would be ideal to look for 
contribution of BM derived cells to epithelial regeneration (5). Out of the two 
major populations of the BM stem cells only the hematopoietic cells have an 
accepted marker, CD45, also called common leukocyte antigen.  We created a 
novel transgenic mouse where we introduced Cre recombinase cDNA into a  
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bacterial artificial chromosome (BAC) containing the complete mouse CD45 
gene (Fig.4). 
 
Fig. 4. The recombinase cDNA was inserted downstream of an internal ribosomal 
entry site (IRES), which in turn was placed downstream of the last coding exon of 
CD45. The resulting BAC was used to make transgenic mice (CD45/Cre) where Cre 
recombinase is made in any cell that expresses CD45. GFP is expressed in CD45+ cells 
of the double-transgenic (CD45/Cre-Z/EG) mice. (A): Upon homologous 
recombination, the IRES-Cre recombination cassette flanked by two homologous 
fragments (A and B) was inserted into exon 33 of the CD45 gene in a BAC containing 
the entire coding region. The recombinant construct was confirmed to be correct by 
restriction mapping, PCR with primers flanking the recombination fragments, and 
sequencing. (B): To track the fate of CD45+ cells, we created a double-transgenic strain 
by breeding CD45/Cre mice with the double-reporter Z/EG mice. In the crossbred mice, 
every CD45+ cell expresses the Cre recombinase that will excise the floxed lacZ 
cassette, thus enabling the activation of GFP. Regardless of the future fate of CD45+ 
cells, GFP will be expressed continuously throughout their life spans. (C): 
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Fluorescence-activated cell sorting of peripheral blood of a double-transgenic animal 
demonstrating a high percentage (85%) of double-positive blood cells using green 
fluorescence for GFP and red for CD45. (D–F): White blood cells immunostained with 
GFP (green) (D), CD45 (red) (E), and an overlay of (D) and (E) with added 4,6-
diamidino-2-phenylindole (nuclear-blue) staining (F). Scale bar = 15 µm. 
Abbreviations: BAC, bacterial artificial chromosome; bp, base pairs; EGFP, enhanced 
green fluorescent protein; GFP, green fluorescent protein; IRES, internal ribosomal 
entry site; PCR, polymerase chain reaction. 
 
 Once we crossed this novel transgenic mouse with the double reporter mice we 
looked at the uterine epithelium and found that the more cycles the mice had the more 
GFP+ epithelial cells we found.  These green cells were always in patches suggesting a 
clonal origin, i.e. that a circulating cell becomes a uterine stem cell and continues to 
repopulate the mucosa.  The most striking 
finding in this study was that following 
pregnancy - at which event the surface area 
of the uterus has to enlarge by a factor of 
20X, about 80% of the uterine epithelium 
became GFP+. 
 
Fig.5.GFP-expressing uterine epithelial cells 
from double transgenic mice of different 
ages and pregnant mice. All nuclei were 
stained in blue with DAPI. (A, B): No GFP-
positive (green) uterine epithelial (red 
staining represents L. tetragonolobus, the 
epitheli-al marker) cells were detect-ed in 6-
week-old animals. (C, D): Sporadic GFP-
positive uterine epitheli-al cells were present 
at 12 weeks of age. Arrow indicates a GFP" 
uterine epithelial cell. (E, F): At 20 weeks 
of age, 6% of uterine epithelial cells 
expressed GFP. (G, H): In 12-week-old 
pregnant mice, there was a robust increase 
in the number of GFP-expressing cells: 82% 
of the uterine epithelial cells were GFP". 
Scale bars : 60 µm (left column) and 20 µm 
(right column) 
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Since our work was published, other groups confirmed that human uterine epithelium 
behaves very similarly and that circulating BM cells contribute to its regeneration 
physiologically.  Our findings also suggest a new possible explanation of endometriosis, 
a painful, difficult to treat human disease, when ectopic uterine epithelium is present in 
the abdominal cavity and responds to hormonal changes. 
2b)  Human cheek cells and salivary glands 
The oral mucosa is constantly exposed to a variety of insults, such as extreme heat 
and cold, spices, mechanical injuries.  All of these cause cell death and the dead cells 
need continuous replacement throughout life.  Fortunately, the oral cavity is also easily 
accessible and sampling the mucosa is quick and painless. For all of the above reasons we 
decided to use the buccal mucosa to test whether BM derived cells contribute to the 
regeneration of this epithelial tissue. We took cheek scrapings from five females who had 
received either a bone-marrow transplant or an allogeneic mobilized peripheral-blood 
progenitor-cell transplant (enriched in CD34+ cells) from male donors years before (6).  
 
Fig.6. In-situ hybridization and immunohistochemistry in human buccal cells (A) Y-
chromosome autoradiography on a smear of buccal cells. The arrows point to the 
autoradiographic grains (black dots) above the nuclei of Y-chromosome containing 
cells. (B, C, D) The cells were first immunostained for cytokeratin 13 (green), then 
hybridized with a human Y-chromosome riboprobe (red fluorescent dots shown by 
the arrows). The nuclei of the cells are stained blue with DAPI. (E, F, G, H) FISH 
with X-chromosome and Y-chromosome probes. Individual buccal cells are shown. 
The green fluorescent dot in the nucleus represents the X probe and the red dot the Y 
probe. The nuclei of the cells are stained blue with DAPI. The scale bar represents 10 
µm in all panels, except 100 µm for panel A.  
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We then performed in-situ hybridization on the cheek cells with Y and X 
chromosome probes. In separate experiments we combined fluorescent ISH for the Y 
chromosome in the buccal epithelial cells with immunohistochemistry to label 
cytokeratin 13, an accepted specific epithelial marker.  When examined 4-6 years 
after male-to-female marrow-cell transplantation, all female recipients had Y-
chromosome-positive buccal cells between 0.8-12.7%. In more than 9700 cells 
studied, we detected only one XXXY-positive cell (0·01%) and one XXY cell 
(0·01%), both of which could have arisen when an XY cell fused with an XX cell.  
These results suggested that BMD cells migrate into the cheek and differentiate into 
epithelial cells, an occurrence that does not depend on fusion of BMD cells to 
recipient cells. This finding might be an example of transdifferentiation of 
haematopoietic or stromal progenitor cells.  The HSCs seem more likely to be the 
cells responsible for this effect because: 
1.  There is no solid proof yet that the BMSCs from the bone marrow circulate; 
2.  Even if they do circulate, their numbers in the BM is orders of magnitude lower 
than their hematopoietic counterparts; and 
3. Three out of the five patients received stem cell enriched peripheral blood instead 
of BM transplant, and the former are enriched in CD34+, CD38- hematopoietic stem 
cells and progenitors. These patients showed as high a percentage of chimerism 
(11%), as the ones receiving full BM (including the stromal stem cells) 
 
Fig.7. Blood from a non-transplanted female control, buccal cells from recipient 5, 
her donor’s blood, and her son’s blood, were analyzed with four sets of Y-
chromosome markers. X axis shows product length in bases, and Y axis shows signal 
strength. 
 
               dc_219_11
 14 
Finally, we wanted to test the hypothesis that the Y chromosome positive cells did 
not derive from the transplanted tissues (BM or PB), but from a previous pregnancy 
with a male fetus.  We succeeded in collecting samples from the donor and the son of 
one of the patients and used microsatellite markers to identify the Y chromosome 
that we found in the cheek cells. The DNA analysis proved that the buccal cell Y 
chromosome was identical to that of the male donor versus the son of the patient.  
We also tested several normal volunteers, who did not receive BM transplants, but 
were pregnant and gave birth to male children.  None of the samples from these 
women had Y chromosome positive buccal cells.  As a follow-up to this study we 
investigated the presence of Y chromosome-positive cells in salivary gland biopsies 
of 5 females who had received a marrow or blood stem cell transplant from male 
donors (7). One to 16 years after transplantation all scattered Y chromosome-positive 
cells were found in the acini, ducts, and stroma of their salivary glands (mean of 
1.01%). Potentially, if their numbers can be boosted, these cells could be used for 
treatment of Sjögren’s syndrome and salivary glands damaged by therapeutic 
irradiation for cancers of the head and neck. 
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III. Immune-regulatory effects of bone marrow stromal cells 
 
 A group from the Karolinska Institute headed by Dr. Katarina LeBlanc had a 
young patient who developed graft vs. host disease (GVHD) as a complication of a 
BM transplantation.  After all known treatment strategies failed, they decided to 
request permission for a new therapeutic intervention.  It was known that BM 
derived stromal cells (BMSCs or also called mesenchymal stem cells-MSCs) 
suppress T cell proliferation. Thus, they infused isolated and cultured BMSCs from 
the patient’s mother and saw a dramatic improvement in the GVHD. They published 
their results in Lancet and started a whole new chapter in the clinical use of BMSCs.  
 
1) Septic conditions 
 
After reading LeBlanc's Lancet paper, we became interested in the biology of 
BMSCs and the mechanisms by which they regulate immune responses.  One of the 
most complicated of these occurs in sepsis, when the response to microbial invasion 
frequently overshoots and ends up killing the host as well.  We wondered if a live 
cellular therapy could be beneficial in a septic environment that changes very quickly 
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and the appropriate immune response at any given timepoint could make the 
difference between life and death.  We used a mouse model of human peritonitis, 
called cecal ligation and puncture (CLP) and either injected the mice with BMSCs of 
different sources or vehicle intravenously at the time of septic injury (8).  We found 
that the injected cells significantly improved the survival of the mice due to an 
improvement in organ functions.  We then studied the mechanism of this action using 
a wide variety of techniques and using BMSCs from many transgenic mice that 
lacked certain factors. With this approach we determined that the injected BMSCs 
induce pro-inflammatory macrophages to become anti-inflammatory and produce 
large amounts of IL-10.  The BMSCs were stuck in the capillaries of the lung where 
they were surrounded by monocytes/macrophages.   Monocytes and/or macrophages 
from septic lungs made more IL-10 when prepared from mice treated with BMSCs 
versus untreated mice. In vitro, lipopolysaccharide (LPS)-stimulated macrophages 
produced more IL-10 when cultured with BMSCs, but this effect was eliminated if 
the BMSCs lacked the genes encoding Toll-like receptor 4 (TLR4), myeloid 
differentiation primary response gene-88 (MyD88), tumor necrosis factor (TNF) 
receptor-1a or cyclooxygenase-2 (COX2). Thus we concluded that BMSCs (activated 
by LPS or TNF-a) can reprogram macrophages by releasing prostaglandin E2 that 
acts through the prostaglandin EP2 and EP4 receptors. 
 
 Fig.8.    Summary of studies of the molecular pathways involved in the interaction 
between BMSC and macrophages. (a) IL-10 concentration changes in supernatants of 
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cocultures in a variety of treatment conditions after LPS stimulation. Colored graphs 
(except for the blue color that labels the bone marrow macro-phages as the source of all 
consecutive experiments) show treatments that eliminate the effect of BMSCs on 
macrophages. Black graphs show IL-10 levels after LPS stimulation, whereas open 
graphs show the control (nonstimulated) values. The experiments where the conditions 
eliminated the effect are colored. Purple color shows the effect of septic environment, 
green color shows agents and cellular compartments related to the PGE2 pathway and 
pink color shows agents related to the nitric oxide pathway. Three separate kinds of 
macrophages (bone marrow macrophages; peritoneal macrophages and the RAW264.7 
cell line) were examined initially. Because they behaved identically in the assay, we used 
bone marrow derived macrophages (BM MF) for the rest of the experiments. In the box 
labeled 1, the effect of septic environment on the BMSCs is studied in BMSCs from 
TLR4-, MyD88-, TNFR1- and TNFR2- deﬁcient mice, or antibody to TNF-α was used to 
neutralize the effect of TNF. The box labeled with 2 shows the cytokines and agents that 
have been implicated in the literature in immunomodulation of T cells by BMSCs, 
including COX1/2 and iNOS inhibitors. The box labeled 3 shows studies of the COX2 
pathway, including the prostaglandin receptors EP1–EP4. Finally, in the box labeled with 
4, we show studies related to nitric oxide. (b) A summary of our current hypothesis about 
the mechanisms that underlie the interactions between BMSCs and macrophages in the 
CLP sepsis model. Bacterial toxins (for example, LPS) and circulating TNF-α act on the 
TLR4 and TNFR-1 receptors of the BMSCs, respectively. This results in the translocation 
of NFkB into the nucleus. This activation process seems to be nitric oxide dependent. 
Activated NFkB induces the production of COX2, resulting in increased production and 
release of PGE2. PGE binds to EP2 and EP4 receptors on the macrophage, increasing its 
IL-10 secretion and reducing inflammation. 
 
 2) Th2 dominant (allergic) environment 
 
 We learned from the sepsis study that BMSCs are able to correctly respond to 
environmental clues and regulate the immune system according the needs of the body. 
Proliferating helper T cells differentiate into two major subtypes of cells known as Th1 
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and Th2 lymphocytes. Our study of sepsis and others as well had shown that BMSC-
driven immunomodulation is mediated by the suppression of proinflammatory Th1 
responses, rebalancing the Th1/Th2 ratio toward Th2. We wondered whether BMSCs 
could act in a Th2-dominant environment—e.g., the one that prevails in the ragweed 
induced mouse asthma model. Intravenous injection of BMSCs at the time of the antigen 
challenge protected the animals from the majority of asthma-specific pathological 
changes (9), including inhibition of eosinophil infiltration and excess mucus production 
in the lung, decreased levels of Th2 cytokines (IL-4, IL-5, and IL-13) in the bronchial 
lavage (BAL), and lowered serum levels of Th2 immunoglobulins (IgG1 and IgE). We 
used BMSCs derived from a variety of transgenic mice; performed in vivo blocking of 
cytokines; studied how asthmatic serum and BAL from ragweed challenged animals 
effect the BMSCs of in vitro to find the mechanism of the effect. Our results suggest that 
IL-4 and/or IL-13 activate the STAT6 pathway in the BMSCs that in turn causes an 
increase of their TGF-b production, which seems to mediate the beneficial effect, either 
alone, or in concert with regulatory T cells, that might also be recruited by the BMSCs.  
 
 
 
Fig. 9. Schematic drawing shows the mechanism of effect based on data of the present 
study. BMSCs “sense” the allergic environment, and as a result of the increased levels 
of IL-4/IL-13, they respond by producing higher amounts of TGF-β that, either alone or 
by recruiting regulatory T cells, will ultimately lead to a decrease of lung eosinophil 
infiltration, as well as allergy-specific cytokine and Ig production. 
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3) Histamine rich environment 
In humans mast cells (MCs) play a major role in the reaction to allergens. Thus 
we examined the effect of MC degranulation and histamine on the function of BMSCs. 
Mast cells (MCs) have a central role in allergic responses, including certain types of 
asthma and in the development of autoimmune disease. These cells represent an 
important link between innate and acquired immunity. We studied the interaction 
between mouse bone marrow-derived stromal cells and mouse bone marrow derived 
MCs (10) and found that BMSCs can efficiently suppress several MC functions in vitro 
as well as in vivo. When MCs are cocultured with BMSCs directly (allowing cell to cell 
contact), the BMSCs suppress MC degranulation, proinflammatory cytokine production, 
chemokinesis, and chemotaxis.    
 
 
Fig. 10.  In vitro studies of the interactions between MCs and BMSCs 
A: Different ratios (1:1; 1:10 and 1:100) of IgE sensitized MCs and BMSCs were 
cultured together for 24 hours prior to IgE specific antigen challenge. -hex release was 
used as a marker of MC degranulation. BMSCs attenuate MC degranulation in all ratios 
tested. B: Different ratios (1:1; 1:10 and 1:100) of IgE sensitized MCs and BMSCs were 
cultured together for 24 hours prior to IgE specific antigen challenge for 12 hours. The 
BMSCs decreased the amount of released TNF-α in a ratio dependent manner as 
measured by ELISA. C: The experiment in B was repeated to measure TNF-α mRNA 
levels at two time-points (30 and 120 min) following antigen challenge. Similar to the 
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levels of TNF-α protein, mRNA synthesis also decreased in response to the presence of 
BMSCs at both time- points in a ratio dependent manner. D: The migration of MCs was 
affected by the presence of BMSCs in the culture – with increasing numbers of BMSCs 
within the co-culture, the spontaneous (upper four columns) as well as SCF induced 
migration (chemokinesis and chemotaxis, respectively) of MCs were significantly 
reduced.  In all Figures:*=p<0.05; **=p<0.01 and ***=p,0.001 
 
Similarly, MC degranulation within mouse skin or the peritoneal cavity was 
suppressed following in vivo administration of BMSCs. Further, we demonstrate that 
these inhibitory effects were dependent on upregulation of COX2 in BMSCs and 
facilitated through the activation of EP4 receptors on MCs.  
 
Fig.11. In vivo confirmation of COX2 mediated mechanism. The peritoneal assay was 
repeated using COX2 KO BMSCs followed by challenging the sensitized resident MCs 
with antigen (Ag). In contrast to wild-type (WT) BMSCs, COX2 deficient BMSCs 
failed to suppress hexosaminidase release by peritoneal MCs.  
 
 Based on these data we suggest that BMSCs might represent a novel cell based 
therapeutic approach in the treatment of MC driven allergic diseases.  
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IV.  Conclusions 
 
I. Contribution of circulating cells to tissue regeneration  
1) CNS 
1a) Rodents  
Cells that circulate in the bloodstream can gain access to the brain in 
rodents.  In animals without brain injury these cells are evenly distributed and 
can become neural cells including microglia, macroglia, endothelial cells and 
neurons. 
When a brain injury (stroke) occurs, the number of circulating cells entering the 
brain seems to increase. Many of these cells become vascular endothelial cells 
and form new vessels.  The neovascularization facilitates healing,  decreasing the 
necrotized volume and increasing the number of surviving cells. 
1b) Humans 
In samples of postmortem human brains we determined the presence of 
donor derived cells in the CNS following gender mismatched bone marrow 
transplants.  As in rodents, we found that cells from the donor bone marrow 
entered the brains and differentiated into neural cells there.  We found the 
greatest numbers of these cells in the youngest patient (2 years old) who also 
survived the longest following BM transplantation.  Although we can not do 
functional tests in postmortem human samples, based on morphology and 
multiple neuronal markers, the donor derived cells were undistinguishable from 
the host neurons.  Another important observation is that statistical analysis of the 
donor derived cells suggest that they are clonal, i.e. a cell from the circulation 
seeds the brain and multiplies and differentiates there. 
Significance of the above findings:  the demonstration that circulating cells cross the 
blood-brain suggests that these cells might be used as vehicles to introduce growth 
factors/differentiation factors or enzymes  into the CNS. The enzymes might correct or 
slow the progression of genetic neurological diseases.  The finding that GCSF/SCF 
treatment significantly enhances neovascularization indicates that this treatment may 
be beneficial in patients with stroke 
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2) Epithelial tissues 
 
2a) Mouse uterus 
Based on the human cheek cell data we used a genetic tool to see if 
hematopoetic progenitors can indeed seed epithelial tissues. Using 
genetic marking of hematopoetic progenitors we have demonstrated that 
these cells get into the endometrium and participate in replenishing lost 
cells during the cycle. In some mice 70% of the epithelium was of 
hematopoetic origin following a pregnancy, which is known to inclrease 
the uterine surface area by 20 fold. 
2b) Human cheek cells and salivary glands 
Using a similar approach to the brain studies, we found that donor 
derived blood cells contribute to the population of cheek epithelium.  Due 
to the unique patient population we were also able to establish the fact that 
in two patients the new cheek cells derived from hematological 
progenitors, since these patients did not receive BM, but isolated 
hematological progenitors from peripheral blood. We also examined the 
possibility that Y chromosome containing cheek cells might derive from 
an earlier pregnancy with a male fetus. DNA analysis conclusively 
showed that the Y chromosome in the cheek cells was from the donor vs 
the male offspring of the recipient. 
 
Significance of the above findings:  the demonstration that circulating BM derived 
cells can contribute to epithelial tissues supplies a. an alternative explanation to the 
pathomechanism of endometriosis, a rather common disease in the female population 
and b. raises the possibility that if this process can be boosted, than oral mucosa and 
salivary gland function could be restored in people who lose them due to autoimmune 
disease (Sjogren’s Syndrome) or head- and neck irradiation. 
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III. Immunoregulatory effect of BMSCs 
 
1) Septic environment 
 We analyzed the role that BMSCs play in regulating immune function in 
sepsis.  Our results demonstrated that iv injected BMSCs are entrapped in the 
lungs where they communicate with monocytes/macro-phages that surround 
them. In the septic environment, these monocytes/macrophages are 
proinflammatory and make TNF-α. When they come in contact with BMSCs they 
change character and becomy anti-inflammatory. This tunes down the immune 
attack on  body organs and allows animals to survive the septic process. 
The crosstalk between BMSCs and the monocytes/macrophages involves the 
production and release of PDG2 by the BMSCs and a resulting increase of the 
monocytes/macrophages IL-10 production.  The final outcome is a decreased 
number of neutrophils in body organs and less oxidative damage.  On the other 
hand, there are more circulating neutrophils, and consequently more efficient 
clearence of bacteria. 
2) Th2 dominant (allergic) environment 
 Using a ragweed induced allergy mouse model we determined that 
BMSCs are able to “sense” the allergic environment (increased levels of IL-4 
/IL-13) and respond by producing large amounts of TGF-β that (either alone or 
by recruiting regulatory T cells) will ultimately lead to a decrease of lung 
eosinophil infiltration, and the allergy-specific cytokine and Ig production.   
 
3) Histamine rich environment 
  As a continuation of the above studies, since mast cells (MCs) 
play a significant role in humans in allergic settings, we examined how BMSCs 
interact with MCs and how they respond to histamine, which is the major MC 
mediator. We demonstrated that BMSCs have the ability to affect the biology of 
MCs by limiting their activation and migration. Our data additionally show that 
these effects are mediated through the EP4 receptor on MCs.  
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Significance of the above findings:   
Our results in the sepsis model indicate that BMSCs might be a very effective 
therapeutic intervention in human sepsis – when no other treatment option is 
available.  Live cells may be superior to drugs, because the cells respond to their 
environment while drugs can only play the role that they were designed for.  
Since a large number of people die of sepsis every year (over 250000 in the US 
alone), a new therapy is badly needed. 
The second set of studies indicate that in steroid resistant asthmatic 
conditions the use of BMSCs should be considered, since they are able to 
mitigate the allergic response and to counter the effects of MC degranulation. 
  
               dc_219_11
 26 
 
V.  ACKNOWLEDGEMENTS 
 
 Looking back at my scientific carreer makes me realize that one needs a village 
(in my case a city and two continents..) to raise a scientist just as one does to raise a 
child. I have to start with my family, who supported all my adventures from 
childhood. My parents were always there to encourage me and help me find my 
way. My Mom planted the seeds of scientific curiosity in me at a very young age 
and my Dad helped me develop independent (and sometimes unusual) patterns of 
thinking. My brother, András, kept me in line and taught me many life skills, and 
both he and his wife, Lasy, gave me tremendous support after my parents were gone.   
My husband, Michael Brownstein, was an incredible force, whose scientific advice 
and input shaped my career in numerous ways. Without him I would not be writing 
this thesis. And as far as family goes, I also have to thank my daughter, Anna, who 
gave me a reason to go on even when things were bad, and whose unconditional 
love and support was always there for me.  Last but not least I want to thank Dr. 
Judit Futo, my best friend since childhood, for all the times we spent discussing life 
and death, fun and misfortunes. She made me feel that if I fell, she would always be 
there to pick me up.   
 Trying to think of all of my mentors (many of whom also became close friends) 
I have to start with Janos Szentagothai, whose lectures during my years in medical 
school attracted me to his Department at the beginning of my student research 
carreer.  Later on he was always supportive and encouraging, and never had a 
problem with untraditional ways of thinking. He permanently engraved in me he 
love of the miracle of the nervous system.  In the Anatomy Department I had the 
fortune of having Miklos Palkovits as my immediate supervisor.  There is not 
enough space in this thesis to list all the ways he shaped my life: my approach to 
problems, the numerous pitfalls of experimental designs and analysis of the results 
and the lessons about how to avoid them (after he let me fall first..).  He knew when 
to keep close control, when to point out my mistakes, and also when to let me go 
and succeed or fail, and take the consequences.  I want to mention Endre Csanda, the 
Chair of Neurology, and a very close personal friend, who was always willing to 
               dc_219_11
 27 
answer my sometimes silly and unusual questions about the brain and life and acted 
as a surrogate father after I lost mine.  My first foreign mentor, Prof. David DeWied 
helped me grow scientifically and remaind supportive long after I left his Institute in 
Utrecht.  After I moved to the US, once again, I met many wonderful people of the 
older and younger generation (including my fellows).  In the interest of saving 
space, I will list their names without giving a detailed description of our interactions, 
but I want to emphasize that each and every one of them helped me in many ways to 
be what I am today as a scientist and as a person. I want to thank Tomas Hokfelt, 
Ronald DeKloet, Irvin Kopin, Julie Axelrod, Bruce Baum, Hal Gainer, Lana 
Skirboll, Pam Robey, Stefan Hansson, Andreas Zimmer, Janet Clark, Ruth Siegel, 
Joe Martin, Harry Webster, William Paul, Martin Eglitis, Karen Chandross, 
Gyongyi Harta, Bela Hunyady, Nancy Buckley, Tal Shahar, Andras Bratincsak, 
Zsuzsanna Toth, Krisztian Nemeth, Sarolta Karpati, Balazs Mayer, Miklos 
Krepuska, Sharon Key, Ildiko Szalayova. Many additional colleagues helped me 
along the way and I apologize to everyone I could not mention here.  In addition, I 
have not listed the many personal friends who stood by me and helped me through 
hard times. These include my beloved dog P.H. who served as both a psychiatrist 
and exercise therapist for more than eleven years and is sorely missed. 
 
               dc_219_11
Proc. Natl. Acad. Sci. USA
Vol. 94, pp. 4080–4085, April 1997
Neurobiology
Hematopoietic cells differentiate into both microglia and
macroglia in the brains of adult mice
(gene transferybone marrow transplantationystem cellsylineage analysis)
MARTIN A. EGLITIS*† AND E´VA MEZEY‡
*Laboratory of Cell Biology, National Institute of Mental Health, and ‡Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke,
Bethesda, MD 20892
Communicated by Richard L. Sidman, Harvard Medical School, Southborough, MA, January 28, 1997 (received for review October 9, 1996)
ABSTRACT Glial cells are thought to derive embryolog-
ically from either myeloid cells of the hematopoietic system
(microglia) or neuroepithelial progenitor cells (astroglia and
oligodendrocytes). However, it is unclear whether the glia in
adult brains free of disease or injury originate solely from
cells present in the brain since the fetal stage of development,
or if there is further input into such adult brains from cells
originating outside the central nervous system. To test the
ability of hematopoietic cells to contribute to the central
nervous system, we have transplanted adult female mice with
donor bone marrow cells genetically marked either with a
retroviral tag or by using male donor cells. Using in situ
hybridization histochemistry, a continuing inf lux of hemato-
poietic cells into the brain was detected. Marrow-derived cells
were already detected in the brains of mice 3 days after
transplant, and their numbers increased over the next several
weeks, exceeding 14,000 cells per brain in several animals.
Marrow-derived cells were widely distributed throughout the
brain, including the cortex, hippocampus, thalamus, brain
stem, and cerebellum. When in situ hybridization histochem-
istry was combined with immunohistochemical staining using
lineage-specific markers, some bone marrow-derived cells
were positive for the microglial antigenic marker F4y80. Other
marrow-derived cells surprisingly expressed the astroglial
marker glial fibrillary acidic protein. These results indicate
that some microglia and astroglia arise from a precursor that
is a normal constituent of adult bone marrow.
Besides the cells of the vasculature, the brain comprises two
general cell types: neurons and glial cells. Glial cells provide
physiological support to neurons and repair neuronal damage
due to injury or disease. Macroglia (astroglia and oligoden-
droglia) are generally considered to be derived from neuro-
ectoderm and are believed to be developmentally distinct from
microglia (1). However, the developmental origin of microglia
remains debatable (2, 3), the two major views being that they
derive either from neuroepithelial cells (4–6) or from hema-
topoietic cells (i.e. monocytes) (7, 8). The extent to which cells
outside the central nervous system (CNS) contribute to the
maintenance of microglia in adults remains debatable (com-
pare refs. 9 and 10), and no such contribution to adult neurons
or macroglia has been previously described.
To learn if cells of the hematopoietic system are a source of
progenitor cells for the CNS, we have used genetically tagged
bonemarrow cells andmonitored their appearance in the brain
by in situ hybridization histochemistry (ISHH). We combined
ISHH and immunohistochemistry, and performed double-
ISHH with digoxigenin and radioactively labeled probes to
analyze which cell types might be derived from bone marrow
stem cells.
MATERIALS AND METHODS
Gene Transfer and Bone Marrow Transplantation. Gene
transfer into hematopoietic precursors was done as previously
described (11, 12), with the addition of stem cell factor to
optimize transduction of reconstituting hematopoietic stem
cells (13). C57BLy6J mice (The Jackson Laboratory), 6–8
weeks old, were used as donors. Forty-eight hours before
marrow harvest, the mice were injected with 5-fluorouracil at
a dose of 150 mgykg to ablate mature blood cells and thereby
induce progenitor cells into cycle. Upon harvest, marrow was
placed into liquid culture in suspension dishes and grown in
DMEM containing 15% fetal bovine serum (BioWhittaker)
and supplemented with interleukin 3 (50 ngyml), interleukin 6
(100 ngyml), and stem cell factor (100 ngyml). Growth factors
were used to maintain early hematopoietic cells in cycle (13).
All were obtained from R & D Systems. After 48 h in culture
with growth factors, marrow cells were collected and added to
tissue culture dishes containing the F5B producer cell line at
subconfluent density. F5B cells shed the N2 retroviral vector,
packaged with the ecotropic envelope and carrying the bac-
terial gene for neomycin resistance (neoR) (14). After 48 h
coculture with F5B cells, bone marrow cells were collected by
gentle aspiration, suspended to 1 3 107 cells per ml in PBS (in
all cases 0.1 M phosphatey140 mM NaCl, pH 7.6) and injected
intravenously (2–33 106 cells per mouse) via the tail vein into
sublethally irradiated (4.5 Gy) female WBB6F1yJ-KitW/KitW-v
mice. WBB6F1yJ-KitW/KitW-v mice are particularly good re-
cipients for bone marrow transplantation because they have
genetically defective stem cells (15). This gives normal
C57BLy6J donor stem cells a strong repopulating advantage.
In transplants of male donor marrow into female recipients,
some marrow was marked with retroviral vector as described.
In other cases, marrow was harvested, washed with PBS, and
transplanted directly into recipient mice without culturing in
growth factor-containing medium or irradiation of recipient
animals.
A total of 46 mice were transplanted, 38 with vector-tagged
marrow and 8 with male marrow. Five of the transplants with
vector-tagged marrow used male donor cells. Mice were
sacrificed at various times after transplantation. At least 2
animals were analyzed at each time point, although more were
used at the 14-day (n 5 10), 35-day (n 5 14), and 70-day (n 5
6) time points. Tissues were collected and immediately frozen
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked ‘‘advertisement’’ in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
0027-8424y97y944080-6$0.00y0
PNAS is available online at http:yywww.pnas.org.
Abbreviations: ISHH, in situ hybridization histochemistry; neoR, neo-
mycin resistance; GFAP, glial fibrillary acidic protein; CNS, central
nervous system; FITC, f luorescein isothiocyanate; DAPI, 49,6-
diamidino-2-phenylindole.
†To whom reprint requests should be sent to the present address:
Experimental Therapeutics Branch, National Institute of Neurolog-
ical Disorders and Stroke, Building 10, Room 5C211, 10 Center
Drive, MSC 1406, Bethesda, MD 20892-1406.
4080
               dc_219_11
on dry ice for subsequent sectioning. Some animals underwent
cardiac perfusion with PBS before tissue harvest. Animals for
perfusion were anesthetized with carbon dioxide, then their
chests were opened, and PBS was introduced through a
cannula placed in the left ventricle. The right atrium was
incised to allow release of blood. Animals were perfused with
50 ml of ice-cold PBS over a period of 5 min.
In Situ Hybridization Histochemistry. Tissues were evalu-
ated with both oligonucleotide and RNA probes. To detect
neoR transcripts, two oligonucleotide probes were prepared,
complementary to the sequence of the neoR gene either from
nucleotides 222–269 or nucleotides 447–494 (numbering with
the A of the initiation codon as 1). The oligonucleotides were
labeled using terminal transferase (Boehringer Mannheim)
and [35S]thio-dATP (New England Nuclear) as described
previously (16). An RNA probe, complementary to the entire
neoR coding region, was labeled with [35S]thio-UTP using SP6
polymerase (17). Labeling with radioactive probes was de-
tected by dipping hybridized sections in photographic emul-
sion. Emulsion was exposed for 14 days, then developed and
sections were stained, air dried, and coverslipped for micro-
scopic examination. To detect male bone marrow cells trans-
planted into female recipients, sequences specific to the donor
mouse Y chromosome were detected using a complementary
RNA probe derived from the plasmid pY353yb (18). Glial
fibrillary acidic protein (GFAP) gene expression was detected
using an RNA probe complementary to the entire GFAP
coding region. The Y chromosome and GFAP probes were
labeled using digoxigenin-UTP (19), and digoxigenin labeling
was developed for GFAP using alkaline phosphatase as de-
scribed (19). For detection of the donor Y chromosome, before
overnight hybridization with digoxigenin-labeled probes at
558C, the slides were heated at 908C for 10 min in hybridization
buffer containing the probes to improve access to nuclear
DNA. The digoxigenin-labeled Y chromosome was visualized
using a modification (20) of an immunostaining amplification
method (21), which results in green fluorescein isothiocyanate
(FITC) fluorescence.
Twelve-micrometer thick frozen sections were cut in a
cryostat, and ISHH was performed as described previously
(16, 17). The sections were fixed, dehydrated, and delipidated
in ethanol and chloroform, and then hybridization buffer
containing the probe(s) was put on the sections. Slides were
incubated overnight in a humidified chamber at 378C (for
oligonucleotide probes) or 558C (for riboprobes).
Nuclear Staining. To confirm that Y chromosome ISHH
coincided with cell nuclei, sections were counterstained with
ethidium bromide or 49,6-diamidino-2-phenylindole (DAPI).
Staining was detected by illumination with a mercury lamp
using a microscope equipped for fluorescence micrography.
Immunohistochemical Analysis. For combined ISHHy
immunohistochemical analysis, sections were fixed as de-
scribed previously (22). They then were incubated for 30 min
at room temperature in 3% normal goat serum diluted in PBS
(containing 0.6% Triton-X 100) to block nonspecific binding.
Then, the sections were exposed for 1 h at room temperature
to either (i) a polyclonal rabbit antibody that detects the mouse
F4y80 monocyteymacrophage marker (23) or (ii) a polyclonal
CY-3-labeled rabbit antibody against the astroglial marker
GFAP (Sigma) used at a dilution of 1:2,000. Binding of
nonlabeled primary antisera was detected with a biotinylated
goat anti-rabbit IgG (Jackson ImmunoResearch) diluted
1:500. To detect biotinylated secondary antibody, the sections
were incubated for 1 h in an avidin-biotin-peroxidase complex
diluted 1:250 in PBS with 0.6% Triton-X 100 (24). The slides
then were transferred into 0.1 M TriszHCl (pH 7.6) and were
developed using diaminobenzidine as a substrate. After a
thorough wash, the sections were processed for ISHH. Cola-
beling of cells was determined using a combination of bright-
field, polarized, f luorescent, and epi-illumination microscopy.
Controls for the immunostaining included leaving out the
primary antibodies and using several secondary antibodies
(from different species) to confirm that there was no nonspe-
cific binding.
RESULTS
Detection of Donor Cells in the Brain After Bone Marrow
Transplantation. To evaluate the appearance and distribution
of donor cells in the brains of recipient mice, animals were
sacrificed 3, 5, 7, 14, 28, 35, 42, and 70 days after transplan-
tation with bone marrow cells. At least two animals trans-
planted with retrovirally tagged marrow were studied at each
time point.Mice transplanted withmalemarrow were analyzed
at 35 days (n 5 9) and 70 days (n 5 4) after transplantation.
Using probes specific to the vector neoR transcripts, donor cells
were detected beginning with day 3, the earliest time of
analysis. Many cells were easily detected throughout the brain
by day 7, and cells continued to be detected at all subsequent
times. To estimate total number of neoR-positive cells in a
brain, every 25th section was collected, and all labeled cells in
the sections were counted. The number of labeled cells was
multiplied by 25 to arrive at the approximate total number of
marked cells in a brain. These calculations showed that the
overall number of marrow-derived cells per brain gradually
increased with increasing time after transplantation. Three
days after transplant, 500 cells were detected per brain. Two to
four weeks after transplant the number of cells present had
increased to at least 2,000 per brain. In several animals more
than 10,000 cells per brain were seen, and in one animal the
number of cells was over 30,000.
At 1 week, and occasionally at later times, concentrations of
neoR-marked cells were observed in the basal subarachnoid
space. Cells marked by the retroviral vector were detected in
the hippocampus (Fig. 1A and B), septum (Fig. 1C), and
hypothalamus (Fig. 1D). Cells were also detected, among other
regions, in the cortex, habenula, pons, and cerebellum (data
not shown). Labeled cells were detected after PBS perfusion,
FIG. 1. Detection of donor cells in the brain after bone marrow
transplantation with retrovirally tagged bone marrow cells. Arrows
indicate representative cells positive by ISHH with 35S-labeled oligo-
nucleotide (A–C) or riboprobe (D). (A and B) Bright (A) and dark (B)
field photographs of the same section. ISHH-positive cells (arrows)
detected in the hippocampus of an animal 14 days postbone marrow
transplantation. (C) Positive cells in the region of the septum of an
animal sacrificed 14 days after bone marrow transplantation. The
photograph is a double exposure of a bright field image with a dark
field image of the same area. The dark field image was photographed
using a red filter so that the autoradiographic grains would appear red.
(D) A cell (arrow) within the ependyma of the third ventricle. [Bars
5 10 mm (A–C) and 40 mm (D).]
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indicating that bone marrow-derived cells were an integral part
of the brain parenchyma.
Similar regional distribution of donor marrow cells was seen
using the Y chromosome probe to detect male donor cells (Fig.
2). Ethidium bromide counter-staining to highlight the nucleus
confirmed the nuclear localization of the Y chromosome
probe. Many male donor-derived cells were easily detected
throughout the brain 35 days after transplantation, and cells
continued to be detected at all subsequent times. Cells positive
for the Y chromosome marker were detected in the mesen-
cephalon (Fig. 2 A–C), septum (Fig. 2D), striatum (Fig. 2E),
and habenula (Fig. 2F). Cells also were detected in the cortex,
pons, and cerebellum, among other regions (data not shown).
Ex vivo manipulation of the bone marrow cells was not
necessary, because male cells were detected in female recip-
ients’ brains even when the transplant was done immediately
after marrow harvest.
Several parameters were used to verify that the labeling
observed after ISHH was specific. First, no labeling was
detected in any tissues of animals transplanted with non-
marked bone marrow cells. That is, without retroviral tagging,
probes for the neoR gene exhibited no background labeling,
and the Y chromosome probe did not label female tissues.
With the Y chromosome riboprobe, we also confirmed that
both sense and antisense probes exhibited the same distribu-
tion, as expected when hybridizing to chromosomal DNA. The
pattern of retrovirally labeled cells was identical in all tissues
analyzed, both qualitatively and quantitatively, regardless of
which probe was used. Finally, we found donor cells in
hematologic organs such as bone marrow and spleen at all time
points analyzed (data not shown). The pattern of engraftment
was qualitatively similar between retrovirally tagged and male
donor cells. However, when female mice were transplanted
with retrovirally tagged male marrow, more donor cells were
detected with the Y chromosome probe than with the neoR
probe. This suggests that not all of the cells migrating from the
bone marrow into the brain expressed the retrovirally intro-
duced neoR gene at a level high enough to be detected by
ISHH.
Labeling of Brain Sections after ISHH with the Microglial
Marker F4y80. The F4y80 antibody detects the plasma mem-
brane protein F4y80 expressed exclusively on macrophages
and microglia (23). Colocalization in brain sections revealed
cells labeled by the N2 retroviral vector that also expressed the
F4y80 antigen (Fig. 3), confirming that bone marrow-derived
cells do contribute to the microglial population in the adult
brain. However, only a small percentage of ISHH-positive cells
were labeled by immunostaining. Similarly, the minority of
antigen-positive cells was doubly labeled by ISHH. The dis-
tribution of doubly labeled cells reflected the distribution of
cells labeled only by ISHH or by immunoshistochemistry, i.e.,
they were widely distributed throughout the brain.
Labeling of Brain Sections for Both the Astroglial Marker
GFAP and the neoR Retroviral or Y Chromosome Donor Cell
Tag. The ISHH-positive, F4y80 negative cells could be cells of
the myeloid lineage that had not differentiated to express the
F4y80 antigen. Or, they could represent a contribution of bone
marrow-derived cells to other than myeloid cell lineages. To
distinguish between these alternative possibilities, ISHH-
positive cells were examined for the expression of another
lineage marker, GFAP, specific for astroglia. Surprisingly, we
found occasional cells (Fig. 4A) which were labeled both by
ISHH (for the donor marrow neoR marker) and by indirect
immunohistochemistry (for GFAP). Counting all of the donor
cells present in every 25th section obtained from recipient mice
4 weeks after transplantation (n 5 3), we calculated that as
many as 3 3 104 neoR-marked donor cells were present per
brain. Of that total donor cell number, we estimated between
0.5% and 2% exhibited GFAP expression.
To confirm that GFAP mRNA was present in some neoR-
positive cells, we also did double-ISHH analysis. Cells coex-
pressing GFAP and neoR mRNAs were identified using a
digoxigenin-labeled riboprobe against GFAP mRNA together
with a 35S-labeled probe for the neoR gene marking the donor
marrow. As illustrated in Fig. 4 B and C, we found cells labeled
with both probes. Their frequency was approximately equal to
the frequency of the ISHHyGFAP immunostained double
cells.
FIG. 2. Detection of donor cells in several brain regions of a female
recipient 6 weeks after transplantation with male bone marrow cells.
Arrows indicate representative cells positive for the Y chromosome by
ISHH. (A–C) Photomicrographs of a section through the ventral
mesencephalon. A is photographed using a rhodamine filter to excite
ethidium bromide staining of the nucleus; B is photographed using a
FITC filter to excite Y chromosome-specific FITC staining; and C is
photographed with a double-pass filter to show overlap of Y chromo-
some labeling and nucleus-specific ethidium bromide staining. Arrows
indicate some of the double-labeled cells. (D–F) Photomicrographs
demonstrating Y chromosome positive cells in other brain regions. (D)
Septum. (E) Striatum. (F) Habenula. (Bars 5 10 mm.)
FIG. 3. Double-labeling of brain sections detects cells coexpressing
the microglial marker F4y80 and the neoR retroviral tag. The F4y80
monocyteymacrophage antigen was detected by indirect immunoflu-
orescent antibody labeling; 35S-radiolabeled probes were used to
hybridize to neoR mRNA. The photomicrograph is of a representative
field from an animal sacrificed 35 days after bone marrow transplan-
tation. A cell in the center stains positive for the F4y80 antigen (red)
and exhibits labeling with radioactive probe to neoR transcripts. The
dark field image was photographed using a green filter so that
autoradiographic grains would appear green (yellow where they
overlap red immunostaining). (Bar 5 10 mm.)
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We also found doubly labeled cells in multiple animals when
ISHH to detect male cells with the Y chromosome marker was
combined with immunohistochemistry to detect GFAP pro-
tein (Fig. 5). Using DAPI staining to highlight the nucleus and
three-channel photomicrography, we confirmed that the Y-
chromosome ISHH was associated with the nuclei of GFAP-
positive cells (Fig. 5 C–H).
DISCUSSION
The results reported here confirm that cells derived from the
bone marrow can migrate into the brains of adult mice.
Furthermore, we have found that this migration is rapid, with
numerous cells present by the third day after transplant. These
new cells are distributed throughout the brain, and appear to
reside within the parenchyma, because perfusion with PBS
does not remove them. Occasional donor marrow-derived cells
were found in association with vascular structures. Moreover,
densities of donor cells in the parenchyma paralleled the
capillary density of a given region. For instance, cortex, with
fewer capillaries, had a lower cell density than the more
vascularized choroid plexus. Regions with a higher capillary
density, such as the area postrema, also had the highest density
of marrow-derived cells within the parenchyma.
Double-labeling analyses show that at least some bone
marrow-derived cells acquire microglial antigenic markers.
However, we also observed many cells positively labeled by
ISHH that did not express the F4y80 antigen. This may be due
simply to a level of antigen below the limits of detection in our
assay. Alternatively, it is possible that the F4y80 marker is
expressed on marrow-derived cells only after they fully differ-
entiate into microglia, while less mature microglial precursors
are not recognized by the antibody to F4y80. Nonetheless, our
results strongly support the view that hematopoietic cells
outside the CNS contribute to the maintenance of microglia in
healthy adults. While a partial CNS origin of adult microglia
cannot be excluded, our data is inconsistent with an exclusively
CNS origin. Moreover, although our experiments did not
examine fetal origins of microglia, the finding of hematopoi-
etically derived microglia in healthy adults is also consistent
with a hematopoietic origin of microglia in development.
Surprisingly, we found that some hematopoietic cells
(tagged either with a retroviral vector or by transplant of male
cells into a female recipient) give rise to cells other than
microglia, specifically to cells that exhibit astroglial markers.
Although this observation is unexpected, it is based on iden-
tical results in multiple animals using two independent means
of cell tagging with both cytoplasmic and nuclear markers.
The appearance of marrow-derived astroglia seems a normal
process in these animals. Because marrow-derived cell num-
bers detected in the brain increased over time, their appear-
ance does not appear to be a consequence of the transplan-
tation procedure itself. If appearance in the brain was a
byproduct of transplantation, one might expect tagged cell
numbers in the brain to peak and then decline, which was not
observed. Rather, the data is consistent with existence of cells,
among the populations of marrow-engrafting cells, capable of
continuous generation of progenitors that migrated to the
brain. Interestingly, cells withmarrowmarkers were seen in the
ventricular ependyma (Fig. 1D). In fact, in many animals,
marrow-derived cells could be found concentrated subependy-
mally (unpublished data). The subependymal zone is an im-
portant source of neuronal and glial progenitors during de-
velopment (25–27) and in adults (28, 29). Finding bone-
marrow derived cells in this location opens the possibility that
such cells receive cues guiding their differentiation once they
enter the brain. Studies evaluating this possibility are ongoing.
No obvious pathology such as gliosis was detected in the
brain of any transplant recipient (n 5 46). Some recipient
animals were irradiated before receiving bone marrow trans-
plants to see if marrow purging enhanced engraftment and
seeding of implanted cells. However, radiation dosages were at
least one order of magnitude below those known to induce
pathological changes in the CNS (30). Indeed, we found
preconditioning of recipients was not necessary. Male donor
cells engrafted and persisted for at least 10 weeks even without
irradiation (Fig. 5 C–H). Furthermore, as many Y chromo-
someyGFAP double-positive cells were seen with as without
irradiation. The wide distribution of GFAP-positive cells in
both gray and white matter suggests that bone marrow-derived
progenitors are not restricted to differentiate into a particular
subclass of astroglia. That is, marrow-marked cells contributed
to both fibrous astrocytes in the white matter (Figs. 4A and 5
C–E) and protoplasmic astrocytes in the gray matter (Figs. 4
B and C and 5A).
One alternative explanation for our observing GFAP stain-
ing of cells bearing marrow markers is that processes from
endogenous astroglia surround the in-migrating cells from the
donor marrow. However, some of our data argue against this
possibility. First, cytoplasmic neoR ISHH labeling coincided
with cytoplasmic GFAP immunostaining (Fig. 4A). Further-
more, upon evaluation of 50 to 100 male nuclei associated with
GFAP staining, no nuclei were seen that could be considered
part of an engulfing astroglial cell. If endogenous astroglia
were the source of the GFAP staining associated with donor
male nuclei, one might expect the geometry in 12 mm sections
to reveal the cell body and nucleus corresponding to the
putative engulfing processes in at least a few cases. After
analyzing dozens of sections, no such cases were observed.
Culturing astroglia obtained from brains of transplant recip-
ients may help to resolve this issue in the future.
Because only about 10% of marrow-derived cells in the brain
exhibit expression of either the microglial F4y80 antigen or the
astroglial marker GFAP, the identity of the majority of bone
marrow-derived cells remains an open question. Nonetheless,
there is clearly a measurable contribution by cells of hemato-
poietic origin to the glial cell population of the brain in adult
mice, which suggests that some glial progenitors reside outside
FIG. 4. Double-labeling of brain sections detects cells coexpressing
the astroglial marker GFAP and the neoR retroviral tag. (A) Detection
of cells within the optic tract expressing GFAP protein using perox-
idase-based immunohistochemical staining combined with ISHH to
detect expression of neoR transcripts. The arrow indicates a double-
labeled cell. Open arrowheads indicate clusters of grains indicative of
a neoR-marked cell that is not expressing GFAP. Filled arrowheads
indicate GFAP-positive positive cells that are not marked with the
retroviral tag. (B andC) Detection of GFAP transcripts by ISHH using
digoxigenin-labeled probes combined with detection of neoR tran-
scripts by ISHH using 35S-labeled probes. The photograph is of a
section through the cerebral cortex. (B) Polarized epifluorescent
illumination to emphasize grains indicative of hybridization with
35S-labeled probe for neoR. (C) Bright field illumination emphasizing
digoxigenin staining of GFAP transcripts. The cell indicated by the
arrow is double-labeled. (All photomicrographs are at the same
magnification. Bar 5 20 mm.)
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the CNS. The observation of marrow-derived astroglia in the
optic tract (Fig. 4A) suggests that some of these marrow-
derived progenitors may be similar to the previously recog-
nized astroglial precursor (31). Alternatively, two classes of
astroglia may exist, one arising from the previously recognized
neuroepithelial astroglial precursor present in the brain from
birth, and another from a different precursor that is a normal
constituent of adult bone marrow. It would be interesting to
determine if astroglia arising from the different sources of
progenitors also exhibit different functional characteristics.
Microglia and astroglia respond differently to brain injury.
In fact, astrogliosis often appears to be a response to primary
microgliosis (32, 33). There is also evidence that different brain
lesions elicit different microglial and astroglial responses (34).
Our results suggest that gene transfer into hematopoietic
progenitors can be used to introduce genes into microglia and
astroglia that then might participate in the gliosis associated
with a CNS pathology. The detection of marrow-derived cells
in brains within days of transplantation implies that genetically
altered hematopoietic cells could be used to treat acute
diseases of the brain.
Although many neurotrophic factors show promise in the
treatment of CNS disorders, their use has been hindered by
their inability to cross the blood-brain barrier and by their
limited diffusion into CNS tissues (35). In addition, adverse
effects have been reported after systemic administration of
some neurotrophins (36). Using marrow-derived cells to de-
liver therapeutic proteins directly to the site of CNS pathology
FIG. 5. Male bone marrow derivative cells express GFAP. Photomicrographs are of double-labeled cells found in the brains of two different
female recipient mice 10 weeks after bone marrow transplantation. Male donor cells were detected with a Y chromosome-specific riboprobe as
described in Fig. 1. Astroglia were identified using a CY3-labeled polyclonal antibody against the astroglial marker GFAP. (A and B) Double-labeled
cells are indicated by arrows. The arrowhead in A points to a Y chromosome-positive cell derived from the male donor marrow that is not GFAP
immunopositive. A is a section through the cortex. B is a section through the septum. (Bar in B applies to A and B and equals 20 mm.) (C, D, and
E) Photomicrographs of a section through the corpus callosum. In C, the section is illuminated with ultraviolet light to excite DAPI fluorescent
staining of the nucleus. Nuclei from all cells are stained. D is illuminated to excite FITC staining of the Y chromosome. E is illuminated to excite
CY3-immunostaining of GFAP. A Y chromosomeyGFAP double labeled cell is indicated by the arrow. (Bar in E applies to C–E and equals 20
mm.) (F, G, and H) Photomicrographs of a single field from a section through the amygdala. F illustrates the green FITC staining associated with
the Y chromosome. G shows the red GFAP immunostaining, and H is a double-exposure of the same field, first with a double band pass filter to
excite FITC and CY3 fluorescence, then with ultraviolet illumination to excite the blue DAPI fluorescent staining of the nucleus (*). The green
Y chromosome fluorescence is indicated by the arrow (F and H). (Bar in H applies to F–H and equals 4 mm.) Sections in A and C–E were obtained
from one mouse, while those in B and F–H were obtained from another.
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may be more benign than systemic administration of toxic
molecules. In addition, using vectors with cell type-specific
promoters could restrict gene expression specifically to reac-
tive astroglia or microglia, thereby providing greater thera-
peutic precision for gene therapy of CNS disease.
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neuronal markers in tissue culture (32);
however, their ability to yield neuronal
phenotypes in response to physiological
signals in vivo has not previously been
shown. Thus, our findings are not only of
fundamental interest but also, once more ro-
bust, could have application as a cell-mediat-
ed therapy. Not only could neurons be con-
tributed to the adult brain, but, if genetically
engineered, they could be a potentially useful
tool for treating disorders characterized by
defective neuronal function or a loss of neu-
rons such as Parkinson’s disease, lysosomal
storage disorders, psychiatric disorders, trau-
ma, and other types of CNS injury.
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Turning Blood into Brain: Cells
Bearing Neuronal Antigens
Generated in Vivo from Bone
Marrow
E´va Mezey,1* Karen J. Chandross,2 Gyo¨ngyi Harta,1
Richard A. Maki,3,4 Scott R. McKercher3
Bone marrow stem cells give rise to a variety of hematopoietic lineages and
repopulate the blood throughout adult life. We show that, in a strain of mice
incapable of developing cells of the myeloid and lymphoid lineages, trans-
planted adult bone marrow cells migrated into the brain and differentiated into
cells that expressed neuron-specific antigens. These findings raise the possi-
bility that bone marrow–derived cells may provide an alternative source of
neurons in patients with neurodegenerative diseases or central nervous system
injury.
Neural stem cells, the self-renewing precur-
sors of neurons and glia, are the focus of
intensive research aimed at developing trans-
plantation strategies to promote neural recov-
ery in the diseased or injured nervous system
(1, 2). Recently, Bjornson et al. (3) demon-
strated that neural stem cells could also dif-
ferentiate into a variety of hematopoietic
cells, including the myeloid and the lymphoid
cell lineages, as well as more immature blood
cells. Circulating T cells, B cells, and macro-
phages enter the brain (4–7). Rodent bone
marrow cells migrate into the brain and dif-
ferentiate into microglia and astrocytes when
transplanted into previously irradiated recip-
ients (8, 9). Recent evidence suggests that,
under experimental culture conditions, hu-
man and rodent bone marrow stromal cells
can differentiate into cells bearing neuronal
markers (10, 11). When transplanted into the
lateral ventricle or striatum of mice, cultured
marrow stromal cells migrate into the brain
and differentiate into astrocytes (12, 13).
There is evidence that other types of meso-
dermal-derived cells can also differentiate
within the mammalian nervous system. For
example, luteinizing hormone-releasing hor-
mone (LHRH)–producing neurons originate
from outside the central nervous system
(CNS) and migrate into the hypothalamus
(14). In the present study, we show that bone
marrow–derived cells enter the brain and dif-
ferentiate into cells that express neuronal
markers, supporting the idea that mesoder-
mal-derived cells can adopt neural cell fates.
Mice homozygous for a mutation in the
PU.1 gene were used as bone marrow trans-
plant recipients. PU.1 is a member of the ETS
(DNA binding domain) family of transcrip-
tion factors and is expressed exclusively in
cells of the hematopoietic lineage. In the
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absence of donor bone marrow cells, PU.1
knockout mice lack macrophages, neutro-
phils, mast cells, osteoclasts, and B and T
cells at birth (15, 16). These animals are born
alive but require a bone marrow transplant
within 48 hours after birth to survive and
develop normally. There are no gross mor-
phological differences in the brain cytoarchi-
tecture of these mice versus wild-type mice.
In the present study, PU.1 null mice were
used as bone marrow recipients to optimize
the number of cells derived from the donor
and to permit an accurate estimation of the
numbers of bone marrow cells that migrate
into the nervous system.
NeuN, a nuclear protein that is found ex-
clusively in neurons (17–19), was used as a
neuronal marker. Specific NeuN immunore-
activity was not present in acutely isolated
(20) bone marrow cells. Acutely isolated
bone marrow cells were also examined for
neural antigens in our transgenic mouse line
in which oligodendrocytes and Schwann cells
express LacZ (21). No LacZ-expressing or
b-galactosidase–immunopositive cells were
present, and there was no specific immuno-
staining for NG2 chondroitin sulfate proteo-
glycan or O4, antigens that are present in
Schwann cells and oligodendrocytes (22–24).
These results strongly suggest that the bone
marrow cell preparations were devoid of neu-
rons and glia at the time of transplantation.
When adult bone marrow cells were grown in
culture for several weeks, the neural stem cell
antigen, nestin, was present in 18% of the
population [see Web fig. 1 (25)], indicating that
bone marrow can give rise to neural stem cells.
Within 24 hours after birth, PU.1 homozy-
gous recipients were given intraperitoneal in-
jections of bone marrow cells from wild-type
mice (20). Seven transplant recipient mice
and nontransplanted control littermates were
examined between 1 and 4 months of age. To
determine the efficiency of the transplanta-
tion, we analyzed different organ tissues for
the presence of donor-derived cells. Y chro-
mosome–positive male cells were identified
in hematopoietic organs of female recipients
by fluorescent in situ hybridization histo-
chemistry. Greater than 90% of spleen cells,
in both white and red pulp, and ;10 to 15%
of liver cells were Y chromosome–positive.
All brains were examined by using a combi-
nation of in situ hybridization (ISH) to detect
the Y chromosome and immunohistochemis-
try to visualize the neuronal nuclear marker,
NeuN. Brains from a 4-month-old nontrans-
planted female [Fig. 1A and Web fig. 2, A to
E (25)] and a nontransplanted male [Fig. 1B
and Web fig. 2, F to J (25)] were processed
together and served as controls for the Y chro-
mosome hybridization specificity and efficien-
cy (26). There was no specific Y chromosome
staining in the female brain. The Y chromo-
some was frequently localized at the periphery
of the nucleus, which is characteristic of het-
erochromatin (27, 28). The NeuN immuno-
staining was predominantly localized to the nu-
cleus, although some neurons [as reported by
others (19)] also exhibited perinuclear staining
[Figs. 1 and 2 and Web figs. 2 to 5 (25)].
Marrow-derived cells (i.e., Y chromo-
some–positive) were present in the CNS of
all of the transplanted mice examined. Be-
tween 2.3 and 4.6% of all cells (i.e., all
identifiable nuclei, including vasculature)
were Y chromosome–positive (Table 1). The
Fig. 1. Y chromosome
staining in the CNS.
Coronal sections from
4-month-old nontrans-
planted (A) female and
(B) male brains were
mounted and pro-
cessed together. The
panels show the over-
lay of the NeuN (red)
immunostaining, Y chro-
mosome nonradioactive
ISH [visualized with ty-
ramide-FITC conjugate
(green)], and DAPI stain-
ing of cell nuclei (blue).
The Y chromosome was
restricted to the male
brain, demonstrating
hybridization speciÞci-
ty. (C) Confocal image
of coronal sections
from a 4-month-old re-
cipient female striatum
that was double-im-
munostained for the
neuron-speciÞc antigens
NeuN and NSE. All
NeuN-expressing cells
(red) were also immu-
noreactive for NSE (green). (D) Sagittal section from a 1-month-old female PU.1 knockout mouse
brain transplanted at birth with male bone marrow. The Y chromosome was visualized with
BCIP/NBT (dark purple dots) to identify anatomical landmarks. cc, corpus callosum; cx, cerebral
cortex; CPu, caudate putamen; Þ, Þmbria hippocampi; hi, hippocampus; LV, lateral ventricle. (E to
G) Identical Þelds showing NeuN, Y chromosome, and DAPI nuclear triple staining in the
hypothalamic dorsomedial nucleus of a 3-month-old female recipient. Colocalization of the Y
chromosome [visualized with tyramide-FITC conjugate (green)] to a NeuN immunopositive (red)
nucleus is shown in (E). In (F), DAPI staining identiÞes all cell nuclei (blue). Overlays of the NeuN,
Y chromosome, and DAPI ßuorescence are shown in (G). The arrow identiÞes a cell nucleus that
contained both the Y chromosome (indicating the bone marrow origin) and NeuN. Scale bar in (G)
represents the following sizes: 30 mm, (A) and (B); 10 mm, (C); 250 mm (D); and 12 mm, (E) to (G).
Similar results were observed with three different animals for each experimental condition.
Table 1. Quantitation of the number of donor cells in the forebrains of
transplanted mice. A total of 21,682 cells was counted from seven animals.
Ten to 20 random Þelds were photographed, and all DAPI-, NeuN-, or Y
chromosomeÐpositive nuclei were counted. Counts of cells represent an
average from three independent investigators. The ratio of total cells to
neurons was in good agreement with previous reports (45, 46).
Age
(months)
DAPI-positive
nuclei counted
NEU-positive
nuclei counted
Y chromosomeÐ
positive cells
Y chromosome/NEU
(double-labeled)
Neu-positive nuclei
in all cells (%)
Y chromosomes
in all cells (%)
Y of Neu-positive
cells (%)
4 4831 1908 120 6 39 2.5 0.3
4 1322 221 60 5 17 4.5 2.3
3 3675 1483 130 16 40 3.5 1.1
3 4550 1825 105 15 40 2.3 0.8
2 3731 1039 162 16 28 4.3 1.5
1 1913 464 86 8 24 4.5 1.7
1 1660 380 76 7 23 4.6 1.8
R E P O R T S
1 DECEMBER 2000 VOL 290 SCIENCE www.sciencemag.org1780
 
o
n
 S
ep
te
m
be
r 8
, 2
01
1
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
               dc_219_11
Y chromosome–bearing cells were evenly
distributed throughout the different brain re-
gions [Fig. 1D and Web fig. 2, K and L (25)],
in both white and gray matter. The Y chro-
mosome was present in 0.3 to 2.3% of the
NeuN-immunoreactive nuclei (Table 1).
Confocal microscopy confirmed the presence
of the Y chromosome in NeuN-immunoposi-
tive nuclei [Fig. 2 and Web figs. 4 and 5
(25)]. Y chromosome staining was localized
to NeuN immunopositive cells and was not
associated with any other neighboring nuclei
in the x, y, or z planes. In the CNS of trans-
planted female mice, all NeuN-immunoposi-
tive nuclei were found in neuron-specific
enolase (NSE)–containing cells (Fig. 1C). In
the brain, NSE is expressed exclusively in
neurons (29), demonstrating that Y chromo-
some–bearing cells can express two neuronal
antigens. Most of these cells were found in
the cerebral cortex [Web fig. 3, A to F (25)];
however, they were also present in the hypo-
thalamus (Fig. 1, E to G), hippocampus,
amygdala [Web fig. 3, G to I (25)], periaq-
ueductal gray, and striatum. We did not de-
tect Y chromosome–positive large motor
neurons in the spinal cord or brainstem. A
substantial number of Y chromosome–posi-
tive cell nuclei were present in cells within
the choroid plexus of the lateral ventricle, in
the ependyma of the ventricular system, and
in the subarachnoid space, suggesting the
cerebrospinal fluid as a primary route of entry
[Web fig. 6 (25)]. We did not observe an
overall increased density of Y chromosome–
positive cell nuclei in neurogenic regions,
including the subventricular zone, olfactory
migratory region, or hippocampus. Because
mesodermal stem cells can differentiate into
microglia (8) and all microglia in these recip-
ient animals arise from the donor bone mar-
row and are also Y chromosome–positive, we
could not determine regional differences in the
distribution of Y chromosome–positive nuclei.
These studies demonstrate that bone mar-
row cells migrate into the brain and differen-
tiate into cells that express neuron-specific
antigens. In combination with previous in
vivo studies (9, 12, 13), the present work
suggests that the bone marrow can supply the
brain with an alternative source of neural
cells. Neurons and macroglia (oligodendro-
cytes and astrocytes) are thought to arise
from pluripotent neural stem cells that are
present both in the developing (30) and adult
mammalian CNS (31–35). It has been esti-
mated that, for every 2000 existing neurons,
one new neuron is produced each day (35,
36). In the rodent brain, there are two well-
characterized neurogenic regions: one in the
subgranular zone of the dentate gyrus and one
in the forebrain subventricular zone (37–41).
Two populations of neural stem cells have
been identified in adult mammals: one in the
ependymal cell layer lining the ventricles
(33) and one in the subventricular zone [glial
fibrillary acidic protein–immunoreactive cells
(34), each of which gives rise to glial cells and
neurons]. We suggest that, in addition to these
sources of neural stem cells, there may be a
continuous influx of bone marrow stem cells
into the ependymal and subependymal zones
that give rise to a variety of CNS neural cell
types. An interesting possibility is that these
entry routes might also serve as portals into the
CNS for diseases that primarily originate in and
affect the hematopoietic system (i.e., leukemia
and AIDS).
Bone marrow is far more accessible than
neural stem cells and has the added advantage
of having inherent host compatibility, thereby
obviating the need to screen for viral and
foreign antigens. Although our study showed
that only a small number of transplanted cells
expressed neuronal antigens in the adult
brain, there may be factors that promote the
differentiation of bone marrow cells into dis-
tinct neural cell types. Once these factors are
identified, bone marrow cells might be ex-
panded in vitro and provide an unlimited
source of cells for the treatment of CNS
disease and injury. Because at least two dif-
ferent types of stem cells have been isolated
from bone marrow (hematopoietic and stro-
mal), characterizing the potential for each
population will be an important step toward
optimizing regenerative therapies.
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Coding the Location of the
Arm by Sight
Michael S. A. Graziano,* Dylan F. Cooke, Charlotte S. R. Taylor
Area 5 in the parietal lobe of the primate brain is thought to be involved in
monitoring the posture and movement of the body. In this study, neurons in
monkey area 5 were found to encode the position of the monkey’s arm while
it was covered from view. The same neurons also responded to the position of
a visible, realistic false arm. The neurons were not sensitive to the sight of
unrealistic substitutes for the arm and were able to distinguish a right from a
left arm. These neurons appear to combine visual and somatosensory signals
in order to monitor the configuration of the limbs. They could form the basis
of the complex body schema that we constantly use to adjust posture and guide
movement.
Without an accurate sense of the position of
the limbs, head, and torso, we would be
unable to guide movement, process the spa-
tial location of nearby objects, or distinguish
our own body parts from external objects.
People with damage to their parietal lobes
can have difficulty in all of these dimensions
(1, 2). Studies in normal humans show that
the body schema is not simply a representa-
tion of joint angles, but a complex integration
of vision, proprioception, touch, and motor
feedback (3–6). Although a great deal is
known about the processing of joint angle
and muscle stretch in the somatosensory sys-
tem (7), little is known about how different
sensory modalities are combined by neurons
in the parietal lobe or elsewhere to construct
the body schema (8, 9).
The present set of studies focused on the
coding of static arm position. The sense of
arm position depends on many sources of
information, including proprioception and vi-
sion (3–6, 10–12). Here we show that neu-
rons in parietal area 5 of the monkey brain,
but not in the primary somatosensory cortex,
respond in relation to the seen position of a
false arm. They are also sensitive to somato-
sensory signals, responding in relation to the
felt position of the monkey’s actual arm.
These somatosensory and visual signals are
combined in individual neurons to provide a
possible code for static limb position.
Responses of single neurons in area 5
were studied in two monkeys (13). The re-
cording site in monkey 1 is shown in Fig. 1A,
and the apparatus is shown in Fig. 1B. The
arm contralateral to the recording electrode
was outstretched, and the ipsilateral arm was
held close to the body (not shown). The arms
were covered with a black plastic plate. On
top of the plate, a realistic false arm was
placed in the monkey’s view. This false arm
was from a monkey of the same species and
had been prepared by a taxidermist. The cut
end was covered from view by a portion of
Department of Psychology, Princeton University,
Princeton, NJ 08544, USA.
*To whom correspondence should be addressed. E-
mail: graziano@princeton.edu
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Adult bone marrow stem cells seem to differentiate into muscle,
skin, liver, lung, and neuronal cells in rodents and have been shown
to regenerate myocardium, hepatocytes, and skin and gastroin-
testinal epithelium in humans. Because we have demonstrated
previously that transplanted bone marrow cells can enter the brain
of mice and differentiate into neurons there, we decided to
examine postmortem brain samples from females who had re-
ceived bone marrow transplants from male donors. The underlying
diseases of the patients were lymphocytic leukemia and genetic
deficiency of the immune system, and they survived between 1 and
9 months after transplant. We used a combination of immunocy-
tochemistry (utilizing neuron-specific antibodies) and fluorescent
in situ hybridization histochemistry to search for Y chromosome-
positive cells. In all four patients studied we found cells containing
Y chromosomes in several brain regions. Most of them were
nonneuronal (endothelial cells and cells in the white matter), but
neurons were certainly labeled, especially in the hippocampus and
cerebral cortex. The youngest patient (2 years old), who also lived
the longest time after transplantation, had the greatest number of
donor-derived neurons (7 in 10,000). The distribution of the labeled
cells was not homogeneous. There were clusters of Y-positive cells,
suggesting that single progenitor cells underwent clonal expansion
and differentiation. We conclude that adult human bone marrow cells
can enter the brain and generate neurons just as rodent cells do.
Perhaps this phenomenon could be exploited to prevent the devel-
opment or progression of neurodegenerative diseases or to repair
tissue damaged by infarction or trauma.
Neurogenesis used to be thought to be completed duringembryonic life in rodents as well as humans. During the last
decade, however, numerous studies have suggested that neuro-
genesis continues in adult animals and humans, at least to a
certain extent in a few privileged areas of the brain (1–4). Most
of these studies have focused on endogenous neural progenitor
cells (neural stem cells) localized in the subventricular zone of
the lateral ventricle and in the dentate gyrus in the hippocampus
in rodents (4). In the monkeys these cells are present in the
hippocampus and neocortex (5, 6). Likewise, Eriksson et al. (7)
found that new neurons are generated continuously in the
human dentate gyrus throughout life.
It is also conceivable that stem cells from other sources might
enter the brain and form neurons there. Uchida et al. (8) isolated
CNS stem cells from human fetal tissue and transplanted them
into the brains of mice, where they subsequently proliferated and
differentiated into neuronal cells. One source of such cells in the
brain could be the bone marrow. Adult bone marrow stem cells
seem able to differentiate into muscle, skin, liver, lung, and
neural cells in rodents (9–18). Furthermore, transplanted bone
marrow cells in humans have also been shown to form myocar-
dial cells (19, 20), hepatocytes (21, 22), and epithelium of the
skin and gastrointestinal tract (20). Because we have demon-
strated previously that transplanted bone marrow cells migrate
into the brains of mice and give rise to neurons there (15), we
hypothesized that the same thing might occur in the human CNS
after bone marrow transplantation. We tested this hypothesis by
looking for Y chromosome-positive neuron-like cells in post-
mortem brain samples from females who had received bone
marrow transplants from male donors.
Methods
Four female patients who had had bone marrow transplants from
male donors were selected from the autopsy files of The Johns
Hopkins Hospital. Patient 1 had Omenn’s syndrome, was trans-
planted at 9 months of age, and died 10 months later. Patient 2
had Hodgkin’s disease and was transplanted at 34 years of age.
Patient 3 had acute lymphocytic leukemia and was transplanted
at 10 years of age. Patient 4 had acute lymphocytic leukemia and
was transplanted at 20 years of age. Patients 2–4 died within 2
months of receiving their transplants.
Formalin-fixed, paraffin-embedded sections (6 m) from the
following brain areas were examined in each case: neocortex,
striatum including the lateral ventricular wall, hippocampus with
adjacent mesial temporal lobe structures, and cerebellum. Sec-
tions from three nontransplanted female patients were used as
negative controls for Y-chromosomal staining. Sections from
four male patients were used as positive controls. One tissue
sample each from a male and a control female brain were
reembedded together into one paraffin block and serially sec-
tioned at a thickness of 6 m; sections from this block were used
as controls in all experimental series.
After deparaffinization in Citrisolv (Fisher Scientific) the
sections were rehydrated, and heat-induced antigen retrieval was
performed in a histology microwave oven by using a citrate
buffer (Citra-plus, Innogenex, San Ramon, CA) for 5 min at 600
W. Next, immunostaining was performed by using primary
antibodies that were detected by the Sternberger peroxidase
antiperoxidase (PAP) method (23) followed by either biotin-
ylated tyramide (for Kv2.1) or FITC-tyramide plus [(for neuro-
nal nuclear antigen (NeuN)] (Perkin–Elmer). The primary an-
tibodies used were directed against two neuronal proteins: NeuN
(24), a neuron-specific nuclear protein, and Kv2.1, a neuron-
specific voltage-gated potassium channel antibody (25, 26).
Kv2.1 was recognized as a neuron-specific potassium channel
that was first described in the principal neurons of the hippocam-
pus and cortex and later shown to be present in the vast majority
of interneurons as well (26). The NeuN antibody was a mouse
monoclonal (used at 1:1,000) (Chemicon), and the Kv2.1 anti-
body was a rabbit polyclonal (used at 1:500, Alomone, Jerusa-
lem). After immunostaining, the in situ hybridization was carried
out as described (15) by using a digoxigenin-labeled riboprobe
complementary to the satellite region of the human Y chromo-
some. We prepared the template from which we made probe
from human genomic DNA by using primers that amplified a
1.3-kb-long DNA of the human Y chromosome. The probe was
visualized by using peroxidase-conjugated antidigoxigenin anti-
body (Roche, Indianapolis) followed by a tyramide-CY3 fluo-
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: NeuN, neuronal nuclear antigen; Kv2.1, neuron-specific potassium channel.
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rochrome plus (Perkin–Elmer) amplification. At the end, all
sections were stained with a 1% Sudan-black solution to mask
lipofuscin-induced autofluorescence, which is a common prob-
lem when working with human brain tissue (27). All sections
were stained with 4,6-diamidino-2-phenylindole (DAPI,
Sigma), a chromosomal stain to label nuclei, and mounted with
80% glycerol20% Tris. A separate series of sections was
hybridized by using a radiolabeled Y chromosome probe, which
is easily visualized at low magnification. This enabled us to count
Y-positive cells and examine their overall distribution. All
sections were viewed with conventional Leitz and confocal Zeiss
microscopes.
In addition to the nontransplanted male and female brains, to
make sure of the specificity of the techniques we ran as controls
immunostaining with amplification without primary andor
without the secondary antibodies.
Analysis of the distribution of Y chromosome-positive cells
was done as follows. The Y chromosome probe was radiolabeled
with [35S]UTP and hybridized to brain sections. After emulsion
coating and autoradiographic development of the sections, the
Y-positive nuclei were counted at low magnification (10). The
counts in individual 1.2-mm2 microsquares (visual field) of a grid
that covered the entire section were determined. The mean and
variance of the counts and the variance-to-mean ratio were
calculated. In a random (Poisson) distribution, the variance-to-
mean ratio is 1. Therefore, the nearness to 1 of this ratio is a
measure of the randomness of the distribution (28).
Results
In the control male brain sections we detected the Y chromo-
some with both the fluorescent and autoradiographic techniques
in 90% of the nuclei, whereas no labeling was observed in the
brain sections of female patients who have not received trans-
plants. In each of the transplanted patients examined we readily
detected Y-positive cells by means of autoradiography. In all
patients using conventional f luorescent microscopy we observed
double-labeled cells that were positive for both the Y chromo-
some and one of the neuronal markers as shown in an example
in Fig. 1. Most of the cells that were double-labeled with the Y
chromosome and the neuronal markers were detected in the
hippocampus and the neocortex of patients (Fig. 2). The anti-
body that binds to Kv2.1 gave a very convincing staining of
neuronal somata and dendrites in all cortical areas and in the
hippocampus (as described in the literature; see ref. 26), and also
a few axons seemed to show a patchy immunostaining after signal
amplification.
Fig. 1. (A) A 6-m-thin section from somatosensory cortex of patient 2 demonstrates the presence of the Y chromosome depicted as red dots and viewed
through a rhodamine filter. The same field as in A is shown when viewed through the FITC filter to demonstrate the immunostaining for the neuronal marker
NeuN in green (B), and the UV filter shows all cell nuclei in blue after staining with 4,6-diamidino-2-phenylindole, a chromosomal stain (C). (D) The overlay of
the three filters, where arrows point to cells that carry all markers, indicating that they derived from the donor bone marrow (Y chromosome-positive) and bear
the specific neuronal marker NeuN. Arrowheads point at nonneuronal donor-derived cells. (Scale bars, 10 m.)
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Confocal z series confirmed the presence of Y chromosomes
in the nuclei of the same cells that were immunopositive for the
neuronal markers. Examples from two patients are shown in Fig.
3. In the patient with the greatest number of double-labeled cells
(patient 1), the distribution of the Y-positive cells suggested that
clonal expansion had occurred: We detected no labeled cells in
many visual fields but typically saw clusters of positive cells when
such cells were detected. This pattern was easier to recognize in
the autoradiographic sections, which could be examined at low
magnification. In several clusters, the Y-positive cells were both
neuronal and nonneuronal. In the cortex, based on morphology
and location, the Y-positive neurons were small pyramidal cells,
whereas in the hippocampus the Y-positive cells seemed to be
granule cells. We also saw Y-positive cells in the white matter,
some of which looked like oligodendrocytes based on the shape,
size, and arrangement of their nuclei. We saw many Y-positive
cells inside vessels (in cross section) and also some Y-positive
endothelial cells in the vascular wall.
We counted all the Y chromosome-positive cells in two entire
sections of striatumcortex and hippocampuscortex blocks
from two patients, analyzing 281 and 247 microscopic fields from
patients 1 and 3, respectively (Table 1). In patient 1 we found 519
Y-positive cell nuclei among 182,000 nuclei (stained with
ethidium bromide), and in patient 3 we found 1,842 Y-positive
nuclei among 196,700. In the same sections we found 19 and 5
Y chromosome-containing nuclei, respectively, that also colo-
calized with neuronal antigens. Based on these observations and
conservatively assuming that 25% of all nuclei in the human
brain are neurons [this number in the cortex of primates varies
between 27% and 60% (29, 30)], one in every 2,000–4,000
neurons might derive from the bone marrow.
When we evaluated the distribution of Y chromosome-
positive cells in patients 1 and 3 we found that it was not random.
The variance-to-mean ratios of all counts in microsquares over-
laying the sections studied were calculated to be 10.2 (patient 1)
and 4.7 (patient 3).
Discussion
Several studies have shown that there is neurogenesis in the adult
brain, even though it may be limited. Cells with neuron-specific
markers can be formed by neural stem cells in vivo (1, 3, 31) as
well as by bone marrow cells in vitro (32, 33) and in vivo (9, 15).
Recently, Priller et al. (34) published a picture of a well differ-
entiated, enhanced GFP-positive Purkinje cell in the cerebellum
of a mouse transplanted with enhanced GFP-tagged bone mar-
row from a second animal. Along with earlier studies, this finding
Fig. 2. Neuronal markers colocalized with the Y chromosome. Fluorescent microscopic images of neocortex from patients 2 (A–C) and 1 (E) and hippocampus
from patients 1 (D) and 3 (F) are shown. The green color represents the immunostaining for neuronal markers Kv2.1 (A–D) and NeuN (E and F), and the Y
chromosome is represented by the red fluorescent dots. All cell nuclei are stained with 4,6-diamidino-2-phenylindole, a chromosomal marker that shows up as
blue fluorescence. All images are overlays of the images seen through the three separate filters to show all colors. Arrows point to cells that are labeled with
neuronal markers and are also Y chromosome-positive. In the Kv2.1 immunostaining the initial axons of some neurons can also be visualized. (Scale bars, 10m.)
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was a significant step toward showing that fully functional
neurons can be generated from bone marrow cells. Based on our
present study, we have no way of knowing which population of
bone marrow cells entered the CNS and differentiated into cells
expressing neuronal morphology and neuronal markers. Mes-
enchymal stem cells have been shown to differentiate into many
different cell lineages (35). All of our patients received total
bone marrow transplants containing both hematopoietic and
mesenchymal stem cells.
Recently, two studies (36, 37) suggested the possibility that
Y-positive cells of bone marrow origin might simply fuse with
embryonic stem cells instead of transdifferentiating into cells
characteristic of various tissues. Although this idea is inter-
esting, no data support its relevance in vivo (see ref. 38). In
fact, the fusion process is very inefficient in vitro: 1 in a million,
which is a figure much lower than the number of double-
labeled cells that we see in the brain. Recently, Castro et al.
(39) failed to detect blue cells in the brains of lethally
Fig. 3. Two confocal z series are shown. (A–D) Optical sections (1-m-thin) of a neocortical neuron from patient 2. (E–F) Optical 1-m-thin slices of a
hippocampal granule cell from patient 1. Both cells are immunostained with the neuronal marker Kv2.1 (green); the Y chromosome is red (CY3-plus), and
the nucleus is blue (4,6-diamidino-2-phenylindole). The arrowheads point to the double-labeled cells. Note that the cell nucleus and the Y chromosome
are consistently in the same plane.
Table 1. Number of Y chromosome-positive (Y) cells in two patient samples
Patient
No. of visual fields
(1 field  0.94 mm2)
No. of
Y nuclei
No. of
all nuclei
No. of Y nuclei
in cells with neuronal markers
1 281 519 182,000 19
3 247 1,842 196,700 5
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irradiated mice that received bone marrow from Rosa26 mice
with a -galactosidase-containing transgene. The use of pro-
tein products of transgenes as markers to follow graft fate is
plagued with problems, but to date these may not have been
emphasized enough. It is practically impossible to achieve
ubiquitous transgene expression. Transgenes, including those
driven by the Rosa26 promoter, suffer from instability in
several tissues. Furthermore, to detect low levels of lacZ is
difficult, and the detection is sensitive to fixation and staining
conditions (40). Because one would have expected to see at
least labeled microglia in the brain, one must assume that the
results reported were due to technical problems.
In the present cases it is difficult to make general statements
about the extent of CNS colonization or to conclude whether
cells enter the brain continuously or just at the time of the
transplant. All of our patients received irradiation to eliminate
the underlying disease. We do not know how much effect the
irradiation might have on the migration of circulating cells into
the brain by either injuring the blood–brain barrier andor
releasing possible recruiting factors due to the injury caused by
the radiation. It is known, however, that circulating blood cells
are able to enter the brain parenchyma freely in healthy
subjects (41). We studied a limited number of patients with
different diseases, ages, survival times after transplant, and
treatments of postmortem tissue. Because of the technical
difficulties of double-labeling cells in paraffin-embedded post-
mortem tissue and the fact that we had to reduce the sensitivity
of the method to eliminate background, we believe that our
numbers are in fact lower that the real number of differenti-
ating cells in vivo. Although we found donor (i.e., Y chromo-
some-positive) cells exhibiting two specific neuronal markers
(NeuN and Kv2.1) in the hippocampus and neocortex in all
three of the patients with technically satisfactory samples, the
numbers of double-labeled cells were much lower than those
reported in rodents (9, 15). We found 2–5 Y-positive neurons
per 10,000 human neurons vs. 50 per 10,000 rodent neurons.
Whether this is a species difference is unclear. The sections
with the highest number of newly formed neurons (7 per 10,000
neurons) were from patient 1, the youngest studied, who had
her transplant in infancy and also had the longest posttrans-
plant survival time. All the other patients lived only weeks
after the transplant, and there was no significant difference in
the number of donor-positive cells in their brains.
It should also be noted that among the Y-positive cells,
neurons were consistently in the minority. Based on their
nuclear morphology, size, and location, we feel that the
nonneuronal cells bearing the Y chromosome were a mixture
of oligodendrocytes, astrocytes, and possibly microglia. We
also detected endothelial, meningeal, and ependymal cells that
were Y-positive. Finally, many circulating white blood cells
within the vascular lumen were also Y-positive, as one would
expect.
Our analysis showed that the distribution of Y-positive cells
within the brain is not random. Instead, the cells appeared in
clusters, a spatial distribution that suggests nondifferentiated
cells may enter an area and then further propagate there. In
these areas we see different kinds of Y-positive cells (neuronal
and nonneuronal). One possibility is that one undifferentiated
cell migrates into an ‘‘area of need’’ and then goes through
asymmetrical divisions to produce different lineages of cells.
Another possibility is that many progenitor cells are ‘‘called in,’’
and they differentiate into different lineages of cells. Whichever
is the case, we speculate that areas in need of new cells (because
of physiological turnover or pathological loss of cells) may be
able to signal to potential stem cells to coax them into the region,
and then clonal expansion occurs to help restore the number of
cells to normal. Therefore, it will be very important to try to find
the factors responsible for inducing stem cells to migrate into
lesioned or sick areas of the brain. Discovering these factors
could aid the attempt to use bone marrow cells to repair the
brain.
We thank Ted Usdin for help in preparing the human Y chromosome
probe; Carolyn Smith for help in confocal microscopy; and Michael
Brownstein and Harold Gainer for helpful suggestions and for editing the
manuscript.
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Corrections
MEDICAL SCIENCES. For the article ‘‘Linkage disequilibrium
in human populations,’’ by Christine Lonjou, Weihua Zhang,
Andrew Collins, William J. Tapper, Eiram Elahi, Nikolas
Maniatis, and Newton E. Morton, which appeared in issue 10,
May 13, 2003, of Proc. Natl. Acad. Sci. USA (100, 6069–6074;
First Published April 29, 2003; 10.1073pnas.1031521100), due
to a printer’s error, the last three column headings in Table 5
incorrectly contained dashes in ‘‘European-Asian,’’ ‘‘African-
American-Yoruban,’’ and ‘‘African-Eurasian’’ instead of the
necessary minus signs. The corrected table appears below.
Table 5. Weighted difference estimates  standard errors: Samples with cosmopolitan maps
Estimated Parameter European  Asian
African-American
 Yoruban African  Eurasian
 estimated  0.001  0.043 0.162  0.053 0.638  0.046
, M estimated  0.005  0.048 0.110  0.052 0.418  0.052
, M estimated ln M 0.002  0.006 0.026  0.011 0.130  0.013
www.pnas.orgcgidoi10.1073pnas.1432848100
MEDICAL SCIENCES. For the article ‘‘Normal viability and altered
pharmacokinetics in mice lacking mdr1-type (drug-transporting)
P-glycoproteins,’’ by Alfred H. Schinkel, Ulrich Mayer, Els
Wagenaar, Carla A. A. M. Mol, Liesbeth van Deemter, Jaap
J. M. Smit, Martin A. van der Valk, Arie C. Voordouw, Hergen
Spits, Olaf van Tellingen, J. Mark J. M. Zijlmans, Willem E.
Fibbe, and Piet Borst, which appeared in issue 8, April 15, 1997,
of Proc. Natl. Acad. Sci. USA (94, 4028–4033), the authors note
the following correction. Fig. 1, and the first few lines of the
Materials and Methods and Results sections, indicate that during
gene disruption, exons 3 and 4 of the Mdr1b gene were deleted.
However, there is an error in the map of the Mdr1b gene: exon
3 is positioned upstream (not downstream) of the first indicated
NcoI site. As a consequence, only exon 4 of Mdr1b was deleted,
and not exons 3 and 4. For the validity of the Mdr1b and
Mdr1a1b knockout mouse strains, this error has no conse-
quences: deletion of exon 4 alone still results in a frameshift and
still removes the first transmembrane segment plus some flank-
ing sequences in Mdr1b. The absence of Mdr1b at the protein
and functional level in the knockout mice also remains well
documented. This correction, therefore, does not affect the
conclusions of the paper.
www.pnas.orgcgidoi10.1073pnas.1332736100
NEUROSCIENCE. For the article ‘‘Transplanted bone marrow gen-
erates new neurons in human brains,’’ by E´va Mezey, Sharon
Key, Georgia Vogelsang, Ildiko Szalayova, G. David Lange, and
Barbara Crain, which appeared in issue 3, February 4, 2003, of
Proc. Natl. Acad. Sci. USA (100, 1364–1369; First Published
January 21, 2003; 10.1073pnas.0336479100), the lettering in the
Fig. 2 legend is incorrect. The corrected legend should read:
‘‘Fig. 2. Neuronal markers colocalize with the Y chromosome.
Fluorescent microscopic images of neocortex from patients 2
(B, D, and F) and 3 (C) and hippocampus from patients 1 (A)
and 3 (E). The green color represents the immunostaining for
neuronal markers Kv2.1 (A–D) and NeuN (E and F), and the red
color represents the Y chromosome. All cell nuclei are stained
with 4,6-diamidino-2-phenylindole, a blue fluorescent chromo-
somal marker. All images are overlays of the images seen
through the three separate filters. Arrows point to cells that are
labeled with neuronal markers and are also Y chromosome-
positive. In the Kv2.1 immunostaining, the initial axons of some
neurons can also be visualized. (Scale bars  10 m.)’’
www.pnas.orgcgidoi10.1073pnas.1332662100
8036–8037  PNAS  June 24, 2003  vol. 100  no. 13 www.pnas.org
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BIOCHEMISTRY. For the article ‘‘Crystal structure of a photoactive
yellow protein from a sensor histidine kinase: Conformational
variability and signal transduction,’’ by Sudarshan Rajagopal
and Keith Moffat, which appeared in issue 4, February 18, 2003,
of Proc. Natl. Acad. Sci. USA (100, 1649–1654; First Published
January 31, 2003; 10.1073pnas.0336353100), the authors note
that part of Fig. 1B was incorrectly labeled as a  helix. It should
have been labeled as a 3–10 helix. This correction does not affect
the conclusions of the article. The corrected figure and its legend
appear below.
Fig. 1. Crystal structure of Ppr-PYP. (A) A simulated annealing composite
omit map at 2.0 level of the1–2 turn of chain B. (B) Chain B of Ppr-PYP with
secondary structure labeled according to ref. 20.
www.pnas.orgcgidoi10.1073pnas.1432896100
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HEMATOPOIESIS AND STEM CELLS
The combination of granulocyte colony-stimulating factor and stem cell factor
significantly increases the number of bone marrow–derived endothelial cells in
brains of mice following cerebral ischemia
*Zsuzsanna E. Toth,1 *Ronen R. Leker,2 *Tal Shahar,2 Sandra Pastorino,3 Ildiko Szalayova,1 Brook Asemenew,1
Sharon Key,1 Alissa Parmelee,1 Balazs Mayer,1 Krisztian Nemeth,1 Andras Bratincsa´k,4 and E´ va Mezey1
1National Institute of Dental and Craniofacial Research, Bethesda, MD; 2National Institute of Neurological Disorders and Stroke, Bethesda, MD; 3National
Cancer Institute, Bethesda, MD; and 4National Institute of Mental Health, National Insitutes of Health, Bethesda, MD
Granulocyte colony-stimulating factor
(G-CSF) induces proliferation of bone
marrow–derived cells. G-CSF is neuropro-
tective after experimental brain injury, but
the mechanisms involved remain unclear.
Stem cell factor (SCF) is a cytokine impor-
tant for the survival and differentiation of
hematopoietic stem cells. Its receptor (c-
kit or CD117) is present in some endothe-
lial cells. We aimed to determine whether
the combination of G-CSF/SCF induces
angiogenesis in the central nervous sys-
tem by promoting entry of endothelial
precursors into the injured brain and
causing them to proliferate there. We
induced permanent middle cerebral ar-
tery occlusion in female mice that
previously underwent sex-mismatched
bone marrow transplantation from en-
hanced green fluorescent protein (EGFP)–
expressing mice. G-CSF/SCF treatment
reduced infarct volumes by more than 50%
and resulted in a 1.5-fold increase in vessel
formation in mice with stroke, a large per-
centage of which contain endothelial cells
of bone marrow origin. Most cells entering
the brain maintained their bone marrow iden-
tity and did not transdifferentiate into neural
cells. G-CSF/SCF treatment also led to a
2-fold increase in the number of newborn
cells in the ischemic hemisphere. These
findings suggest that G-CSF/SCF treatment
might help recovery through induction of
bone marrow–derived angiogenesis, thus
improving neuronal survival and functional
outcome. (Blood. 2008;111:5544-5552)
Introduction
Granulocyte colony-stimulating factor (G-CSF) was identified
more than 2 decades ago,1 and was found to mobilize hematopoi-
etic bone marrow cells to the systemic circulation. Although G-CSF
has been used in many patients to counter the side effects of chemo-
therapy as well as to prepare donors for peripheral cell harvesting, some
concerns regarding its long-term safety still remain.2-4 G-CSF may have
several beneficial effects in animals with stroke.5,6 Thus, it was reported
that rats treated with G-CSF following middle cerebral artery occlusion
(MCAO) have smaller infarcts and better functional outcome compared
with controls.5,7-9 The molecular basis of these neuroprotective
effects has not yet been fully determined, but signaling through the
JAK-STAT and PI3K-Akt pathways leading to a reduction in
proapoptotic factors, and an increase in antiapoptotic factors was
suggested to play an important role.10 Furthermore, it was shown
that rats that received transplants of G-CSF–mobilized peripheral
blood precursor cells (PBPCs) demonstrated a significant improve-
ment in functional recovery following permanent MCAO
(PMCAO).11 Moreover, G-CSF reportedly has an important role in
inducing neurogenesis in the brain.12 Combinations of G-CSF and
stem cell factor (SCF) may further increase the positive effects of
G-CSF by augmenting tyrosine kinase–related downstream effects
and increasing prosurvival signals.10
Lee and colleagues13 found that G-CSF treatment increased
angiogenesis after focal cerebral ischemia. However, the origin of
these newly formed blood vessels remains unclear. Thus, they may
arise from in situ proliferation of existing endothelial cells in the
central nervous system (CNS), or they might originate from bone
marrow–derived endothelial precursor cells (BMDECs) that home
to the brain. Because G-CSF in combination with SCF mobilizes
BMDECs from bone marrow, we used enhanced green fluorescent
protein (EGFP) chimeric animals that underwent PMCAO to see if
G-CSF/SCF treatment might induce angiogenesis from BMDECs
and whether this combination would have beneficial effects on
functional outcome.
Methods
Preparation of the mice and surgery
All experiments were approved by the institutional animal care and use
committee and were conducted according to National Institutes of Health
(NIH) guidelines. Female 4- to 6-week-old C57B mice were subjected to
irradiation (2  4.5 Gy [450 rad] 6 hours apart) to deplete their own bone
marrow (BM), and then were given transplants of BM14 generated from
male mice that ubiquitously express GFP (with the exception of erythro-
cytes) and kept in a sterile environment for 10 days. After recovery, they
were subjected to PMCAO as described before.15 This model results in
cortical injury limited to the frontal and parietal cortex and spares the
subcortical structures. Mice received vehicle or a combination of 200 g/kg
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G-CSF and 50 g/kg SCF per day intraperitoneally, respectively (Pepro-
tech, Rocky Hill, NJ), to increase the number of circulating bone marrow
stem cells (BMSCs) for 5 days following the surgery. All mice were given
BrdU (50 mg/kg twice daily intraperitoneally; Roche Applied Sciences,
Indianapolis, IN) to follow cell proliferation on days 1 to 5 after PMCAO.
Infarct size determination
At 60 days after stroke, serial sections of the forebrains of the mice studied
(n  7 per group) were cut at 200-m intervals. The sections were stained
with toluidine blue and photographed using a DM16000 Leica inverted
fluorescence microscope (Wetzlar, Germany), and the hemispheres were
traced using Image J software (NIH, Bethesda, MD). Because the cortical
stroke tissue had already liquefied and disappeared by the time of death, the
infarct volume was calculated as the difference between the sizes of the
2 hemispheres multiplied by the distance between the sections.
Immunohistochemistry
Mice were perfused at different time points (2 to 6 months after surgery)
using 4% paraformaldehyde through the ascending aorta. Following
perfusion, the brains were taken out and processed using cryoprotection
achieved by increasing concentration of sucrose. The brains were then
frozen on dry ice, and serial sections were cut at a 10-m thickness and
mounted on positively charged microscope slides. The slides were kept
at 80°C until used. Immunohistochemistry was performed to visualize
GFP as well as other markers. For photography, all sections were freshly
mounted with 0.01 M Tris-HCI buffer (pH 7.8).
The perfused sections were washed in phosphate-buffered saline (PBS)
3 times for 3 minutes, microwaved for antigen retrieval when needed in
10 mM citric acid buffer (pH 6.1) for 5 minutes after the liquid started to
boil, and then cooled at room temperature (RT) for 30 minutes. Following
pretreatment, the sections were blocked with Universal Blocking Reagent
(Biogenex, San Ramon, CA) for 10 minutes. The primary antibody was
applied according to Table 1, diluted in 1% bovine serum albumin (BSA)
containing 0.25% Triton-X 100 and followed by blocking endogenous
peroxidase activity using 3% H2O2 for 15 minutes. In case of a double
staining with a second tyramide amplification step, we added 0.5%
sodium-azide to the H2O2 solution in order to block the horseradish
peroxidase (HRP) still present from the first staining. The secondary
antibodies were anti-rabbit HRP polymer conjugate (Zymed-Invitrogen,
Carlsbad, CA) applied for 30 minutes, biotinylated donkey anti–chicken
IgY or goat Ig-G (Jackson ImmunoResearch, West Grove, PA) at 1:1000 for
1 hour, and HRP-conjugated anti–rat IgG (Jackson ImmunoResearch) at
1:500 overnight. The AlexaFluor or FITC-conjugated tyramides were
homemade and used in ratios of 1:2000 or 1:20 000, respectively. When
antibodies were derived from the same host, we used a microwave
treatment step to eliminate any nonspecific cross reaction.16 Controls were
performed with no primary antibodies.
Y chromosome hybridization
To further confirm the origin of the GFP in a few animals, we colocalized
Y chromosome in the same cells as GFP as follows: sections were washed
in PBS (pH: 7.4) 3 times for 3 minutes, rinsed in distilled water, and
incubated in universal blocking reagent for 10 minutes. The sections were
then incubated in rabbit anti-GFP antibody (Molecular Probes-Invitrogen,
Carlsbad, CA) for 1 hour at room temperature. The endogenous peroxidase
activity was blocked with a 3% hydrogen peroxide, and following PBS
washes, the secondary antibody—an anti-rabbit HRP polymer conjugate—
was applied undiluted for 30 minutes. The staining was then visualized
using FITC-conjugated tyramide at 1:10 000 for 10 minutes at RT. To
perform Y chromosomal fluorescence in situ hybridization (FISH), the
same sections were immersed in 10 mM citric acid (pH 6.1) and
microwaved in a kitchen microwave (700 W; GE, Louisville, KY) for
2  5 minutes at 50% power after the liquid started to boil. The water that
evaporated was replaced with distilled water between and after the
microwaving sessions, and the sections were left in the solution to cool for
2 hours at RT. Microwave treatment inactivates any HRP activity that is
present in the tissue (ie, endogenous HRP and/or HRP incorporated in
reagents used in previous steps).16 The Y chromosomal hybridization was
performed as described earlier14 using a 1.5-kb RNA probe (pY3531B)
generated against a repeat sequence of the mouse Y chromosome that was
labeled with digoxigenin using a labeling kit (Roche Applied Sciences).
After the hybridization step and several washes in salt sodium citrate (for
details, see http://intramural.nimh.nih.gov/lcmr/snge/), the digoxigenin was
detected with an antidigoxigenin antibody that was conjugated to HRP
(1:600; Roche Applied Sciences) and visualized using the TSA-Plus
CY3 System (1:600; Invitrogen, Carlsbad, CA). Determination of
colocalization of the Y chromosome with GFP was performed by counting
the cells manually on 3 different sections per animal, 5 animals per
group, and by 2 independent people using a DMI6000 Leica inverted
fluorescence microscope.
Vascular density analysis
To determine the percentage of area surface of vessels, an alkaline
phosphatase reaction was performed using BCIP/NBT substrates (Roche
Applied Sciences). The stained sections were scanned and photographed
using the motorized stage and brightfield illumination. For colocalization
studies between GFP, CD31, the Y chromosome, and BRDU, the immuno-
stained sections were evaluated with a DMI6000 Leica inverted fluores-
cence microscope or a Leica TCS SP2 with AOBS and 2-Photon on an
upright Leica DM RE-7 confocal microscope. Conventional fluorescent
images were captured using the Volocity 4.01 software (Improvision;
PerkinElmer, Waltham, MA). Z-stacks were collected at 0.5-m intervals
using a motorized stage. After image capturing, iterative restoration was
performed at a 95% confidence level. The images were evaluated using the
NIH Image J software. The data were analyzed using analysis of variance
(ANOVA) and the Prism software (GraphPad, San Diego, CA).
In vitro endothelial cell proliferation assay
Mouse brain endothelial cells were acquired from ATCC (Manassas, VA)
and maintained in Dulbecco modified Eagle medium (DMEM) containing
10% fetal bovine serum (FBS) at 37°C, 5% CO2.17 Cells were plated in
96-well cell-culture plates, 3000 cells/well, in 150 L medium without FBS
Table 1. List of antibodies used
Antigen Source (catalog no.) Host Dilution Pretreatment Incubation Detection
GFP Molecular Probes/Invitrogen (11122) Rabbit 1:40000 — 1 h at RT anti–rabbit HRP, FITC-Tyr
GFP Chemicon/Millipore, Billerica, MA (AB16901) Chicken 1:5000 — 1 h at RT anti–chicken biotin, ABC, FITC-Tyr
GFP Abcam, Cambridge, MA (Ab290) Rabbit 1:10000 — 1 h at RT anti–rabbit HRP, FITC-Tyr
VWF Novocastra, Newcastle Upon Tyne, United Kingdom
(NCL-VWFp)
Rabbit 1:500 Microwave Overnight at 4°C anti–rabbit HRP, A594-Tyr
CD31 PharMingen, San Diego, CA, (550274) Rat 1:200 — Overnight at 4°C anti–rat A594, -rat A647
VE-cadherin Santa Cruz Biotechnology, Santa Cruz, CA (Sc-6458) Goat 1:100 — Overnight at 4°C anti–goat biotin, SA-A594
Iba1 WAKO, Richmond, VA (019-19741) Rabbit 1:1000 — 1 h at RT anti–rabbit HRP, A594-Tyr
BrdU Accurate, Westbury, NY (OBT0030) Rat 1:200 Microwave Overnight at 4°C anti–rat HRP, A350-Tyr
A350, A594, A647 indicate AlexaFluor dyes; ABC, avidin-biotin complex (Vector Laboratories, Burlingame, CA); TYR, tyramide conjugate; VWF, von Willebrand factor; and
—, none.
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or growth factors. After 24 hours, different concentrations of G-CSF and
SCF were added to the medium together with BrdU (1:1000 dilution of
BrdU; final dilution, 1:4000). The plates were then placed into a normal
(37°C, 5% CO2) or hypoxic (37°C, 5% CO2, 1% O2) incubator for 24 hours.
The cell proliferation assay was performed according to the manufacturer’s
instructions (catalog no. 11647229001; Roche Applied Sciences). Control
experiments included cells cultured without the growth factors. The
experiment was done twice with triplicate samples.
Results
Infarct volumes
Injury size was measured 60 days after PMCAO. Lesion size was
significantly smaller (P .012) in animals treated with G-CSF/SCF
(11.3 2.5 mm3) as compared with controls (25.1 3.7 mm3; Figure 1).
G-CSF/SCF increases influx of GFP cells into the injured brain
In animals that underwent PMCAO but did not receive G-CSF/
SCF that were killed at 2 months, we observed a 2.4 fold
increase in the number of GFP cells (Figure 2A,C,E) in the
ischemic hemisphere compared with the nonischemic hemi-
sphere (343  24.7 vs 140  31; P  .05, n  4). Most of these
cells expressed the microglial marker Iba1 (data not shown).
Stimulation of peripheral stem cells using a combination of
G-CSF and SCF after PMCAO resulted in a significant,
3.75-fold increase in the number of GFP cells in the ischemic
hemisphere as compared with the controls (Figure 2B,D,E). In
the G-CSF/SCF–stimulated mice, the number of GFP cells in
the ischemic side were 1288 plus or minus 272 versus 229.8 plus
or minus 54.2 in the nonischemic side (P  .01, n  4; Figure
2E). To ensure that cells expressing GFP originate from donor
BM, we used FISH to determine the presence of a Y chromo-
some in the GFP cells (Figure 3 and Figure S1, available on the
Blood website; see the Supplemental Materials link at the top of
the online article).18 The present findings confirmed our previ-
ously published results18 that about 10% of cells expressing the
Y chromosome were not positive for GFP (even when signal
amplification was used), suggesting that when using only GFP
as a marker we significantly underestimate the percentage of
brain cells originating from the donor BM. This may be due to
silencing of the GFP expression during neural differentiation. At
2 months after the injury, many of the GFP cells coexpressed
Iba1, suggesting that the early influx of BM-derived cells
consists of mainly inflammatory cells. At this time point we
could identify occasional GFP cells that colocalized with
neuronal markers such as NeuN and rare cells that coexpressed
GFP and the glial marker GFAP (not shown).
G-CSF/SCF increases cell proliferation in the ischemic brain
Cell proliferation was studied with BrdU immunostaining at
60 days after PMCAO (n  4 in each group). Following
PMCAO, BrdU cells were significantly more abundant in the
ischemic hemisphere (140  27 vs 30  5; P  .002; Figure
2F). The number of proliferating cells significantly increased
following G-CSF/SCF treatment in both hemispheres, but a
much larger increase was noted on the ischemic side (358  64
vs 68  15.5; P  .001). Overall, G-CSF/SCF treatment re-
sulted in a 2.5-fold increase in the absolute number of BrdU
cells in the ischemic side. When we tried to colocalize GFP with
BrdU, we found less than 1% of GFP cells that were double
labeled; most of these were endothelial cells based on their
location, nuclear morphology, and their elongated endothelial-
like shape. Specifically, at this time point we could not identify
any cells that coexpressed GFP, BrdU, and neuronal markers,
and only very rare cells that coexpressed GFP, BrdU, and GFAP.
Most of the BRDU cells were astrocytes or microglial or
endothelial cells. These results suggest that most BM-derived
cells failed to proliferate in the brain for long periods of time
and that most of those that did proliferate maintained a BM fate.
However, because G-CSF/SCF treatment did increase the num-
ber of BrdU-expressing cells, it presumably did increase
endogenous neurogenesis in the brain.
G-CSF/SCF increases angiogenesis in the injured brain
Alkaline phosphatase staining of vascular endothelium was
performed on all brains at the level of the bregma plus 0.5 mm
(n  4 in the G-CSF/SCF and n  3 in the control groups,
respectively). Blood vessel density was also counted in naive
mice and in mice that did not undergo PMCAO but received
G-CSF/SCF. Ischemic and nonischemic hemispheres were com-
pared in PMCAO mice that received G-CSF/SCF or vehicle. As
shown in Figure 4A-C, we found that vessels occupy 3% plus
0.1% of the surface area in naive mice. In control animals that
did not suffer from stroke, but received G-CSF/SCF, the surface
area occupied by vascular endothelium increases slightly
(3.9%  0.2%). In ischemic animals in the ischemic hemi-
sphere, the area occupied by blood vessels increased signifi-
cantly (4.8%  0.3%) and there was a further, statistically
significant (P  .001) increase in PMCAO mice that also
received G-CSF/SCF (6.7%  0.45%; Figure 4). Overall, we
observed a 2.23-fold increase in the number of blood vessels in
ischemic animals treated with G-CSF/SCF compared with naive
animals. Interestingly, G-CSF/SCF also significantly increased
blood vessel density in the nonischemic hemisphere.
Figure 1. Infarct volumes in vehicle and G-CSF/SCF–treated mice. Columnar
graph showing the infarct volume in millimeters cubed in the brains of the saline-
treated versus GSCF-treated mice. Values are means plus SEM. **P .01.
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Figure 2. GFP expression and proliferation at
2 months following PMCAO. (A) Coronal section of a
vehicle-treated brain at 2 months after PMCAO at the
level of the lesion. GFP-immunopositive cells were
visualized using amplified immunostaining. (B) Similar
level in the brain like in panel A from a mouse that
received daily injection of G-CSF/SCF for 5 consecu-
tive days following the stroke. (C,D) Magnifications of
the boxed areas in panels A and B, respectively. Note
the significantly higher number of green fluorescent
cells in the G-CSF/SCF–treated animal’s brain. Horizon-
tal side of box equals 500 m (A,B) and 125 m (C,D).
Panels A,B: objective, 10; numeric aperture, 0.3, Plan
Fluo. (E) Columnar graph showing the mean number of
GFP- and (F) BRDU-immunopositive cells in the sec-
tions of the saline-treated versus G-CSF–treated mice
in both hemispheres.
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Figure 3. Demonstration of the technique of colocalization of the GFP and the Y chromosome in a female brain at 2 months after PMCAO. Y chromosome
hybridization was performed in sex-mismatched GFP BM-transplanted mice brains. (A) Presence of the Y chromosomes in red (Alexa-594); green fluorescence indicates the
presence of the GFP, and blue fluorescence labels cell nuclei based on DAPI, a chromosomal stain. The section is one level of a Z-series demonstrating that the Y chromosome
is localized in the same cells that are also GFP (side panels). (B) Cross-section of a capillary (*) of a Z-series depicting several luminally localized GFP cells that are also positive for the
Y chromosome (red dots). The inset (C) shows another example, where the side panel of the confocal image illustrates that the Y chromosome and the GFP colocalize in a cell that borders
the vascular lumen (*). Objective, 40; numeric aperture, 0.6 (A); and objective, 20; numeric aperture, 0.7 (B). Scale bar equals 16m.
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Newly formed blood vessels at the infarct border originate from
BM endothelial precursors
We used GFP- and endothelium-specific immunostaining in the
same sections to see if endothelial cells and precursors in newly
formed blood vessels derive from BM. We chose 3 markers that are
generally accepted to be specific for vascular endothelium: von
Willebrand factor, CD31 (PECAM1), and VE-cadherin. GFP
immunostaining was amplified to ensure visualization of cells that
express the marker protein at very low levels. We found that many
endothelial cells in the immediate infarct vicinity expressed GFP.
In the untreated ischemic animals GFP endothelial cells were
identified in both hemispheres with a frequency of 0.1% and 0.08%
of all endothelial surface for the nonischemic versus ischemic
hemisphere, respectively. In G-CSF/SCF–treated mice there was a
robust increase of new GFP endothelial cells compared with the
saline-treated cells that was more significant on the side of the
stroke than in the control side (0.35% 0.07% vs 0.22% 0.05%;
P  .008; Figures 4D-F; S3). The colocalization of CD31 (Figures
5A-C; S2), von Willebrand factor (Figure 5D,E), and VE-cadherin
(Figure 5F) and BRDU (Figures S4; 5G) with GFP was demon-
strated using confocal Z-stacks (at 0.5-m intervals) and iterative
restoration. Except for occasional rare cells, we could not detect
GFP endothelial cells in control chimeric animals that did not
experience stroke with or without G-CSF/SCF treatment.
Figure 4. G-CSF/SCF treatment increases angiogen-
esis and many of the new endothelial cells are of
donor BM origin. Vascular density is demonstrated in
untreated (A) and G-CSF/SCF–treated (B) mice after
stroke (➝). The insets are high-magnification represen-
tative images of coronal sections from similar rostro-
caudal levels of the brains. (C) Columnar graph show-
ing the percentage of the surface area occupied by
vessels based on alkaline phosphatase staining in the
sections of the saline-treated versus G-CSF/SCF–
treated mice in both hemispheres. Vascular density is
demonstrated in untreated (D) and G-CSF/SCF–
treated (E) mice after stroke. The vascular endothelial
cells are immunostained for CD31 (red fluorescence
due to Alexa-594), and the GFP cells are immuno-
stained in green following signal amplification using
FITC-tyramide. For panels A,B,D,E: objective, 10;
numeric aperture, 0.3, Plan Fluo. Note the increased
density of vessels as well as more green vascular
structures in the G-CSF/SCF–treated brain. (F) The
columnar graph demonstrates the percentage of GFP
(ie, BM-derived; green) cell surfaces compared with all
(red) endothelial (CD31-stained) surfaces in the saline-
treated versus G-CS/SCF–treated mice brains in both
hemispheres (n  4). Values are means plus SEM.
**P  .01. CC indicates corpus callosum; v, lateral
ventricle.
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SCF induces proliferation of cerebral vascular endothelium
in vitro
Our in vitro data show that SCF induces endothelial proliferation at
concentrations between 5 and 100 ng/mL, while G-CSF seems to
have no direct effect on proliferation (Figure 6). When the cells are
grown in a hypoxic environment, the proliferative effect of SCF is
significantly enhanced. The combination of SCF/G-CSF has the
same effect as SCF alone.
Discussion
The current study identifies BM-derived cells as a major source of
poststroke angiogenesis in the brain. The number of newly formed
blood vessels increased 2.2-fold when we applied G-CSF/SCF after
PMCAO. To ensure that newly formed blood vessels did originate
from BMDECs, we used BM from GFP-expressing male donors
that engrafted into the BM of recipient female mice prior to
PMCAO. We then identified donor marrow cells as expressing GFP
and the Y chromosome. Using this system, we could isolate newly
formed blood vessels originating from BMDECs from those
derived from the brain’s resident endothelial cell population.
Our results show that most newly formed blood vessels in the
infarct vicinity were composed of GFP/Y cells, indicating their
BM origin. Given the fact that not all Y cells expressed
GFP—probably due to silencing of the transgene related with
progressive differentiation—it is highly likely that our results
based on GFP expression in newly formed blood vessels are an
Figure 5. Cells of BM origin populate the vascular endothelium in
mice with PMCAO treated with G-CSF/SCF. (A-C) Images from
Z-stacks, where sections from G-CSF/SCF–treated PMCAO mice were
immunostained with CD31, a specific marker of vascular endothelium,
and GFP to track the bone marrow origin. The side panels demonstrate
the colocalization of the 2 markers (endothelial marker and GFP) in
several cells of the vascular wall. (D,E) demonstrates colocalization of
GFP with the von Willebrand factor in vascular endothelium shown in
red. (F) One level of a Z-series with side panels demonstrating that a
GFP cell lining the lumen of a capillary (*) is also labeled with red dots
representing the antibody staining for VE-cadherin, another specific
endothelial cell marker. (G) Colocalization of BRDU (red dots over
labeled nuclei) with GFP in a luminal cell lining a capillary (*). Arrow
points to the colocalization of the red and green in the main panel as well
as in the side panels. Arrows point to BRDU nuclei that do not belong to
GFP cells. The images are a single level taken out of a Z-series, where
the section was optically sliced into 0.5-m–thin sections and iterative
restoration was perfomed using Volocity 4.0 software. Objective, 40;
numeric aperture, 0.6 (A-E); and objective, 63; numeric aperture, 0.7
(F). Scale bar equals 25 m (A-C), 10 m (D-F), and 16 m (G).
Figure 6. Proliferative effect of G-CSF, SCF, and its
combination on murine cerebral endothelial cells in
vitro. A mouse brain endothelial cell line (b.end3) was
used in the experiment. Following a 24-hour incubation
of the cells with the factors at different concentrations
(values are mean nanograms per milliliter media) and
BRDU, the proliferation rate was calculated based on
optical density (OD) measurements. represents pro-
liferation at normoxic conditions; f shows proliferation
rate in hypoxic conditions. Controls received no
factors but BRDU. G-CSF seems to be ineffective in
the concentrations used, while SCF has a dose-
dependent, significant proliferative effect, starting at
5 ng/mL. Combining the 2 factors results in prolifera-
tion rates similar to that of SCF alone. Hypoxic
conditions seem to further increase the effectiveness
of SCF. Values are means plus SD.
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underestimate of the true contribution of BMDECs to angiogenesis
in the injured brain.
Our results corroborate previous reports that found increased
recruitment of BM-derived cells to the brain following injury and
those that found G-CSF to augment this process.19,20 However,
while others focused on the short-term effects of this recruitment
we waited for 2 months prior to analysis of the effects. This allowed
us to avoid the early phase in which most recruited cells represent
inflammatory cells and focus on angiogenesis, which takes a longer
time to accomplish. In contrast to work reported earlier, in our
studies we treated animals with a combination of G-CSF/SCF. This
results in a 2-fold increase in circulating CD34cells21 versus
treatment with G-CSF alone. Both G-CSF and SCF are known to
stimulate the survival, proliferation, and differentiation of BM
cells, including endothelial cells.21-27 Our results suggest that while
G-CSF is important in recruiting cells from the BM into the
circulation, SCF might be responsible for the proliferation of
vascular endothelial cells, many of which are derived from the
donor BM. The in vitro data also suggest that hypoxia, which is
found in ischemic tissue, significantly enhances the proliferative
effect exhibited by SCF. This may be due to an increased
expression of endothelial c-kit receptors under hypoxic conditions.
The finding of BRDU and GFP double-positive cells (ie, proliferat-
ing endothelial cells of BM origin) among the lining of cerebral
vasculature in ischemic areas suggest that our in vitro observations
may indeed be important in vivo as well.
Our current set of results argues against transdifferentiation of
BM-derived cells into neurons as an important mechanism to
functional improvement in stroke.28,29 Thus, despite a major
increase in the influx of GFP BM-derived cells into the injured
brain with G-CSF/SCF, we could only identify isolated astrocytes
in the brain that coexpressed GFP and almost no GFP neurons. In
contrast, most BM-derived GFP cells in the brain retained their
BM fate and represented either microglia, which were most
prevalent in the early poststroke period, or endothelial cells, which
were the prevalent GFP cell type at 2 months after stroke.
However, we cannot rule out a more significant contribution of
BM-derived neurogenesis in other circumstances.14,30,31
Importantly, G-CSF reduces infarct volumes in injury models
by activation of antiapoptotic and anti-inflammatory mecha-
nisms.19,32 A neuroprotective effect for G-CSF/SCF was also
identified in the current experiment, lending further validity to our
results. G-CSF treatment in stroke animals also results in greater
improvements in neurologic deficits. Our data suggest that G-CSF/
SCF–driven angiogenesis is likely another mechanism that could
contribute to functional gains after stroke by improving metabo-
lism and function of surviving cells in the peri-infarct area.
Furthermore, given the increase in BrdU cells that were not of BM
origin following G-CSF/SCF therapy, it is also likely that stimula-
tion of endogenous neurogenesis is another mechanism that could
improve functional outcome after stroke.
In conclusion, the combination of G-CSF/SCF may have
synergistic beneficial effects both on lesion size and on angiogen-
esis. G-CSF/SCF–driven angiogenesis results from G-CSF–
induced recruitment of BM-derived cells into the ischemic brain,
and SCF might facilitate the proliferation and survival of endothe-
lial cells. Most of the BM-derived cells maintain their BM identity
and do not appear to significantly transdifferentiate into neural
cells. These angiogenic and neuroprotective effects translate into
better functional outcome after stroke and should promote future
clinical studies in humans to study the efficacy of this therapeutic
avenue in stroke victims.
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ABSTRACT
The uterine endometrium is composed of epithelial and
stromal cells, which undergo extensive degeneration and
regeneration in every estrous cycle, and dramatic changes
occur during pregnancy. The high turnover of cells re-
quires a correspondingly high level of cell division by
progenitor cells in the uterus, but the character and
source of these cells remain obscure. In the present study,
using a novel transgenic mouse, we showed that CD45-
positive hematopoietic progenitor cells colonize the uter-
ine epithelium and that in pregnancy more than 80% of
the epithelium can derive from these cells. Since we also
found green fluorescent protein (GFP)-positive uterine
endothelial cells in long-term GFP bone marrow-trans-
planted mice, we conclude that circulating CD45 cells
play an important role in regenerating the uterine epithe-
lium. STEM CELLS 2007;25:2820 –2826
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
The lining of the uterus goes through extensive regeneration
during the cycle and in pregnancy [1, 2]. Tanaka et al. studied
the clonality of endometrium and demonstrated that individual
uterine endometrial glands consist of monoclonal populations of
epithelial cells [3]. Their findings indicated that single or mul-
tiple as yet unidentified stem cells with uniform clonality exist
on the bottom of each endometrial gland [3]. Several investiga-
tors have used bone marrow (BM) transplants to show that bone
marrow-derived stem cells can repopulate a variety of organs in
irradiated hosts [4–7]. The existence of a uterine endometrial
stem cell has been proposed, but its character, origin, and exact
anatomical location have proven elusive [8]. Recently, Taylor
showed that transplanted bone marrow cells give rise to uterine
epithelial cells in humans [9]. Taylor’s patients were exposed to
full body irradiation and chemotherapy before they received BM
transplants [9]; thus, the physiological significance of his find-
ing, as well as the nature of the BM-derived cells that entered
the uterus and differentiated there, could not be determined.
Recently, Du and Taylor demonstrated in lethally irradiated
mice that transplanted full bone marrow gives rise to endome-
trial tissue, including epithelium, and suggested that BM mes-
enchymal cells might be responsible for the phenomenon [10].
On the basis of these data and a recent article demonstrating the
presence of hematopoietic stem cells and lymphoid progenitors
in endometrial biopsies in women [11], we asked the following
questions: Do BM cells contribute to the uterine epithelium in
healthy animals? If they do, what kind of BM cells populate the
tissue? How extensive is their contribution? To answer these
questions, we first injected green fluorescent protein (GFP)-
tagged BM cells [12] into lethally irradiated female C57BL/6J
mice and confirmed the fact that uterine epithelial cells can
indeed arise from BM. We then created a transgenic mouse
model to determine whether CD45 cells might contribute to
the epithelium.
MATERIALS AND METHODS
Bone Marrow Transplantation Studies
Allogenic bone marrow transplantation was used to detect progeny
of GFP BM-derived cells. Briefly, C57BL/6J mice (n  6) re-
ceived whole-body irradiation (900 rad) and were transplanted
intravenously 2 hours after irradiation with 106 bone marrow cells
harvested from a GFP mouse (C57BL/6-Tg [ACTB-EGFP]
1Osb/J, 003291; Jackson Laboratory, Bar Harbor, ME, http://www.
jax.org). At later time points, transplanted animals were sacrificed
and tissues harvested as described above.
Transgenic Mouse Studies
To determine whether CD45 cell progeny contribute to the repopu-
lation of the uterine epithelium under physiological conditions, we
generated a novel transgenic mouse. First, we introduced Cre re-
combinase cDNA into a bacterial artificial chromosome (BAC)
containing the complete mouse CD45 gene (Fig. 1A). The recom-
binase cDNA was inserted downstream of an internal ribosomal
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301-435-5635; Fax: 301-496-1339; e-mail: mezeye@mail.nih.gov Received April 24, 2007; accepted for publication July 20, 2007; first
published online in STEM CELLS EXPRESS July 26, 2007; available online without subscription through the open access option. ©AlphaMed
Press 1066-5099/2007/$30.00/0 doi: 10.1634/stemcells.2007-0301
TISSUE-SPECIFIC STEM CELLS
STEMCELLS 2007;25:2820–2826 www.StemCells.com
               dc_219_11
entry site (IRES), which in turn was placed downstream of the last
coding exon of CD45. The resulting BAC was used to make
transgenic mice (CD45/Cre). In such mice, Cre recombinase is
produced in any cell that expresses CD45. First-generation het-
erozygous mice carrying the Cre transgene were bred. These CD45/
Cre animals were then bred with Z/EG double reporter mice [13].
The latter express lacZ ubiquitously during embryonic development
and adulthood. In the presence of Cre recombinase, the lacZ gene
and the transcriptional stop following it are excised (Fig. 1B),
activating the expression of a second reporter, enhanced green
fluorescent protein (EGFP) (Fig. 1D). Only first-generation Cre
transgenics were used because the transgene is prone to rearrange-
ment. Thus, in subsequent generations, ectopic expression, even
ubiquitous expression, can be seen (unpublished observations).
Construction of Recombination Cassette
The recombination cassette was constructed by cloning the IRES-
Cre-frt-pgk/em7/Neo/bpA-frt expression cassette from p459 (a gift
from Neal G. Copeland) with two flanking polymerase chain reac-
tion (PCR)-amplified recombination fragments (A and B) into the
pBC KS shuttle vector (Invitrogen, Carlsbad, CA, http://www.
invitrogen.com). Fragments A (263 base pairs [bp]: 3,305–3,567;
GenBank accession number nm_011210) and B (319 bp: 3,568–
3,886; from nm_011210) were designed to flank the insertion site
for the expression cassette upstream of the stop codon at the 3 end
of exon 33 of the CD45 gene (Fig. 1A). The plasmid was introduced
into Escherichia coli using heat shock, single ampicillin-resistant
colonies were selected and propagated, and the plasmid was isolated
by mini-prep and linearized for homologous recombination.
Homologous Recombination
BAC 131H7 (RPCI-23 mouse BAC library; Invitrogen) was used
for these studies. This BAC is approximately 190,000 bp long.
There are approximately 30,000 bp of DNA 5 to the first exon of
CD45 and 50,000 bp 3 to the last exon. The recombination cassette
was inserted to the BAC by homologous recombination [14] (Fig.
1A). Briefly, the BAC was electroporated into E. coli EL250, which
hosts a temperature-inducible  prophage that facilitates recombi-
nation. BAC-containing bacteria were incubated at 42°C for 15
minutes and transformed with the linearized recombination cassette
by means of electroporation. Double-resistant (kanamycin-chloram-
phenicol) colonies were selected and propagated, and the recombi-
nant BAC was isolated using a NucleoBond BAC Maxi Kit (BD
Biosciences, San Diego, http://www.bdbiosciences.com). Homolo-
gous recombination was confirmed by enzymatic digestion, PCR,
and DNA sequencing (Fig. 1A).
Production of Double-Transgenic Mice
Recombined BAC DNA was microinjected into C57BL/6J zygotes
that were implanted into estrogen-primed foster mothers, and trans-
genic founders were selected by PCR using the following primers
amplifying Cre: 5-ccggtcgatgcaacgagtgatgagg-3 and 5-gcgttaatg-
gctaatcgccatcttcc-3. The resulting CD45/Cre mice were bred with
C57BL/6J mice. Subsequently, CD45/Cre offspring were bred with
heterozygous Z/EG double reporter mice (Jackson Laboratory) that
express GFP upon Cre-mediated recombination, and their offspring
were screened by PCR for Cre using the primers described above
and for GFP (5-gggcgatgccacctacggcaagctgaccct-3 and 5-ccgtc-
ctccttgaagtcgatgcccttcagc-3) (Fig. 1B). Double-transgenic (CD45/
Cre-Z/EG) animals were selected and used for the studies reported.
The majority of nucleated cells in the blood of the double-transgenic
mice produced from all four founder lines were GFP, and their
progeny seemed GFP as well (Fig. 1C–1F). Thus, although we did
not study this extensively, we observed no line-to-line variation, and
we have no evidence that the site of integration of the recombinant
BAC affected Cre expression.
Animal Procedures
Animal care and procedures were approved by the Animal Care and
Use Committee of National Institute of Mental Health, NIH. Dou-
ble-transgenic (CD45/Cre-Z/EG) animals were anesthetized, sacri-
ficed by perfusion, and examined at different ages: 18-day-old
embryos (n  2), 3-day-old pups (n  2), 6-week-old young adult
(n  1), 12-week-old adults (n  2), 12-week-old pregnant animals
Figure 1. GFP is expressed in CD45 cells of the double-transgenic
(CD45/Cre-Z/EG) mice. (A): Upon homologous recombination, the IRES-
Cre recombination cassette flanked by two homologous fragments (A and
B) was inserted into exon 33 of the CD45 gene in a BAC containing the
entire coding region. The recombinant construct was confirmed to be
correct by restriction mapping, PCR with primers flanking the recombina-
tion fragments, and sequencing. (B): To track the fate of CD45 cells, we
created a double-transgenic strain by breeding CD45/Cre mice with the
double-reporter Z/EG mice. In the crossbred mice, every CD45 cell
expresses the Cre recombinase that will excise the floxed lacZ cassette, thus
enabling the activation of GFP. Regardless of the future fate of CD45
cells, GFP will be expressed continuously throughout their life spans. (C):
Fluorescence-activated cell sorting of peripheral blood of a double-trans-
genic animal demonstrating a high percentage (85%) of double-positive
blood cells using green fluorescence for GFP and red for CD45. (D–F):
White blood cells immunostained with GFP (green) (D), CD45 (red) (E),
and an overlay of (D) and (E) with added 4,6-diamidino-2-phenylindole
(nuclear-blue) staining (F). Scale bar  15 m. Abbreviations: BAC,
bacterial artificial chromosome; bp, base pairs; EGFP, enhanced green
fluorescent protein; GFP, green fluorescent protein; IRES, internal ribo-
somal entry site; PCR, polymerase chain reaction.
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(n  2), and 20-week-old adult (n  1). Tissues were fixed by
transcardiac perfusion or immersion (used for fixing embryos) with
Zamboni solution, harvested, and processed for immunostaining.
Immunohistochemistry
Perfused tissues were cryoprotected by immersion in 20% sucrose
solution and frozen. Twelve-m-thick sections were cut at 24°C
in a Leica cryostat (Heerbrugg, Switzerland, http://www.leica.com),
thaw-mounted, and stained using the following reagents: 1:1,000
anti-GFP antibody (A11122; Molecular Probes Inc., Eugene, OR,
http://probes.invitrogen.com) followed by 1:1,000 Alexa-488 con-
jugated anti-rabbit antibody (A31565; Molecular Probes), 1:100
anti-CD45 antibody (ab3088-100; Abcam, Cambridge, MA, http://
www.abcam.com) followed by 1:1,000 Alexa-594-conjugated anti-
rat antibody (A11007; Molecular Probes), 1:20,000 4,6-diamidino-
2-phenylindole (DAPI) (D1306; Molecular Probes), and 1:200
biotinylated Lotus tetragonolobus lectin (B-1325; Vector Laborato-
ries, Burlingame, CA, http://www.vectorlabs.com) followed by
1:1,000 Alexa-594-conjugated streptavidin (S11227; Molecular
Probes) or 1:1,000 horseradish-peroxidase-conjugated streptavidin
and 1:10,000 Alexa-350-conjugated tyramide (T20937; Molecular
Probes). As a second marker, we also used a wide-spectrum cyto-
keratin antibody (MU-131-UC; BioGenex, San Ramon, CA, http://
www.biogenex.com) at a 1:200 dilution followed by an anti-mouse
IgG conjugated to Alexa-594 (1:1,000) to confirm the characteriza-
tion of epithelial cells. GFP immunostaining was confirmed by a
second anti-GFP antibody (1:2,000; AB16901; Chemicon, Te-
mecula, CA, http://www.chemicon.com) that detects a different
epitope of GFP and showed results identical to those described
before (data not shown). Control immunohistochemistry stainings
were performed using secondary antibodies after omitting the pri-
mary antibodies. Detailed controls and variations of GFP stainings
are described in Toth et al. [15]. Random areas of sections were
photographed at low magnification, and epithelial cells (approxi-
mately 500–1,000 per animal) were counted by two independent
investigators. The number of GFP-positive cells was expressed as a
percentage of all epithelial nuclei based on DAPI and Lotus stain-
ing.
In Situ Hybridization Histochemistry
Radiographic in situ hybridization was performed on 12-m fixed
sections as described before (http://intramural.nimh.nih.gov/lcmr/
snge/Protocol.html). The primers that included a T7 and a T3
polymerase site were constructed to generate a template comple-
mentary to the GFP mRNA between nucleotides 1,524 and 1,823
(accession no. AB234879). This template was then transcribed
using the Ambion (Austin, TX, http://www.ambion.com) Maxis-
cript transcription kit (catalog number 1324) following the manu-
facturer’s instructions. After hybridization, the slides were dipped
into autoradiographic emulsion (Nuclear Track Emulsion B; Kodak,
Rochester, NY, http://www.kodak.com) and developed 2 weeks
later. A Giemsa background staining was applied, and the slides
were dried and coverslipped. The sections were viewed with a Leica
DMI6000 inverted microscope, and images were captured using
Volocity software (PerkinElmer Life and Analytical Sciences, Bos-
ton, http://www.perkinelmer.com).
Fluorescence In Situ Hybridization in Combination
with GFP Immunostaining
The STARFISH kit (catalog no. 1597-KD-50; Cambio, Cambridge,
U.K., http://www.cambio.co.uk) was used to detect the X chromo-
some in 6-m thin sections of uterine epithelium from fixed mouse
sections. This allowed us to determine whether GFP cells were the
products of cell-fusion events. Following microwave-induced anti-
gen retrieval, GFP immunostaining was performed as described
above. Then the sections were dehydrated and stained according to
the Cambio protocol. A Cy3-labeled chromosomal paint probe was
used for final visualization. Random areas of eight sections of
uterine epithelium from one of the pregnant mice were chosen, and
865 cell nuclei were examined, focusing throughout the whole
thickness of the section to count the number of X chromosomes per
nuclei. Of these nuclei, 240 belonged to GFP-positive epithelium,
and we found no evidence of fusion; that is, we did not see any
nondividing nucleus with four X chromosomes. In fact, all the
nuclei that were uncut in the sections exhibited two X chromo-
somes.
Flow Cytometry
After preincubation with anti-mouse CD16/32 (Caltag Laboratories,
Burlingame, CA, http://www.caltag.com) to block the Fc receptor,
peripheral blood mononuclear cells were stained with the anti-
mouse CD45 R-phycoerythrin-conjugated antibody (catalog no.
MCD4504; Caltag). Rat R-phycoerythrin-conjugated IgG2b (Caltag)
was used as an isotype control. CD45 staining and EGFP direct
fluorescence were analyzed using a fluorescence-activated cell sorting
(FACS) flow cytometer (Becton, Dickinson and Company, San Jose,
CA, http://www.bd.com).
RESULTS
Analysis of Blood Cells in the CD45/Cre/Z/EG Mice
As expected, in adult CD45/Cre-Z/EG mice, CD45 cells, such
as lymphocytes, (Fig. 1D–1F) and the derivatives of CD45
cells, such as Kupfer cells and microglia (data not shown), were
GFP-positive. Most, but not all, of the white cells in blood that
could be stained with an anti-CD45 antibody were GFP. In
some cells, the fluorescent signal may have been too weak to
detect, or excision of the floxed lacZ cassette may not have
occurred because expression of the Cre recombinase was poor.
FACS analysis of peripheral blood showed that the majority
(65%–85% in several animals tested) of the CD45-positive
white blood cells of double-transgenic mice expressed GFP
(Fig. 1C).
Analysis of Uterine Histology in Long-Term
Irradiated and GFP Bone Marrow-Transplanted
Mice
Irradiated mice are known to keep on cycling, although the
length of the cycles may be more variable [16]. Eight to 12
months after we transplanted GFP-tagged bone marrow cells
(including hematopoietic, mesenchymal, and any other BM
stem cell populations) into six irradiated female mice, green
cells were detected in the uterine endometrial epithelium and
stroma of five of six animals (Fig. 2A, 2C). These bone marrow-
derived GFP epithelial cells bound L. tetragonolobus lectin, a
marker with affinity for glycoprotein on the luminal surface of
epithelial cells in the uterus [17]. The GFP epithelial (i.e.,
immunopositive for L. tetragonolobus [Fig. 2D, 2E]) cells did
not express the common leukocyte antigen CD45, but numerous
CD45/GFP cells were detected in the uterine stroma (Fig.
2A), which is known to harbor CD45 lymphoid cells [18].
Immunostaining using a pan-cytokeratin (cytokeratins [CKs] 8,
18, and 19) antibody also showed colocalization with GFP (Fig.
2B), further confirming the epithelial character of the GFP-
positive cells.
Analysis of Uterine Histology in the Virgin and
Pregnant CD45/Cre/Z/EG Mice
Resident macrophages and lymphocytes in the endometrial
stroma are known to express CD45 [18], and indeed, we saw
many CD45/GFP cells in the stroma of the transplanted
mice and of the CD45/Cre-Z/EG mice (Figs. 2A, 3B). We also
found GFP cells in the epithelial layer of the endometrium
(Figs. 2, 3A). Although these GFP cells could be stained with
L. tetragonolobus lectin (Figs. 2D, 2E, 3C, 3D) and with anti-
keratin-8, -18, and -19 antibody (Fig. 2B), another marker for
epithelial cells, they could not be stained with anti-CD45 anti-
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body (Figs. 2A, 3B). Expression of GFP mRNA was further
confirmed by in situ hybridization histochemistry (Fig. 3E, 3F).
Thus, CD45 cells appear to give rise to epithelial cells in the
uterus of nonirradiated transgenic animals.
To determine the rate at which CD45 cells contribute to
the uterine epithelium and the extent of this contribution, we
studied CD45/Cre-Z/EG animals at different ages. In mice, the
estrous cycle is 5–6 days long [16, 19]. In contrast to humans,
the epithelium does not shed, but it exhibits continuous degen-
eration and regeneration [20]. In the course of the cycle, epi-
thelial cells undergo vacuolar degeneration and apoptosis and
are replaced by newly generated cells [21]. The first cycle in
mice occurs at 4–6 weeks of age. Consequently, a 1-week-old
pup has not cycled yet, and 6-, 12-, and 20-week old animals
have gone through approximately 2, 10, and 26 cycles, respec-
tively. In the double-transgenic mice, we detected many
CD45/GFP cells in the uterine stroma (Fig. 4) at all ages
examined (1, 6, 12, and 20 weeks). Although no GFP epithe-
lial cells could be detected in the uterine epithelium in 1- and
6-week-old animals (Fig. 4A, 4B), 0.5% of the epithelial cells in
12-week-old mice and 6% in a 20-week-old animal were GFP
(Fig. 4C–4F). The GFP epithelial cells were found in patches,
suggesting that clonal expansion of individual progenitor cells
gave rise to islands of epithelial cells. Thus, although we did not
have enough animals at each time point to do a statistical
analysis, we think that the number of uterine epithelial cells
produced from CD45 precursors increases with age and is
related to the number of estrous cycles through which the
animals have passed.
During pregnancy, the uterus undergoes marked prolifera-
tion. The endometrial surface of the pregnant mouse is approx-
imately 25 times larger than that of a nonpregnant animal, and
we wondered whether CD45 cells might contribute to this
increase. We were surprised to find that in one pregnant CD45/
Cre-Z/EG mouse, the vast majority (82%) of uterine epithelial
cells were also GFP (Fig. 4G, 4H). Our observations indicate
that CD45 progenitors could be the source of most of the new
epithelial cells in the pregnant uterus. Based on double staining
of GFP and the X chromosome, these cells seem unlikely to be
the products of cell-fusion events, since they never contain more
than two X chromosomes (Fig. 5).
DISCUSSION
Eight to 12 months following the bone marrow transplantation
using GFP-positive BM, the GFP-positive cells were detected in
the endometrial epithelium and stroma of recipient animals.
Bone marrow-derived GFP cells bound L. tetragonolobus
lectin, which is an indicator of their epithelial nature. These
GFP epithelial cells, however, did not express the common
Figure 2. Endometrium of a mouse previously (10 months before)
transplanted with enhanced green fluorescence protein bone marrow
(BM) following irradiation. Green fluorescent protein (GFP) is
shown in green, CD45 (A) and L. tetragonolobus (C, D) in red, and
4,6-diamidino-2-phenylindole (DAPI), the nuclear marker, in blue. (A):
GFP and CD45 uterine epithelium in the recipient endometrium
shows that BM cells can contribute to the regeneration of uterine
epithelial cells. CD45/GFP hematopoietic cells are present in the
stromal layer. (B): Colocalization of a pan-cytokeratin immunostaining
(in red) with GFP (in green) in epithelial cells. The image shows one
level of a Z-stack in three-panel view. The stack was captured at 0.5-m
intervals, and iterative restoration was performed using Volocity 4.0
software (PerkinElmer) and a Leica DMI6000 inverted microscope.
(C–E): GFP-positive nucleated (DAPI staining) cells appeared in the
epithelial layer (C), colocalized with L. tetragonolobus, a uterine epi-
thelial marker (D). (E): Overlay of (C) and (D). Solid arrowheads
indicate GFP; open arrowheads indicate GFP uterine epithelial cells.
Scale bar in (A)  20 m (A) and 14 m (C–E).
Figure 3. Green fluorescent protein (GFP)-expressing uterine epithe-
lium of a double-transgenic (CD45/Cre-Z/EG) mouse. We observed
GFP-positive (green) epithelial cells in the uterus (A) that did not
express CD45 (red) (B) but bound the uterine epithelial marker L.
tetragonolobus (blue) (C). (D): Overlay of the three stainings (A–C).
(A–D): Solid arrowheads point to GFP/CD45 uterine epithelial cell;
open arrowheads indicate GFP/CD45 stromal cell. (E, F): Uterine
epithelium expressing GFP mRNA in bright-field (E) and dark-field (F)
illumination. Scale bar  20 m (A–D) and 50 m (E–F). Abbrevia-
tion: GFP, green fluorescent protein.
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leukocyte antigen CD45, whereas numerous CD45/GFP
cells were detected in the uterine stroma, which is known to
harbor CD45 lymphoid cells [18]. These findings clearly
demonstrate that upon transplantation, BM cells enter the uterus
and differentiate into epithelial cells there. The BM cells are
unlikely to have fused with uterine cells after colonizing the
organ because the GFP cells all appear to be diploid. BM cells
are heterogeneous, however, and transplantation of tagged cells
did not not allow us to determine which sort of BM cell might
give rise to the labeled epithelial cells in the recipient mice or
whether irradiating the animals affected what we observed.
CD45 is expressed in hematopoietic cells and their deriva-
tives [22] including muscle satellite cells [23]. As expected, in
the CD45/Cre-Z/EG mice, CD45 cells (such as lymphocytes
[Fig. 2D–2F]) and the derivatives of CD45 cells (such as
tissue resident macrophages, Kupfer cells, and microglia [data
not shown]) were GFP-positive. Most, but not all, white cells in
the blood that could be stained with an anti-CD45 antibody were
also GFP-positive.
To determine the rate at which CD45 cells contribute to
the uterine epithelium and the extent of this contribution, we
studied female CD45/Cre-Z/EG animals at different ages. The
number of uterine epithelial cells produced from CD45 pre-
cursors seemed to increase with time and correlate with the
number of estrous cycles through which the animals have
passed.
During pregnancy, endometrial surface of the rodent uterus
is approximately 25 times larger than that of a nonpregnant
animal, and this change happens in a very short time. We
wondered whether CD45 cells might contribute to this in-
crease and were surprised to find that in a pregnant CD45/Cre-
Z/EG mouse, the vast majority (82%) of uterine epithelial cells
were also GFP (Fig. 4G, 4H). Our observations indicate that
CD45 progenitors maybe the source of most of the new
epithelial cells in the pregnant uterus.
Stem cells residing in the uterus were thought to be respon-
sible for the expansion of epithelial cells that accompanies
pregnancy [24]. The nature of these stem cells, whether they are
replenished, and how replenishment might occur have been a
matter of speculation, but a population of “label-retaining”
putative stem cells (LRCs) has recently been observed in the
uterus [25, 26]. Chan reported that these LRCs are frequently
localized near vessels in the mouse endometrium [26]. Since our
results show that CD45 cells give rise to epithelial cells, we
suggest that circulating CD45 cells provide a renewable pool
of epithelial precursors in the uterus. The fact that Chan et al.
[24] did not detect CD45 in LRCs suggests that endometrial
stem cells turn the marker off after they select their fates.
Circulating hematopoietic stem or progenitor cells might
enter the stroma and, when they are needed, migrate toward the
lumen, where they could serve to regenerate the epithelium.
Alternatively, hematopoietic cells could colonize the stromal
layer during fetal life and reside there from birth onwards,
entering the epithelium on demand. CD45 was not thought to be
produced by cells other than hematopoietic stem cells and their
progeny [27], but recent work suggests that it may be made
transiently by oligodendrocyte precursors during development
Figure 4. Green fluorescent protein (GFP)-expressing (green) uterine
epithelial cells from double-transgenic animals of different ages and
pregnant mice. All nuclei were stained in blue with 4,6-diamidino-2-
phenylindole. (A, B): No GFP-positive (green) uterine epithelial (red
staining represents L. tetragonolobus, the epithelial marker) cells were
detected in 6-week-old animals. (C, D): Sporadic GFP-positive uterine
epithelial cells were present at 12 weeks of age. Arrow indicates a
GFP uterine epithelial cell. (E, F): At 20 weeks of age, 6% of uterine
epithelial cells expressed GFP. (G, H): In 12-week-old pregnant mice,
there was a robust increase in the number of GFP-expressing cells: 82%
of the uterine epithelial cells were GFP. Scale bars  60 m (left
column) and 20 m (right column).
Figure 5. Arrows point to nuclei (4,6-diamidino-2-phenylindole, blue)
of green fluorescent protein (GFP)-expressing (green) uterine epithelial
cells (A) from double-transgenic animals that have two X chromosomes
(red dots) (B). GFP was visualized with a tyramide-fluorescein isothio-
cyanate conjugate, whereas the X chromosome was labeled by a Cy3-
conjugated chromosomal paint probe. Scale bar  10 m.
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[28], and several groups have demonstrated that lung epithelial
cells might derive from hematopoietic stem cells in injury
models [29–31]. Uterine epithelial progenitors might also tran-
siently express CD45 and then turn it off before they differen-
tiate. Were this the case, their progeny would be GFP in the
double-transgenic mice that we generated, but given the lack of
GFP expression in the uterine epithelium during early postnatal
development and during the first several estrous cycles, it seems
unlikely that CD45 is activated in resident epithelial progenitors.
Alternatively, if the BAC-based expression of Cre recombinase
“leaks” briefly when the epithelial population expands, the cells
could turn green. Since all of CD45’s introns and long 5 and 3
flanking sequences are present in the BAC that we used (de-
scribed in Materials and Methods), and since several founder
animals gave similar results to those reported above, we feel that
leakiness is unlikely to have been a problem. Instead, we prefer
the hypothesis that circulating CD45 BM cells are responsible
for the phenomena that we observed. The fact that GFP-tagged
bone marrow cells transplanted into adult C57BL/6J mice gen-
erate patches of GFP uterine epithelium supports this hypoth-
esis.
We also observed GFP and GFP mRNA-positive uterine
epithelial cells from animals studied 8–12 months after they
underwent irradiation and transplantation with green bone mar-
row, suggesting that the colonization of the uterus by CD45-
expressing cells and their conversion into uterine epithelium can
take place after development is completed. Although whole-
body irradiation prior to BM transplantation affects fertility and
changes the length/number of estrus cycles in mice, uterine
function seems to remain quite intact, and turnover of the
epithelium does not stop [16]. This appears to be true in humans
too; in fact, women who have received myeloablative doses of
radiation can become pregnant and carry their fetus to term [32].
If BM progenitor cells do in fact contribute to the uterine
epithelium, it is possible that alterations in these cells might
result in clinical problems. For example, extramedullary hema-
topoiesis in the endometrium, although rare, is known to occur
[33] and could be caused by CD45 cells there. Furthermore,
we agree with Gargett [8] that endometriosis might be caused
by misplaced endometrial stem/progenitor cells, specifically
CD45 derivatives. Du and Taylor suggested in their recent
work that bone marrow-derived cells contribute to the endome-
trium in a mouse model of endometriosis [10]. This chronic,
painful condition results when endometrium-like tissue grows
on the uterus, ovaries, fallopian tubes, uterine ligaments, ab-
dominal lining, or lower part of the large intestine. In addition,
such tissue has been seen in the axillary glands, lung, retina,
sciatic nerve, skin, and even brain.
Like the endometrium, these ectopic growths respond to
hormones; they grow, swell with blood, and degenerate in a
cyclic manner. Since their breakdown products have no way to
exit the body, however, they cause severe menstrual, abdominal,
and lower back pain, and—in up to 40% of women suffering
from it—scarring and infertility. Endometriosis is thought to
have a genetic component; it is associated with autoimmune
diseases, and it can be induced in rhesus monkeys by treatment
with dioxin [34]. We feel that regardless of the abnormality
(genetic, immunological, or hormonal) that drives the process,
changes in CD45 BM-derived cells could cause them to
colonize sites other than the uterine lining and to differentiate
and proliferate once they are there. If this is the case, one
wonders whether the cells are conditioned in the endometrium
and subsequently escape and take up residence in other, nearby
tissues [35]. Alternatively, stem cells may occasionally make
inappropriate fate choices in tissues (e.g., lung or brain) where
they migrate via the blood. The fact that endometriosis has been
reported in males might seem to lend support to the second of
these suggestions; however, it appears that in some cases the
growths may arise in the prostatic utricle, a uterine remnant
found in men [36].
Clearly, it would be interesting to know whether CD45
cells are important for regenerating tissues other than the endo-
metrium and what cues are used to attract them into any given
organ and to drive their differentiation. The CD45/Cre-Z/EG
mouse strain may serve as a useful model for such studies.
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Summary
Background Adult bone marrow-derived (BMD) cells could be
used to repair damaged organs and tissues, but the intrinsic
plasticity of these cells has been questioned by results of in-
vitro studies suggesting that such cells might fuse with other
cells giving the appearance of differentiation. We aimed to
determine whether fusion events are important in vivo.
Methods To test whether BMD cells can colonise an epithelial
tissue and differentiate there without fusion, we did in-situ
hybridisation with Y and X chromosome probes labelled with
35-sulphur or digoxigenin, or labelled fluorescently. We did
immunohistochemistry with anticytokeratin 13 along with
fluorescence in-situ hybridisation to identify Y-chromosome
positive buccal epithelial cells in cheek scrapings obtained
from five females who had received either a bone-marrow
transplant or an allogeneic mobilised peripheral-blood
progenitor-cell transplant (enriched in CD34+ cells) from male
donors.
Findings When examined 4–6 years after male-to-female
marrow-cell transplantation, all female recipients had 
Y-chromosome-positive buccal cells (0·8–12·7%). In more
than 9700 cells studied, we detected only one XXXY-positive
cell (0·01%) and one XXY cell (0·01%), both of which could
have arisen when an XY cell fused with an XX cell.
Interpretation Male BMD cells migrate into the cheek and
differentiate into epithelial cells, an occurrence that does not
depend on fusion of BMD cells to recipient cells. This finding
might be an example of transdifferentiation of haemopoietic
or stromal progenitor cells. Plasticity of BMD cells could be
useful in regenerative medicine.
Lancet 2003; 361: 1084–88
Introduction
Evidence from studies in recipients of bone-marrow
transplants shows that bone marrow-derived (BMD) cells
can differentiate into cells other than blood. This
occurrence is of importance because such cells could be
used to regenerate organs after disease or trauma.1–5
However, the plasticity of BMD cells has been
questioned by results of studies suggesting that stem cells
might fuse with other cells and give the appearance of
differentiation.6,7 Furthermore, caution is needed in
interpretation of data purporting to show that non-
haemopoietic cells are derived from donor BMD cells.8–10
Tissues, especially when affected by graft-versus-host
disease (GVHD), might contain infiltrating donor
haemopoietic or lymphoid cells. In histological sections,
non-haemopoietic tissue cells might be confounded with
haemopoietic cells because of cell overlap (attributable to
the thickness of the sections) or loss of haemopoietic
lineage-specific markers. 
We aimed to establish whether BMD cells differentiate
into cells of another tissue lineage, and to assess whether
this event is attributable to fusion. To avoid
contamination of our samples by haemopoietic
inflammatory cells, we did our studies on healthy
transplant recipients without oral GVHD, several years
after bone-marrow transplantation.
Methods
Patients
Bone-marrow stem-cell transplant recipients residing
within the USA, who each had received an allogeneic
transplant from a male sibling donor through protocols
from the National Heart, Lung, and Blood Institute, were
invited to participate in the study. All those who agreed
to participate were well, in haematological remission,
with full donor lymphohaemopoietic engraftment and no
active oral GVHD. The transplants these patients had
received consisted of at least 3106 CD34+ cells/kg and a
total of 1107–3108 CD3+ lymphocytes/kg given within 
3 months of the stem cells. After the transplant, all
patients received only irradiated blood products. We also
recruited healthy volunteers as controls. This study was
approved by the Institutional Review Board of the
National Institute of Dental and Craniofacial Research
(NIDCR), National Institutes of Health (NIH).
Procedures
We obtained cheek scrapings from all women to look for
Y-chromosome-positive buccal epithelial cells. Study of
buccal cells has the advantage of providing a non-
invasively obtained, pure single-cell population of mature
nucleated cells with a characteristic morphology and
phenotype (anticytokeratin 13+). Cheek scrapings spread
on glass slides were independently examined by two
pathologists. We also gathered blood samples from these
women.
Differentiation of human bone marrow-derived cells into buccal
epithelial cells in vivo: a molecular analytical study 
Simon D Tran, Stanley R Pillemer, Amalia Dutra, A John Barrett, Michael J Brownstein, Sharon Key, Evgenia Pak, 
Rose Anne Leakan, Albert Kingman, Kenneth M Yamada, Bruce J Baum, Eva Mezey
National Institute of Dental and Craniofacial Research, Gene
Therapy and Therapeutics Branch (S D Tran DMD, S R Pillemer MD,
R A Leakan RN, B J Baum DMD); Craniofacial Developmental Biology
and Regeneration Branch (K M Yamada MD); Biostatistics Core 
(A Kingman PhD); National Human Genome Research Institute,
Cytogenetic Core (A Dutra PhD, E Pak MD); National Heart Lung and
Blood Institute, Hematology Branch (A J Barrett MD); National
Institute of Mental Health, Laboratory of Genetics
(M J Brownstein MD); National Institute of Neurological Disorders
and Stroke, Basic Neuroscience Programme (S Key BS,
E Mezey MD); National Institutes of Health, Bethesda, MD, USA
Correspondence to: Dr Simon Tran, National Institutes of
Health/NIDCR, 10 Center Drive, Room 1N113, MSC 1190,
Bethesda MD 20892-1190, USA 
(e-mail: stran@dir.nidcr.nih.gov)
               dc_219_11
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
the digoxigenin-labelled probe was visualised with a
peroxidase-conjugated antidigoxigenin antibody (Roche,
Indianapolis, IN, USA), followed by tyramide signal
amplification with the FITC-tyramide plus reagent (TSA
System, Perkin-Elmer, Boston, MA, USA). For
autoradiographic detection of the Y chromosome, we used
the method described elsewhere.12 For double-labelling of
cytokeratin and Y chromosome, buccal cells were fixed in a
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In situ hybridisation and immunohistochemistry
We did in-situ hybridisation as described,3 with a
digoxigenin-labelled riboprobe complementary to
nucleotides 729–2053 of the Y-chromosomal marker
DYZ1 (accession number X06228).11 We prepared the
template from human genomic DNA and produced a 1·3
kb riboprobe by T7 polymerase and either 35-sulphur-
labelled or digoxigenin-labelled UTP. After hybridisation,
Recipient
1 2 3 4 5
Characteristic
Age at transplant (years) 31 36 37 56 40
Reason for transplant CML MDS AML CML CML
Type of transplant BM PBPC PBPC PBPC BM
Chemotherapy/radiotherapy Yes/Yes Yes/Yes Yes/Yes Yes/No Yes/Yes
Time from transplant to buccal samples 5·2 4·5 4 4·2 6
(years)
History of pregnancy Never Never 1 daughter, 2 daughters, 1 son 2 daughters, 1 son, 
2 miscarriages 1 miscarriage
History of blood transfusion Never Yes Yes Never Never
AML=acute myelogenous leukaemia. BM=bone marrow transplant; CML=chronic myelogenous leukaemia; MDS=myelodysplastic syndrome; PBPC=peripheral-blood
progenitor-cell allogeneic transplant (granulocyte-colony stimulating factor mobilised).
Table 1: Characteristics of female transplant-recipients
Figure 1: In-situ hybridisation and immunohistochemistry in human buccal cells
(A) Y-chromosome autoradiography on a smear of buccal cells from recipient 3 is shown in brightfield. The arrows point to the autoradiographic grains
(black dots) above the nuclei of Y-chromosome containing cells. (B, C, D) Buccal cells from recipients 4, 2, and 3, respectively. The cells were first
immunostained for cytokeratin 13 (green), then hybridised in situ with a human Y-chromosome riboprobe (red fluorescent dots shown by the arrows). The
nuclei of the cells are stained blue with DAPI. (E, F, G, H) FISH with X-chromosome and Y-chromosome probes. Individual buccal cells are shown from a
healthy female control (E), a healthy male control (F), recipient 3 (G), and recipient 1 (H). The green fluorescent dot in the nucleus represents the X probe
and the red dot the Y probe hybridised to the appropriate regions of the sex chromosomes. The nuclei of the cells are stained blue with DAPI. The
cytoplasm of cells in panels E–H are autofluorescent. The scale bar represents 10 m in all panels, except 100 m for panel A. An RGB version of this
figure is available at http://image.thelancet.com/extras/02art10351webfigure.pdf.
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picric acid-aldehyde fixative for 15 min at room
temperature, and we did immunocytochemistry first with a
cytokeratin 13 antibody at a 1:1000 dilution (132M,
BioGenex, San Ramon, CA, USA) followed by tyramide
signal amplification (Perkin-Elmer). After immunostaining,
we processed the slides for fluorescence in-situ
hybridisation (FISH) and assessed them with a Leitz or
Zeiss fluorescence microscope.12
FISH with X and Y chromosome probes
We placed buccal cells in Carnoy’s fixative for 15 min at
room temperature. A mixture of two centromeric probes—
CEP X (alpha satellite DNA) labelled with spectrum green
and CEP Y (satellite III DNA) labelled with spectrum
orange (Vysis, Downers Grove, IL, USA)—was denatured
at 74ºC for 5 min and hybridised overnight at 37°C in a
humidified chamber. We did post-hybridisation washes at
45°C in 50% formamide and 2SSC for 15 min and
1SSC for 15 min. We counterstained slides with 250
mg/L DAPI (4,6-diamidino-2-phenylindole dihydrochlo-
ride) in mounting medium (Vectashield, Vector
Laboratories, Burlingame, CA, USA).
Genotyping
DNA was extracted from the cheek cells and donor blood
samples with PureGene reagents (Gentra, Minneapolis,
MN, USA). We obtained markers from Research
Genetics, amplified with TaqGold (Applied Biosystems,
Foster City, CA, USA) in accordance with the
manufacturer’s protocol, and analysed them on an ABI
3100 capillary sequencer. Allele sizing was done with
Genotyper software (version 2.5, Applied Biosystems).
Role of the funding source
The sponsor of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.
Results
Five females, 4–6 years after receiving a transplant from an
HLA-identical brother for leukaemia, agreed to participate
(table 1). Recipients 1, 2, 3, and 5 underwent a
myeloablative conditioning regimen consisting of 4 days of
total body irradiation (13·6 Gy) and 2 days of
cyclophosphamide 60 mg/kg. Recipient 4 received the same
dose of cyclophosphamide plus fludarabine 125 mg/m2 over
5 days. GVHD developed in four: acute grade 1 in recipient
1; chronic liver GVHD in recipient 3; extensive chronic
GVHD in recipient 4; and acute grade 4 in recipient 5.
Only recipient 3 had active GVHD at the time of testing.
Cheek scrapings from these five women consisted of
discrete epithelial cells without contamination by
mononuclear cells or macrophages. The S35-radiolabelled
Y-chromosome probe hybridised in situ with 97·7% of the
5354 buccal cells obtained from four healthy male
volunteers and none of the buccal cells obtained from ten
female volunteers (500–1000 buccal cells were counted
per female volunteer). Therefore, the sensitivity of the S35-
radiolabelled Y-chromosomal probe was 97·7% (95% CI
96·9–98·5) and the specificity was 100% (99·8–100). 
In the five transplant-recipients, frequency of Y-positive
nuclei in buccal epithelial cells ranged between 1·4% and
11% (mean 5·76; 95% CI 0·24–11·28; figure 1 A, and
table 2). Presence of male cells was confirmed in recipient
5 by DNA genotyping of the donor’s blood, the patient’s
buccal epithelial cells, and her son’s blood cells, with 
Y-chromosomal markers 289, 388, 390, and 391; none of
these markers gave products when female control DNA
was used as template (figure 2). On the other hand, 
patient 5’s donor’s blood and her own cheek samples
always had the same genotypes. The alleles for the above
markers were 148, 126, 211, and 287, respectively.
However, patient 5’s son had alleles 148, 126, 215, and
283. This finding shows that the patient’s Y-chromosome-
positive cheek cells could not have arisen by
microchimerism,13 and the fact that the genotypes of the
patient’s buccal cells and donor’s blood cells are identical
strongly suggests that the former arose from the graft. We
detected no Y-positive amplicons in untransplanted female
control samples, and no Y-positive buccal cells in ten
healthy control women who have sons. Combined staining
for the Y-chromosome by FISH and by histochemistry for
anticytokeratin 13 confirmed the presence of male buccal
epithelial cells (figure 1 B, C, and D). Cryopreserved
bone-marrow samples, available from the donors of
recipients 1 and 5, were negative for cytokeratin 13,
indicating no epithelial cells were present in the bone-
marrow transplant specimen.
We next used X and Y chromosomal FISH to search for
cell fusion. As controls we analysed 3693 female and 
1855 male buccal cells obtained from two female and two
male healthy volunteers (figure 1 E and F). The sensitivity
of detection of the Y-chromosome probe was 98·6% 
(95% CI 96·8–100) and the specificity was 100%
(99·9–100). The X-chromosome probe hybridised to two
X chromosomes in 99·0% of 3693 female control buccal
cells (sensitivity 99·0%; 95% CI 97·8–100). We analysed
between 1300 and 2800 cells per female transplant-
recipient. The overall frequency of Y-positive nuclei in
cheek scrapings of female transplant-recipients varied from
0·8 to 12·7% (mean 6·81; 95% CI 0·28–13·34; figure 1 G
and H, and table 2). Of 9748 cells examined from the five
transplant-recipients, one cell (0·01%) was XXXY and
one was XXY (0·01%).
Discussion
These results indicate that cells derived from marrow or
granulocyte-colony stimulating factor mobilised blood cells
migrate into the cheek and differentiate into epithelial
cells. These results might therefore represent transdif-
ferentiation of haemopoietic or stromal stem cells, or
transplantation of a hypothetical epithelial progenitor cell. 
Four criteria have been proposed to show plasticity of
adult stem cells.14,15 The first criterion states that cells
grafted should be clonal. Our study did not fulfil this
requirement because small populations of blood-derived or
Recipient
1 2 3 4 5
S35-radiolabelled Y probe
Number of nuclei examined 3907 747 2658 966 1285
Number of Y-positive nuclei (%) 194 (5·0%) 13 (1·7%) 293 (11·0%) 13 (1·4%) 125 (9·7%)
FISH with X and Y probes
Number of nuclei examined 1824 1779 1315 2853 1977
Number of Y-positive nuclei (%) 206 (11·3%) 42 (2·4%) 167 (12·7%) 23 (0·8%) 136 (6·9%)
Table 2: Detection of Y-chromosome-positive cells in cheek scrapings from female transplant-recipients
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The third criterion, which requires that the phenotype of
the transdifferentiated cells be shown anatomically,
molecularly, and functionally, is met: Y-chromosome
positive buccal cells were morphologically distinguishable
as buccal epithelial cells, and they expressed cytokeratin 13,
a recognised epithelial marker located in the superficial
buccal-cell layer of the cheek. Although the function of the
differentiated cells could not be verified, the buccal
mucosa of these individuals seemed unremarkable and
intact.
The fourth criterion is to report the frequency of the
transdifferentiation event. We noted that 0·8–12·7% of the
nuclei studied were Y-chromosome positive. This high
frequency of engraftment might be related to the rapid
turnover rate (every 7–10 days) of the oral mucosa. Buccal
epithelial cells obtained from cheek scrapings were
dispersed on a glass slide. Thus, we could not establish
whether the high frequency of transdifferentiation seen was
attributable to clonal expansion of epithelial stem cells or
ARTICLES
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marrow-derived cells other than the CD34+ selected
haemopoietic progenitors could have been transplanted.
Therefore, the Y-chromosome positive buccal epithelial
cells seen in our female transplant recipients could have
originated from male donor haemopoietic stem cells,
mesenchymal stem cells, or epithelial stem cells. Results of
many reports suggest that both haemopoietic stem cells
and mesenchymal stem cells can differentiate into
epithelial cells.5,16,17 However, results of some reports argue
against the possibility that haemopoietic stem cells can
differentiate into non-haemopoietic tissues.18 Epithelial
stem cells have not been described in the bone marrow,
nor was cytokeratin 13 detected in the bone marrow of two
male donors tested. 
The second criterion for plasticity of adult stem cells
requires that transplanted cells be prospectively isolated
and transplanted without in-vitro culturing. Our study
meets this criterion, since the sorted CD34+ fractions were
transplanted without any in-vitro culturing. 
Figure 2: DNA analysis
Blood from a non-transplanted female control, buccal cells from recipient 5, her donor’s blood, and her son’s blood, were analysed with four sets of 
Y-chromosome markers. X axis shows product length in bases, and Y axis shows signal strength.
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frequent transdifferentiation of individual graft-derived
cells. To answer this question, one would need to obtain
incisional biopsy specimens of the oral mucosa. Overall,
this study meets three of the four proposed criteria for
adult stem-cell plasticity.
A second important finding is that fusion between donor
and recipient cells was a rare occurrence in vivo, just as it is
in vitro.6,7 With one or two exceptions, the greater than
9700 differentiated buccal cells seen in this study showed
no evidence of fusion. Thus, differentiation was not
attributable to host and donor cell fusion. Although the
clinical implications of adult bone-marrow cell plasticity
are still unclear, focusing on non-fusion mechanisms by
which cell fate is ascertained in man is likely to benefit the
areas of cell therapy and regenerative medicine.
Contributors
S D Tran, S R Pillemer, B J Baum, and E Mezey wrote the protocol for
this clinical study. They were assisted in haematological consultation and
management by A J Barrett, in cell biology consultation by K M Yamada,
and in statistical consultation by A Kingman. A Dutra and E Pak provided
the FISH X/Y results. E Mezey and S Key provided the in-situ
hybridisation and immunohistochemistry results. M J Brownstein
provided the DNA genotyping results. R A Leakan managed and
coordinated the patients enrolled in this study. All authors were involved
in the preparation of this report and agreed to its final version.
Conflict of interest statement
None declared.
Acknowledgments
We thank Marc R Kok, Antony Voutetakis, and Jonathan M Bryant
(NIDCR), Ildiko Szalayova (NINDS), and Carol Markey (NIMH) for
technical assistance; Robert S Redman (Veterans’ Affairs Medical
Center), Ana P Cotrim (NIDCR), Andrea Abatti and David Kleiner
(NCI) for their expert advice in cytology; Peiman Hematti, Sheila Phang,
and Adeira Greene (NHLBI) for patients’ recruitment; Vidya Sankar
(NIDCR) for her expertise in oral medicine; and James S Hodges
(University of Minnesota) for statistical advice.
This research was supported solely by US government funding,
through allocations of the Department of Health and Human Services to
the National Institutes of Health Intramural Research Programmes for the
following Institutes: National Institute of Dental and Craniofacial
Research, National Human Genome Research Institute, National Heart
Lung and Blood Institute, National Institute of Mental Health, and the
National Institute of Neurological Disorders and Stroke. The views
expressed in this manuscript are those of the authors, and are not to be
construed as representing official viewpoints of the US government.
References
1 Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone
marrow-derived mesenchymal cells engraft and stimulate growth in
children with osteogenesis imperfecta: implications for cell therapy of
bone. Proc Natl Acad Sci USA 2002; 99: 8932–37.
2 Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability 
and therapeutic effects of bone marrow-derived mesenchymal 
cells in children with osteogenesis imperfecta. Nat Med 1999; 5:
309–13.
3 Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning
blood into brain: cells bearing neuronal antigens generated in vivo
from bone marrow. Science 2000; 290: 1779–82.
4 Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate
infarcted myocardium. Nature 2001; 410: 701–05.
5 Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of
mesenchymal stem cells derived from adult marrow. Nature 2002; 418:
41–49.
6 Terada N, Hamazaki T, Oka M, et al. Bone marrow cells adopt the
phenotype of other cells by spontaneous cell fusion. Nature 2002; 416:
542–45.
7 Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by
spontaneous fusion. Nature 2002; 416: 545–48.
8 Abkowitz JL. Can human hematopoietic stem cells become skin, gut,
or liver cells? N Engl J Med 2002; 346: 770–72.
9 Brouard M, Barrandon Y. Male cells in female recipients of
hematopoietic-cell transplants. N Engl J Med 2002; 347: 218–20.
10 Fogt F, Beyser KH, Poremba C, et al. Recipient-derived hepatocytes
in liver transplants: a rare event in sex-mismatched transplants.
Hepatology 2002; 36: 173–76.
11 Nakahori Y, Mitani K, Yamada M, Nakagome Y. A human 
Y-chromosome specific repeated DNA family (DYZ1) consists 
of a tandem array of pentanucleotides. Nucl Acids Res 1986; 14:
7569–80.
12 Laboratory of Cellular and Molecular Recognition, National Institute
of Mental Health. Section on Neural Gene Expression.
http://intramural.nimh.nih.gov/lcmr/snge/ (accessed Jan 24, 2003).
13 Nelson JL. Microchimerism: incidental byproduct of pregnancy 
or active participant in human health? Trends Mol Med 2002; 8:
109–13.
14 Anderson DJ, Gage FH, Weissman IL. Can stem cells cross lineage
boundaries? Nat Med 2001; 7: 393–95.
15 Wells WA. Is transdifferentiation in trouble? J Cell Biol 2002; 157:
15–18.
16 Clarke D, Frisen J. Differentiation potential of adult stem cells. 
Curr Opin Genet Dev 2001; 11: 575–80.
17 Verfaillie CM. Adult stem cells: assessing the case for pluripotency.
Trends Cell Biol 2002; 12: 502–08.
18 Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little
evidence for developmental plasticity of adult hematopoietic stem
cells. Science 2002; 297: 2256–59.
               dc_219_11
               dc_219_11From the
Canad
of Ve
Cell A
Heart
4Expe
Cente
Bethe
facial
Regen
7Macr
Financial d
Correspon
McGi
Room
simon
Received A
 2011 Am
1083-8791
doi:10.101Microchimerism in Salivary Glands after Blood- and
Marrow-Derived Stem Cell Transplantation
Simon D. Tran,1 Robert S. Redman,2 A. John Barrett,3 Steven Z. Pavletic,4 Sharon Key,5
Younan Liu,1 Ashley Carpenter,4 Hieu M. Nguyen,1 Yoshinori Sumita,1,6
Bruce J. Baum,5 Stanley R. Pillemer,7 Eva Mezey5Blood- andmarrow-derived stem cells (BMDSCs) provide disease-ameliorating effects for cardiovascular and
autoimmune diseases. Microchimerism from donor BMDSCs has been reported in several recipient tissues.
We hypothesized that this finding suggests a potential use of BMDSCs in the treatment of salivary dysfunc-
tions. We investigated the presence of Y chromosome-positive cells in salivary gland biopsies of 5 females
who had received a marrow or blood stem cell transplant from male donors. One to 16 years after trans-
plantation, all recipients exhibited scattered Y chromosome-positive cells in the acini, ducts, and stroma
of their salivary glands (mean of 1.01%). Potentially, these cells can be markers of transplantation tolerance,
contribute to neoplastic epithelial tissues, or engraft at sites of injury. In addition, transplantation of BMDSCs
could be used for treatment of Sj€ogren’s syndrome and salivary glands damaged by therapeutic irradiation for
cancers of the head and neck.
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Recent reviews suggest transplantation of blood-
and marrow-derived stem cells (BMDSCs) provide
disease-ameliorating effects for cardiovascular and
autoimmune diseases [1,2]. Microchimerism arising
from BMDSCs and organ transplantations has been
reported in a variety of recipient tissues (heart, liver,
kidney, gastrointestinal [GI] tract, lung, endometrium,
buccal epithelium) [3-12]. We hypothesized that this
phenomenon has implications for the potential use of
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6/j.bbmt.2010.09.021(eg, Sj€ogren’s syndrome and salivary glands damaged
by irradiation) for which no suitable conventional
treatments are currently available. Here we report, for
the first time, evidence of microchimerism resulting
from BMDSCs in salivary glands of recipients.METHODS
This study was approved by the institutional review
boards at McGill University, National Institutes of
Health, andVeteransAffairsMedicalCenter.Labial sal-
ivary gland tissue was collected from 5 female subjects
who had previously received either an allogeneic bone
marrow or peripheral blood stem cell transplant from
their brothers (Table 1).This gender-mismatched strat-
egy allowed us to detect donor Y chromosomes in cells
of the female-recipient salivary tissue. At the time of sal-
ivary gland biopsy, all patientswerewell, in hematologic
remission, with full donor lymphohematopoietic
engraftment. We chose to biopsy minor labial salivary
glands because they share abundant similarities with
the major salivary glands (ie, parotid, submandibular,
and sublingual glands), they are routinely used to obtain
information about all salivary tissue in patients with
Sj€ogren’s syndrome and they can be obtained with little
discomfort and morbidity compared to biopsies from
the major glands [13]. We performed colocalization
techniques to genetic and protein markers as we de-
scribed previously [10]. Using fluorescence microscopy429
Table 1. Characteristics of the Female Transplant Recipients
#1 #2 Recipient #3 #4 #5
Characteristic
Age at transplant (years) 31 36 37 52 28
Reason for transplant CML chronic phase MDS (RAEB) AML CR1 Aplastic anemia CML chronic phase
Type of transplant BM PBSC PBSC PBSC BM
Conditioning Cy 120
TBI 13 Gy
Cy 120
TBI 12 Gy
Cy 120
TBI 12 Gy
Cy 120, Flu 125,
ATG 120
Cy 120, AraC 500
TBI 5.5 Gy
Time from transplant to salivary gland biopsy 57 months 50 months 40 months 13 months 201 months
History of pregnancy Never Never 1 daughter
2 miscarriages
1 daughter
1 son
Never
History of blood transfusion Never Yes Yes Yes Yes
GVHD COP None Liver Skin, oral Skin, oral
Active at time of biopsy no — no yes yes
% of positive male cells in salivary gland 1.09% 0.95% 0.65% 0.92% 1.44%
% of positive male cells in buccal mucosa 11.3% 2.4% 12.7% n/a n/a
AML CR1 indicates acute myelogenous leukemia in first complete remission; AraC, Cytarabine 500 mg/m2; ATG, antithymocyte globulin 120 mg/kg; BM,
bone marrow transplant; CML, chronic myelogenous leukemia; COP, cryptogenic organizing pneumonia; Cy, Cyclophosphamide 120 mg/kg; Flu, Fludar-
abine 125 mg/m2; MDS (RAEB), myelodysplastic syndromewith excess of blasts; PBSC, peripheral blood stem cell transplant; TBI, total-body irradiation;
GVHD, graft-versus-host disease.
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               dc_219_11on 10-mm-thick frozen salivary tissue sections: (1) cells
from the male donors were identified using fluores-
cence in situ hybridization (FISH) using a human Y
chromosome probe conjugated with digoxigenin and
visualized with Tyramide-FITC, and in the same sec-
tions, (2) salivary epithelial cells were identified by the
presence of epithelial markers (cytokeratins; CK) using
fluorescence immunohistochemistry (FIHC). The CK
antibodies (BioGenex, San Ramon, CA) stain the sali-
vary gland parenchymal cellswhile leaving nonepithelial
cells (such as endothelial cells, stromal cells, and blood
cells) unstained. We further determined whether male
donor BMDSCs had fused with female recipient cells
using FISH with X and Y chromosomal probes (Vysis,
Downers Grove, IL). The sensitivity and specificity of
the Y and X chromosomal probes used was between
97% and 100% [10]. As negative and positive controls,
the DNA probes and antibodies were tested on labial
salivary glands of normal healthy male and female
volunteers.RESULTS AND DISCUSSION
One to 16 years after male-to-female BMDSC
transplantation, all 5 female recipients had Y chromo-
some-positive salivary cells (mean of 1.01%, range:
0.65%-1.44%) in the gland parenchymal tissue
(Table 1). Our Y chromosome probe used in FISH
has a false-positive rate between 0% to 0.2%, and
a false-negative rate between 1.5% to 3.1% (ie, we
were using aY chromosome probe that underestimated
the true frequency of Y chromosome-positive cells, but
was unlikely to overestimate it). These Y chromosome-
positive cells expressed CK-8, -9, -13, -18 (markers for
salivary cells) (Figure 1A-C). Many of these cells were
identified in each of the parenchymal components of
the glands, that is, acini and intercalated, striated, andexcretory ducts. We also used the following markers
to further characterize the phenotypes of the Y chro-
mosome-positive cells (Figure 1D-F): Na1
-K1-2Cl2 cotransporter (NKCC1, a marker for acini;
donated by R.J. Turner), claudin-1 (a tight junction
protein in salivary ducts; Zymed, San Francisco, CA),
and vonWillebrand factor IV (amarker for endothelial
cells; Novocastra, Newcastle, UK). Our salivary gland
specimens had few foci of lymphocytic infiltration.
However, in situations where these lymphocytic infil-
trations were detected by H&E staining in proximity
to salivary cells, we immunostained an additional slide
combining a hematopoietic lineage (CD45) marker, an
epithelial marker (NKCC1) and the Y chromosome
probe. This modification of the technique described
earlier [14] using different fluorescent colors, showed
scattered Y1/CD451 cells in the stroma, but these
were exceedingly rare in the epithelial structures
(Figure 1G). Therefore, we conclude that the vast
majority of the Y chromosome-positive cells in the
intercalated ducts and acini of our specimens were of
epithelial phenotype. Inmore than 1000 cells examined
per patient, we detected no XXXY-positive cells (no
cell fusion events).We previously reported in our stud-
ies of buccal epithelial cells in a female recipient that
DNA genotyping had excluded the possibility that all
observed Y chromosome-positive cells were trans-
ferred in utero by her son during pregnancy (a process
referred to as fetal microchimerism) [10].
Our results indicate that a small percentage (about
1%) of cells derived from marrow or granulocyte-
colony stimulating factor (G-CSF) mobilized blood
cells can migrate into the salivary glands. Higher rates
of microchimerism seem to occur in tissues with high
cell turnover rates and/or that are sites of frequent in-
juries, for example, buccal (oral) epithelial cells
(10%) [10], endometrial glands [12,15], skin
(20%) [16], and liver (25%; an organ exposed to
Figure 1. Labial salivary gland biopsies from female recipients of male BMDSCs. (A) Salivary cells are stained with the epithelial marker cytokeratin 13
(green). Y chromosome-positive cells (nuclei with red fluorescent dots, shown by the arrows) reside in an intercalated duct (left) and a striated duct
(right). (B, C) Cytokeratins 8, 18, 19 are shown in red. Y-positive cells (green) reside in epithelial cells (arrows) and stromal cells (arrowheads). Panel C
shows 3 planes restored from a Z-stack of sections taken at 0.5-mm intervals. The y and z dimensions are shown on the two sides of the x plane image and
demonstrate the presence of the Y chromosome (green) in the same plane with the cytokeratins (red) and the nuclei (DAPI, blue). Further character-
ization of the phenotypes of Y chromosome-positive cells using additional cell markers (shown in green) such as: (D) claudin-1 (a tight junction protein in
salivary ducts), (E) Na1-K1-2Cl2 cotransporter (NKCC1; a marker for acini), and (F) vonWillebrand factor IV (a marker for endothelial cells) indicate
several epithelial and endothelial cells that are Y chromosome-positive (arrows); other Y-positive cells (arrowheads) in or near the wall of this blood
vessel may be smooth muscle cells, fibroblasts, etc. (G) CD45 (a marker of the white blood cell lineage) in green (FITC); NKCC1 in yellow (CY5) and the
Y chromosome in red (Alexa-594). All nuclei are blue (DAPI). The two arrows point to 2 CD45-positive cells in proximity to salivary cells. The inter-
section of the 2 red lines in this panel indicates a salivary epithelial cell (NKCC1, yellow) of male donor origin (Y chromosome, red dot). Panels D-G
show 3 planes restored from a Z-stack of sections taken at 0.5-mm intervals. Scale bars equal 10 mm (A-C) and 16 mm in D-G.
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frequent chemical injuries) [7]. It is very interesting to
compare our previous results on buccal cells to the re-
sults presented in this article in the partially overlap-
ping patient population (3 out of the 5 patients were
the same in both studies). The comparison clearly
shows that tissues with high turnover rates (ie, the buc-
cal epithelium) might need to replace stem cells more
frequently during the life-span of the individual than
tissues with slow turnover rates (ie, salivary glands).
We found almost 10 times more differentiated epithe-
lial cells of donor origin in the oral mucosa than in sal-
ivary glands of the same patients (Table 1).
The physiological significance of finding micro-
chimerism in recipients’ tissues after donor BMDSCs
or organ transplantations is at present unclear. Ayala
et al. [17] suggest using donor chimerism as a marker
of transplantation tolerance that may help to tailor
immunosuppressive treatment. Other groups have
suggested that microchimerism might contribute to
the development of neoplastic epithelial tissues
[18,19]. However, this remains unresolved as there
are also data arguing against the possibility that
BMDSCs represent a direct source of carcinomas in
the recipients [20]. There are reports of better
BMDSC donor cell engraftment at sites with injury,
such as lung after radiation [6], GI inflammation
[21], and skin blistering [16]. Regarding the latter in-
jury, Wagner et al. [16] showed histologic evidence
of increased amounts of collagen type VII (C7) at the
dermal-epidermal junction of children with recessive
dystrophic epidermolysis bullosa, a genetic skin disor-
der caused by amutation in the C7 gene. They hypoth-
esized that donor BMDSCs mobilized to the skin
secreted C7, which resulted in reduced blistering and
increased clinical benefit for their patients. Of particu-
lar interest with the findings reported here are specific
injuries that occur to the salivary glands, such as from
therapeutic radiation for head and neck cancers and
autoimmune insults in Sj€ogren’s syndrome. These in-
juries (either radiation induced or immunologic) might
increase donor cell engraftment/microchimerism. A
more efficient delivery of BMDSCs into irradiation-
damaged salivary glandsmight be achieved via infusion
up the ductal tree [22]. For now, we demonstrate, as
a proof-of-concept, that donor cell microchimerism
can be identified in human salivary glands.ACKNOWLEDGMENTS
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Bone marrow stromal cells attenuate sepsis via
prostaglandin E2–dependent reprogramming of host
macrophages to increase their interleukin-10 production
Krisztia´n Ne´meth1,6, Asada Leelahavanichkul2,6, Peter S T Yuen2, Bala´zs Mayer1, Alissa Parmelee1, Kent Doi2,
Pamela G Robey1, Kantima Leelahavanichkul1, Beverly H Koller4, Jared M Brown5, Xuzhen Hu2, Ivett Jelinek3,
Robert A Star2,6 & E´va Mezey1,6
Sepsis causes over 200,000 deaths yearly in the US; better treatments are urgently needed. Administering bone marrow
stromal cells (BMSCs—also known as mesenchymal stem cells) to mice before or shortly after inducing sepsis by cecal
ligation and puncture reduced mortality and improved organ function. The beneficial effect of BMSCs was eliminated by
macrophage depletion or pretreatment with antibodies specific for interleukin-10 (IL-10) or IL-10 receptor. Monocytes
and/or macrophages from septic lungs made more IL-10 when prepared from mice treated with BMSCs versus untreated mice.
Lipopolysaccharide (LPS)-stimulated macrophages produced more IL-10 when cultured with BMSCs, but this effect was
eliminated if the BMSCs lacked the genes encoding Toll-like receptor 4, myeloid differentiation primary response gene-88, tumor
necrosis factor (TNF) receptor-1a or cyclooxygenase-2. Our results suggest that BMSCs (activated by LPS or TNF-a) reprogram
macrophages by releasing prostaglandin E2 that acts on the macrophages through the prostaglandin EP2 and EP4 receptors.
Because BMSCs have been successfully given to humans and can easily be cultured and might be used without human
leukocyte antigen matching, we suggest that cultured, banked human BMSCs may be effective in treating sepsis in high-risk
patient groups.
Sepsis, a serious medical condition that affects 18 million people per
year worldwide, is characterized by a generalized inflammatory state
caused by infection. Widespread activation of inflammation and
coagulation pathways progresses to multiple organ dysfunction,
collapse of the circulatory system (septic shock) and death. Because
as many people die of sepsis annually as from acute myocardial
infarction1, a new treatment regimen is desperately needed. In the
last few years, it has been discovered that BMSCs are potent mod-
ulators of immune responses2–5. We wondered whether such cells
could bring the immune response back into balance, thus attenuating
the underlying pathophysiology that eventually leads to severe sepsis,
septic shock and death6,7.
As a model of sepsis, we chose cecal ligation and puncture (CLP),
a procedure that has been used for more than two decades8.
This mouse model closely resembles the human disease: it has a
focal origin (cecum), is caused by multiple intestinal organisms,
and results in septicemia with release of bacterial toxins into the
circulation. With no treatment, the majority of the mice die
24–48 h postoperatively.
RESULTS
BMSC treatment improves survival and organ function after CLP
First, we looked at survival rates after CLP in untreated and BMSC-
treated mice. There was a statistically significant (Po 0.01) improve-
ment in the survival of mice given 1 million BMSCs intravenously at
the time of surgery; 50% of the mice survived until the end of day 4,
when all were killed (Fig. 1a). The beneficial effect on survival was
seen when the cells were injected 24 h before or 1 h after CLP
(Fig. 1a). In contrast, intravenous injection of isolated skin fibroblasts,
whole bone marrow or heat-killed BMSCs did not alter survival
(Fig. 1a). BMSCs isolated from different strains of mice (C57/BL6,
BALB/c or FVB/NJ) all rescued the C57/BL6 mice that we used in our
studies (Fig. 1a).
Because the lethality in sepsis is associated with organ failure, we
examined the pathology and function of major organs often injured in
human subjects. Kidney function, as measured by serum creatinine
and renal tubular injury scores, was markedly improved in the treated
mice (Fig. 1b). BMSCs reduced organ damage when they were
administered up to 24 h before CLP surgery (Supplementary Fig. 1
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online). In the livers, improved glycogen storage was observed in
treated mice versus control mice (Fig. 1c). Concentrations of liver
enzymes (alanine aminotransferase and aspartate aminotransferase)
that are released into the circulation upon injury and death of liver
cells were significantly decreased in the serum after treatment
(Fig. 1d), as were serum amylase values, which mirror pancreatic
damage (Fig. 1e). Similarly, there was a significant decrease in the
number of apoptotic (activated caspase-3–positive) and necrotic cells
in the spleen (Fig. 1f). These results suggest that BMSCs protect
infected mice from death and organ damage.
Effect of BMSCs on plasma cytokine concentrations
We hypothesized that BMSCs might alter the immune response to
infection; therefore, we studied TNF-a and IL-6, proinflammatory
cytokines that have a central role in sepsis1. Twenty-four hours
after injection of BMSCs, there was a signifi-
cant reduction in serum TNF-a and IL-6
concentrations in treated versus untreated
mice (Fig. 1g). Serum concentrations of
interferon-g were unaltered by BMSCs (Sup-
plementary Fig. 2 online), but IL-10 abun-
dance started to rise 3 h after the cells were
given, almost doubled by the sixth hour and
was still elevated 12 h afterward. (Fig. 1h).
To learn where injected BMSCs go and
how long they remain detectable, we pre-
labeled the cells with carboxyfluorescein
diacetate succinimidyl ester (CFDA-SE)
fluorescent tracking dye and visualized
them 1–24 h later. We found BMSCs in the
blood up to 1 h after intravenous injections
and saw many cells in the lung parenchyma,
with some in the spleen and kidney. The
labeled cells in the lung seemed to be sur-
rounded by macrophages (Fig. 2a–c). What
attracts these cells to each other remains to
be determined. The number of cells in the
lung gradually decreased over time; few were
visible 24 h after they were administered
(data not shown).
Alterations in vascular permeability are
central to the pathogenesis of sepsis-induced
organ injury, and the benefits of BMSC
treatment in reducing vascular permeability
have already been reported9–12. We studied
this in the peritoneum, lung, liver and kidney
by measuring Evans blue dye leakage 24 h
after CLP. CLP surgery significantly increased
peritoneal, liver and renal vascular perme-
ability (P o 0.01, P o 0.01 and P o 0.001,
respectively); all three were significantly
(P o 0.05, P o 0.05 and P o 0.05, respec-
tively) decreased in mice treated with BMSCs
(Supplementary Fig. 3 online).
Involvement of immune cell subtypes in
the effect of BMSCs
The observations summarized above sug-
gested that BMSCs might quickly act to
reprogram a specific population of cells
involved in mediating the immune response.
To test this hypothesis, we examined the effects of BMSCs in mice that
genetically lack mature T and B cells (Rag2–/–)13 or are depleted of
natural killer (NK) cells with a rabbit ganglio-N-tetraosylceramide
(asialo GM1)-specific antibody, resulting in nearly complete elimina-
tion of NK cell activity14,15. The effect of BMSC injections on the
survival of the mice was still present in both of these models,
suggesting that lymphocyte populations of T, B and NK cells do not
mediate the effect of BMSCs in the CLP model (Supplementary Fig. 4
online). Because BMSCs were found in close proximity to lung
macrophages, we asked whether monocytes and/or macrophages are
needed for the beneficial effects of the BMSCs. To deplete monocytes
and macrophages, we administered clodronate-filled liposomes to the
mice16 before we performed the CLP procedure and then treated them
with BMSCs. BMSCs were no longer effective in mice lacking mono-
cytes and macrophages (Fig. 2d).
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Figure 1 Effect of intravenous injection of BMSCs on the course of sepsis after CLP. (a) Survival curves
of mice after CLP and a variety of treatments using BMSCs from C57/BL6, FVB/NJ and BALB/c mice,
as well as C57/BL6-derived fibroblasts. (b) BMSC treatment effects on kidney function, as reflected by
serum concentration of creatinine (SCr). The number of mice in all measurements is as follows: sham,
n ¼ 5; CLP, n ¼ 13; CLP + BMSC, n ¼ 14. Tubular injury scores are shown at right. (c) Intense PAS
staining of hepatocytes is shown after sham operation and BMSC treatment. No staining can be seen in
CLP. After treatment (CLP + BMSC), the red staining by PAS in hepatocytes indicates partial glycogen
storage capacity. Scale bar, 20 mm. (d) Alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) concentrations in the liver after sham and BMSC, CLP or CLP and BMSC treatment. (e) Serum
amylase concentrations after sham and BMSC, CLP or CLP and BMSC treatment. (f) DAB staining of
caspase-3 cells in untreated spleen sections and BMSC-treated spleen sections. A quantitative
comparison between the numbers of apoptotic splenic cells in treated versus untreated mice (right)
shows a significant decrease with BMSC treatment. Scale bar, 100 mm. (g) Serum TNF-a and IL-6
concentrations after sham and BMSC, CLP or CLP and BMSC treatment. (h) Serum IL-10
concentrations at 3, 6 and 12 h after CLP. n ¼ 8–11 at each time point. Error bars represent
means ± s.e.m.; *P o 0.05; **P o 0.01.
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Macrophage-derived IL-10 is key for the effect of BMSCs
Because IL-10 serum levels were increased in CLP mice that were
treated with BMSCs as compared to sham controls, we asked whether
IL-10 might be important for the actions of BMSCs. To test this
hypothesis, we treated mice with an antibody to IL-10 or an antibody
to the IL-10 receptor before CLP. In both of these groups, the BMSC
injections were ineffective (Fig. 2e), suggesting that IL-10 is a major
mediator of the effect. To see whether the injected BMSCs might be
producing an essential pool of IL-10, we used BMSCs isolated from
Il10–/– mice. These BMSCs were still effective in improving the
survival of mice after CLP (Fig. 2f), suggesting that the source of
the IL-10 is an endogenous population of cells. Large amounts of
IL-10 are known to be produced by subsets of T cells and monocytes
and macrophages17. As mentioned earlier (Fig. 2d), monocyte and
consequent macrophage depletion eliminated the beneficial effect of
BMSCs; thus, we focused on monocytes and macrophages as the
probable source of IL-10 required for survival after CLP. BMSC
treatment resulted in a significant decrease in the number of circulat-
ing monocytes and an increase in the number of circulating neutro-
phils (Fig. 3a,b). Because tissue macrophages are derived from
circulating monocytes, we speculated that the decrease in monocyte
numbers might be due to their tissue invasion. We found a significant
increase in the number of lung monocytes and macrophages in CLP
versus unoperated mice by immunocytochemistry (data not shown).
This increase was completely eliminated when circulating monocytes
were depleted with clodronate-filled liposomes (Fig. 3c). To confirm
the histological findings, we used FACS to determine the relative
percentages of immune cells isolated from the lungs of four treated
versus four untreated septic mice. There was an increase in monocytes
but not lymphoid cells in the lung (Fig. 4a,b). Monocytes and
macrophages (CD11b+) were isolated from the lungs of BMSC-treated
and untreated mice18, placed in culture and restimulated with LPS.
Three and five hours after LPS stimulation ex vivo, monocytes and
macrophages from BMSC-treated septic mice produced and released
significantly more IL-10 than did untreated mice (Fig. 4c). To
determine whether the change in IL-10 production was due to direct
interaction between BMSCs and monocytes and macrophages, we
cultured the two cell populations together or placed them in a
transwell system in which two cell populations were separated from
one another by a permeable membrane. In addition, we put mono-
cytes and macrophages in BMSC-conditioned medium. When the©
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Figure 2 Fate of injected BMSCs and effect of BMSC treatment on survival
of normal and immune cell–depleted mice. (a–c) Immunohistochemical
staining showing that BMSCs prelabeled with Q-dot (red punctate staining;
a) travel to the lung (b) and take up residence in close proximity to
macrophages (c). The latter cells were immunostained with an antibody to
Iba1 (ionized calcium-binding adaptor molecule-1, a specific marker of the
macrophage lineage47) and visualized with Alexa-Fluor-488 conjugated to
a secondary antibody (green). Scale bar, 10 mm. (d–f) Summary of the
effectiveness of BMSC treatment of mice genetically lacking or depleted of
certain subsets of immune cells or soluble mediators. Survival curves show
survival percentage of macrophage-depleted mice with or without BMSC
treatment (d), survival percentage of BMSC-treated CLP mice and untreated
mice after neutralizing IL-10 or blocking the IL-10 receptor (e) and survival
percentage of after treatment with BMSCs derived from Il10–/– septic
mice (f). *P o 0.05.
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Figure 3 Effect of BMSC treatment on leukocyte trafficking. (a,b) The
average number of circulating monocytes (a) and the number of circulating
neutrophils (b) after BMSC treatment. The cell counts are the average of
data from five mice per group, 24 h after the induction of CLP. (c) The
average number of macrophages isolated from lungs of CLP mice with no
treatment, with BMSC treatment and BMSC treatment after depletion of
circulating monocytes using clodronate. The numbers of macrophages are
per random microscope visual field. Five mice were studied in each group.
The numbers in parentheses are the total number of fields in which
cells were counted. Error bars represent means ± s.e.m. **P o 0.01;
***P o 0.001.
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macrophages were in direct contact with BMSCs (Fig. 4d), they
produced significantly (P o 0.001) more IL-10 in response to LPS
stimulation than when they were cultured in transwell plates without
direct contact with the BMSCs or exposed to BMSC-conditioned
medium. We also used intracellular cytokine staining by FACS to
compare the number of IL-10–producing monocytes and macro-
phages isolated from treated versus untreated septic mice and found
a significantly higher number of IL-10–producing monocytes and
macrophages in the treated mice (Fig. 4e).
Because IL-10 has been reported to inhibit the rolling, adhesion19
and transepithelial migration20–22 of neutrophils, we examined the
white cell counts in the circulation of treated and untreated CLP mice
and found a significant increase in the number of circulating neu-
trophils in the treated mice (Fig. 3a). It is possible that the high
circulating neutrophil counts in the BMSC-treated mice could help
lower blood bacterial counts (Fig. 4f), but further studies are
necessary to explore this hypothesis. Neutrophils are also known to
migrate into the tissues in septic states, where they can cause oxidative
organ damage23–25, an unwanted side effect of myeloperoxidase, an
enzyme that neutrophils use to eliminate bacteria26. To see whether a
change in myeloperoxidase abundance could contribute to BMSC-
related organ protection, we measured the amount of myeloperoxidase
in the kidney and liver of septic mice with and without BMSC
treatment. We found that the amount of myeloperoxidase was
significantly decreased (Fig. 4g) in the mice that received BMSC
injections, which would be consistent with the lack of neutrophil
invasion and the lesser extent of organ damage. The above data
suggest that the intravenously injected BMSCs are able to optimally
balance circulating and tissue-bound immune cells to maximize
bacterial killing in the circulation while minimizing organ damage
due to leukocyte invasion.
Molecular basis of the BMSC-macrophage interaction
To understand the molecular basis of the interaction between BMSCs
and macrophages, we performed a series of experiments in vitro and
in vivo. Wild-type BMSCs showed NF-kB activation 30 min after LPS
stimulation (Fig. 5a). In a number of cell types, NF-kB has been shown
to induce prostaglandin production and release through a pathway
involving cyclooxygenase-2 (COX2; refs. 26–29). BMSCs have been
shown to produce prostaglandin E2 and possibly affect other immune
cells via EP1–EP4 receptors30,31. We found a significant increase in the
expression and activity of COX2 (which produces the substrate for
prostaglandin synthase enzymes) in BMSCs 3 h and 5 h after LPS
stimulation (Fig. 5b,c), but when the BMSCs were treated with an
antibody to TNF-a or collected from Tlr4–/– mice, the COX2 expres-
sion did not change (Fig. 5d). This suggested that prostaglandin E2
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Figure 4 Characterization of control and
stimulated mononuclear cells in CLP mice
in vivo and in vitro. (a) The distribution of
monocytes (Mon), macrophages (Mac) and
polymorphonuclear cells (PMN) among
cells isolated from septic lungs. Error bars
represent means ± s.e.m. (b) FACS plots of
lung mononuclear cells. The cells were first
gated on forward scatter (FSC) and CD11b.
The R1 group (high FSC, dim CD11b)
represents resident macrophages. R2 (high
FSC and bright CD11b) represents a group
of myeloid cells. R3 (medium FSC and bright
CD11b) is a mixed population of monocytes
and PMN cells when it is further gated on a
monocyte-lineage marker (F4/80) and a PMN
marker (GR1). The FACS is a representative example of the four mice shown on the bar graph in a. Blue color indicates monocytes and red indicates
polymorphonuclear cells in both a and b expressed as percentage of total number of cells analyzed. (c) Quantification of IL-10 secretion after ex vivo LPS
treatment of lung macrophages. Six hours after the induction of CLP, lung macrophages were isolated from mice with or without BMSC treatment (four mice
per group), cultured and treated ex vivo with LPS. IL-10 production of these isolated macrophages is shown 3 and 5 h after LPS stimulation. (d) To test
whether the increased IL-10 production could be due to a BMSC-macrophage interaction, macrophages from bone marrow were cocultured in vitro with
BMSCs and stimulated with LPS. IL-10 production of macrophages cocultured with BMSCs is shown compared to macrophages that had no contact with
BMSCs at 1, 3, 5 and 7 h after LPS stimulation. (e) Lungs of four BMSC-treated and four untreated mice were used for a FACS experiment with CD11b
and an intracellular marker for IL-10. The number of IL-10 producing monocytes and macrophages after the treatment is shown. (f) Bacterial counts in the
peritoneal space and in the circulation in 12 untreated (red) and 10 BMSC treated (blue) mice. (g) Myeloperoxidase (MPO) abundance in the kidney and the
liver after BMSC treatment. Error bars represent means ± s.e.m. *P o 0.05, **P o 0.01 and ***P o 0.001.
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might indeed be responsible for reprogramming the macrophages. For
this reason, we measured the amount of prostaglandin E2 in the
coculture medium and found a significant increase in its concentration
after LPS stimulation (Fig. 5e). This increase was eliminated if the
BMSCs lacked TLR4 or if they were incubated with antibody to TNF-a
(Fig. 5e). Inducible nitric oxide synthase (iNOS) inhibition resulted in
a significant reduction of COX2 enzyme activity 1 h, 3 h and 5 h after
LPS stimulation (Fig. 5f). Although IL-10 concentrations in the
medium were increased by LPS when BMSCs from Ptgs1–/– mice
(lacking COX1) were used in the assay or when the cells were treated
with a COX1 inhibitor (SC-560), the increased IL-10 release was not
seen when Ptgs2–/– cells (lacking COX2) were used or a COX2 inhibitor
(NS-398) was added (Fig. 6a).
To further examine the effect of BMSCs on macrophages, we
cultured macrophages with BMSCs, added LPS and measured the
IL-10 concentration in the culture medium. Because Toll-like
receptor-4 (TLR4) is the receptor to which LPS binds and through
which it acts32, we were not surprised to see that BMSCs from Tlr4–/–
mice could not increase IL-10 production and secretion in our assay
(Fig. 6a). Myeloid differentiation primary response gene-88 (MyD88)
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Figure 5 Studies of molecular alterations
underlying the effect of BMSCs on macrophages.
(a) NF-kB abundance in nuclei isolated from
triplicate samples of BMSCs 30, 60 and 90 min
after addition of LPS to the culture medium.
(b) Western blot (WB) analysis of COX2
abundance in LPS-stimulated cocultures.
Density measurements of three western blots
are quantified in the bar graph. (c) The COX2
activity after LPS treatment of cocultures
(triplicate samples). (d) Western blot analysis
of COX2 abundance in Tlr4–/– (KO) BMSCs or
in cultures treated with antibody to TNF-a
(anti–TNFa). (e) Prostaglandin E2 (PGE2)
abundance in macrophage cultures or coculture
supernatants in a variety of conditions 3 and
5 h after LPS stimulation. Four samples were
run for each condition. (f) COX2 enzyme activity
after iNOS inhibition and 1, 3 and 5 h after
LPS stimulation in triplicate samples. Error
bars represent means ± s.e.m. *P o 0.05,
***P o .001.
Figure 6 Summary of studies of the molecular
pathways involved in the interaction between
BMSC and macrophages. (a) IL-10 concentration
changes in supernatants of cocultures in a variety
of treatment conditions after LPS stimulation.
Colored graphs (except for the blue color that
labels the bone marrow macrophages as the
source of all consecutive experiments) show
treatments that eliminate the effect of BMSCs
on macrophages. Black graphs show IL-10 levels
after LPS stimulation, whereas open graphs
show the control (nonstimulated) values. The
experiments where the conditions eliminated the
effect are colored. Purple color shows the effect
of septic environment, green color shows agents
and cellular compartments related to the PGE2
pathway and pink color shows agents related to
the nitric oxide pathway. Three separate kinds
of macrophages (bone marrow macrophages;
peritoneal macrophages and the RAW264.7
cell line) were examined initially. Because they
behaved identically in the assay, we used bone
marrow derived macrophages (BM MF) for the
rest of the experiments. In the box labeled 1, the effect of septic environment on the BMSCs is studied in BMSCs from TLR4-, MyD88-, TNFR1- and
TNFR2- deficient mice, or antibody to TNF-a was used to neutralize the effect of TNF. The box labeled with 2 shows the cytokines and agents that have been
implicated in the literature in immunomodulation of T cells by BMSCs, including COX1/2 and iNOS inhibitors. The box labeled 3 shows studies of the COX2
pathway, including the prostaglandin receptors EP1–EP4. Finally, in the box labeled with 4, we show studies related to nitric oxide. (b) A summary of our
current hypothesis about the mechanisms that underlie the interactions between BMSCs and macrophages in the CLP sepsis model. Bacterial toxins (for
example, LPS) and circulating TNF-a act on the TLR4 and TNFR-1 of the BMSCs, respectively. This results in the translocation of NF-kB into the nucleus.
This activation process seems to be nitric oxide dependent. Activated NF-kB induces the production of COX2, resulting in increased production and release
of PGE2. PGE2 binds to EP2 and EP4 receptors on the macrophage, increasing its IL-10 secretion and reducing inflammation.
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is required for activation of nuclear factor-kB (NF-kB) by TLR4, and
cells from Myd88–/– mice did not stimulate IL-10 secretion either
(Fig. 6a). Because TNF-a has also been implicated in upregulating
NF-kB in BMSCs, and both TNF receptor-1 (TNFR-1) and TNFR-2
have been reported to be present in BMSCs33, we next tested whether
these receptors are involved in the function. We used antibody to
TNF-a and BMSCs from Tnfrsf1a–/– or Tnfrsf1b–/– mice and found
that TNF-a and TNFR-1 are also necessary for the activation
of BMSCs (Fig. 6a). In the absence of TNFR-2, BMSCs still increased
IL-10 concentrations in the cocultures (Fig. 6a).
Because it seemed that prostaglandin E2 might mediate the effect of
BMSCs on macrophage cytokine production, we asked whether
specific EP receptors could be involved in transducing the prostaglan-
din signal. To answer this question, we used prostaglandin receptor
antagonists and macrophages from EP receptor–knockout mice. EP1
and EP3 receptor antagonists had no effect on LPS-induced IL-10
secretion, and neither did substituting Ptger1–/– macrophages (lacking
the gene encoding prostaglandin E receptor-1) or Ptger3–/– macro-
phages (lacking the gene encoding prostaglandin E receptor-3) for
wild-type cells in the assay (Fig. 6a). However, both EP2 and EP4
receptor antagonists prevented the increase in IL-10 secretion, as did
using Ptger2–/– or Ptger4–/– macrophages instead of wild-type ones
(Fig. 6a). TNFR-1 and TLR4 do not seem to be the only elements in
the BMSCs required for COX2 induction. Nitric oxide produced in the
BMSCs, the macrophages or both may be involved. Using BMSCs
from Nos2–/– mice with WT macrophages or Nos2–/– mice macro-
phages with WT BMSCs did not eliminate the effect on IL-10
production (Fig. 6a). However, when BMSCs and macrophages
were both derived from Nos2–/– mice (lacking iNOS-2), IL-10 was
not induced (Fig. 6a). To show that this effect is specifically related to
loss of iNOS activity and reduced production of nitric oxide, we added
S-nitroso-N-acetylpenicillamine (SNAP), an external nitric oxide
donor, to the system34. SNAP fully restored the ability of Nos2–/–
cells to increase IL-10 production in response to LPS (Fig. 6a). To
determine whether nitric oxide might act through guanylyl cyclase in
the BMSCs, we pretreated these cells with 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ), an irreversible inhibitor of soluble gua-
nylyl cyclase35 (Fig. 6a). The IL-10 increase was eliminated when the
BMSCs, but not the macrophages, were treated with ODQ. This
suggests that the BMSCs need nitric oxide to achieve the effect on
IL-10. Apparently, the nitric oxide can either be produced by the
BMSCs themselves or by the macrophages. Thus, on the basis of our
in vitro studies, we concluded that BMSCs respond to the presence of
infectious agents by increasing prostaglandin E2 synthesis and secre-
tion, and that subsequent activation of prostaglandin E2 and E4
receptors on the macrophages results in IL-10 induction. We tested
this hypothesis in vivo, and, as predicted, BMSCs lacking TNFR1,
MyD88 or COX2 all failed to rescue mice subjected to CLP
(Supplementary Fig. 5 online). Cells from Tlr4–/– mice had partial
efficacy, reflecting the fact that their detection of pathogens is
impaired but not absent (Supplementary Fig. 5), raising the possibi-
lity of the involvement of other TLRs in vivo.
DISCUSSION
Our results suggest that an intravenous injection of bone marrow
stromal cells can beneficially modulate the response of the host
immune system to sepsis and improve survival. BMSCs were first
reported to have a potent immunosuppressive effect in vivo in humans
in 2004, when a young individual with resistant graft-versus-host
disease was successfully treated with transplanted haploidentical
mesenchymal stem cells2. Subsequently, cases of hemorrhagic cystitis
and peritonitis were treated with allogeneic mesenchymal stem cells5.
Thus, in humans and in animals3,36–39, bone marrow stromal cells
seem to be potent immunomodulators, but their mechanism of action
has been unclear. BMSCs are known to inhibit T cell proliferation4
and to modulate B cell function40. In the present study, we show that
BMSCs can be used to fight sepsis in mice. We suggest that the
injected BMSCs interact with circulating and tissue (mostly lung)
monocytes and macrophages and reprogram them. Treated monocytes
and macrophages produce large amounts of IL-10, and the treatment
decreases the amounts of circulating TNF-a and IL-6. This reduces
harm caused by unbridled immune responses to the host tissues. The
observation that the macrophages isolated from treated septic mice
produce significantly higher amounts of IL-10 than those from
nontreated mice suggest a temporary reprogramming of monocyte
and macrophage function that persists for at least 12 h. The monocyte
and macrophage–derived IL-10 seems to prevent neutrophils from
migrating into tissues and causing oxidative damage, thus mitigating
multiorgan damage. This inhibition of neutrophil migration into
tissues also results in a buildup of neutrophils in the blood, allowing
for more efficient bacterial clearance. The combination of our in vitro
and in vivo experiments shows that the beneficial effect is likely to be
due to an increased release of prostaglandin E2 from the BMSCs acting
on the EP2 and EP4 receptors of the macrophages and stimulating the
production and release of IL-10, an anti-inflammatory cytokine
(Fig. 6b). Simultaneous stimulation of EP2 and EP4 receptor subtypes
by prostaglandin E2 has been shown to promote monocyte-derived
dendritic cell maturation41. In peritoneal macrophages, prostaglandin
E2 was shown to modulate inflammatory reactions via the EP2 and
EP4 receptors42, and EP2 and EP4 agonists were shown to cause
upregulation of zymosan-induced IL-10 production42. Because both
of these receptors work through cyclic AMP, one wonders why both
are necessary for the effect to take place. Why eliminating either the
EP2 or the EP4 receptor affects IL-10 induction remains to be
determined. The two receptors could increase cyclic AMP levels
more when they act in concert than they do alone, or they could
have partially nonoverlapping actions that are essential for induction
to occur43. It is also possible that the receptors form functional
heterodimers in macrophages.
Our model is somewhat similar to peritonitis in humans. The
mechanism of how BMSCs are beneficial might be universal in
infectious diseases, or it might be unique to this model. It is possible
that the mechanism described could be harmful in other models or
that there are other beneficial mechanisms related to BMSCs in other
infectious or noninfectious diseases. Owing to the effectiveness of
BMSCs in the CLP model, and because BMSCs have been successfully
given to humans2,44 and can easily be cultured and used without
human leukocyte antigen matching, we suggest that cultured, banked
human BMSCs should be tested for their ability to prevent sepsis in
very high-risk groups.
METHODS
Mice. Mouse care was in full compliance with the US NIH criteria for the care
and use of laboratory animals in research and all studies were approved by the
Animal Care and Use Committee of the NIDDK and NIDCR, NIH. Aged (42–
44 weeks old) male C57BL/6 mice (NIH) had free access to water and chow
before and after surgery. In addition, 8–12-week-old males with a variety of
genetic manipulations were used as listed in the Supplementary Methods
online. All reagents used are summarized in Supplementary Table 1 online.
Polymicrobial cecal ligation and puncture sepsis. We performed CLP as
previously described, with some modifications, in C57BL/6 mice45,46. We
ligated the cecum by silk 4-0 and punctured it twice with a 21-gauge needle,
©
20
08
 N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
ht
tp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
em
ed
ic
in
e
ART ICL ES
NATURE MEDICINE VOLUME 15 [ NUMBER 1 [ JANUARY 2009 47
               dc_219_11
gently squeezed it to express a small amount of fecal material and then returned
it to the central abdominal cavity. In sham-operated mice, we located the
cecum but neither ligated nor punctured it. We closed the abdominal incision
in two layers with 6-0 nylon sutures. After surgery, we gave 1 ml per 30 g body
weight of pre-warmed normal saline. All mice received antibiotic and
fluid therapy subcutaneously (a combination of imipenem and cilastatin;
14 mg per kg in 1.5 ml of normal saline at 6 h and 7 mg per kg in 1.5 ml
of normal saline at 18 h after surgery). The details of the tissue harvest are
described in the Supplementary Methods.
Treatment of cecal ligation and puncture mice with bone marrow stromal
cells. We injected one million BMSCs in 0.3 ml sterile PBS via the tail vein. We
gave untreated control mice 0.3 ml sterile PBS with no cells. There was no
difference in organ injury, cytokine abundance, Evans blue dye level or
pathology in the sham-operated mice with or without BMSC injection. Details
of cell isolation and culture are provided in the Supplementary Methods.
Survival studies. We assessed survival after surgery every 6 h within the first
48 h and then every 8 h for 4 d. We began antibiotic injection and fluid
resuscitation 6 h after CLP by subcutaneous injection and repeated it every 12 h
for 4 d. We killed all mice at the end of the fourth day.
Ex vivo studies on isolated lung monocytes and macrophages. We killed
septic mice 6 h after CLP induction with or without intravenous injection of
1 million BMSCs. We removed the lungs, minced them into small pieces and
incubated the pieces in RPMI 1640 medium with 1% penicillin-streptomycin
and 1% glutamine for 30 min at 37 1C 5% CO2 in the presence of collagenase
type 1 (300 U ml–1) and DNase I (50 U ml–1) (Worthington Biochemicals).
After the incubation, we filtered the cell suspension through a 70-mm cell
strainer and then washed it with complete RPMI medium. We incubated the
resulting cells for 15 min at 4 1C with CD11b magnetic beads and subsequently
applied them to MS columns (Miltenyi) for the positive selection of CD11b
cells. The cell purity of the CD11b+ cells, as assessed by FACS analysis, was
greater than 97%. After washing, we plated the isolated cells in 96-well plates at
a concentration of 50,000 cells per well per 200 ml RPMI medium (with 10%
FBS, 1% glutamine and 1% penicillin-streptomycin) containing 10 mg ml–1 LPS
(from Escherichia coli O111:B4, Sigma). We incubated cells for 1, 3, 5 and 7 h
after stimulation and collected supernatants sequentially from wells dedicated
to each time point. For each time point, we used triplicate wells. We collected
supernatants in microtubes, spun the tubes down at maximum speed for
10 min to get rid of cell debris, aliquoted the supernatants and froze them at
–20 1C until use. We performed ELISA for IL-10 (R&D Systems) on the
samples. We made measurements in duplicates from three independent
experiments. To determine intracellular amounts of IL-10 produced in lung
cells, we prepared single-cell suspensions as described above and plated cells in
six-well plates containing 10 mg ml–1 LPS and 3 mg ml–1 brefeldin A, a Golgi-
blocking agent frequently used to prepare samples for intracellular FACS
analysis. After 5 h of LPS restimulation, we collected the cells, washed them
and performed intracellular IL-10 staining combined with cell surface staining.
Macrophage–bone marrow stromal cells coculture experiments. First, we
plated macrophages in 96-well plates at a concentration of 40,000 cells per
200 ml. After 1 h, we removed the supernatants and added either 40,000 BMSCs
in fresh medium or fresh medium alone to the wells. As a control, we plated
BMSCs without macrophages. After an overnight incubation, we added LPS to
the cocultures to reach a final concentration of 1 mg ml–1. We collected
supernatants 1, 3, 5 and 7 h after the stimulation and performed ELISA
(R&D Systems) on the samples to detect the released IL-10. For the transwell or
conditioned medium experiments, we either added BMSCs on the insert
membrane of the transwell system (HTS Transwell 0.4-mm pore size poly-
carbonate membrane, from Corning Incorporated) or added conditioned
medium diluted 1:1 with fresh medium to the macrophages. For generation
of BMSC-conditioned medium, we cultured BMSCs in complete medium.
After 3 d, we collected supernatants, spun them down to remove possible
cell contamination (500g for 10 min) and stored the resulting supernatants
at –20 1C until further use. Further details on ELISA and western blotting are in
the Supplementary Methods.
Blood chemistry, natural killer cell and macrophage depletion and IL-10
neutralization, microvascular permeability, bacterial counts, cell tracking,
histology and flow cytometry. Detailed methodology is described in the
Supplementary Methods.
Statistical analyses. We examined the differences between the groups for
statistical significance by Student’s t-test or analysis of variance with an
appropriate correction. We compared survival curves with a log-rank test
(Prism 4.0; Graphpad Software). A P value of o0.05 was accepted as
statistically significant.
Note: Supplementary information is available on the Nature Medicine website.
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(y axis) and GR1 expression (x axis). In panel (c), the curves should start at 1 h. In panel (d), the text labeling the y axis should read “in vitro,” not 
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Bone marrow stromal cells use TGF-β to suppress
allergic responses in a mouse model of ragweed-
induced asthma
Krisztian Nemetha,b,1, Andrea Keane-Myers , Jared M. Brown , Dean D. Metcalfe , James   D.c c c Gorhamd, Virgilio  G. Bundocc,
Marcus G. Hodgesc, Ivett Jelineke, Satish Madalac, Sarolta Karpatib, and Eva Mezeya,1
aNational InstituteofDental andCraniofacial Research, Craniofacial and SkeletalDiseases Branch,National Institutes ofHealth, Bethesda,MD20892; bDepartment
of Dermato-Venereology and Dermato-Oncology, Semmelweis University, H-1085 Budapest, Hungary; cLaboratory of Allergic Diseases, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, Bethesda,MD 20892; dDepartment of Pathology and ofMicrobiology and Immunology, Dartmouth
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Edited* by Susan E. Leeman, Boston University School of Medicine, Boston, MA, and approved January 22, 2010 (received for review September 18, 2009)
Bone marrow stromal cells [BMSCs; also known as mesenchymal
stem cells (MSCs)] effectively suppress inﬂammatory responses in
acute graft-versus-host disease in humans and in a number of
disease models in mice. Many of the studies concluded that BMSC-
driven immunomodulation is mediated by the suppression of pro-
inﬂammatory Th1 responses while rebalancing the Th1/Th2 ratio
toward Th2. In this study, using a ragweed induced mouse asthma
model, we studied if BMSCs could be beneﬁcial in an allergic, Th2-
dominant environment. When BMSCs were injected i.v. at the time
of the antigen challenge, they protected the animals from the
majority of asthma-speciﬁc pathological changes, including inhib-
ition of eosinophil inﬁltration and excess mucus production in the
lung, decreased levels of Th2 cytokines (IL-4, IL-5, and IL-13) in
bronchial lavage, and lowered serum levels of Th2 immunoglobu-
lins (IgG1 and IgE). To explore the mechanism of the effect we
used BMSCs isolated from a variety of knockout mice, performed
in vivo blocking of cytokines and studied the effect of asthmatic
serum and bronchoalveolar lavage from ragweed challenged
animals on the BMSCs in vitro. Our results suggest that IL-4 and/
or IL-13 activate the STAT6 pathway in the BMSCs resulting in an
increase of their TGF-β production, which seems to mediate the
beneﬁcial effect, either alone, or together with regulatory T cells,
some of which might be recruited by the BMSCs. These data sug-
gest that, in addition to focusing on graft-versus-host disease and
autoimmune diseases, allergic conditions—speciﬁcally therapy
resistant asthma—might also be a likely target of the recently
discovered cellular therapy approach using BMSCs.
allergy | cellular therapy | immunomodulation | mesenchymal stem cell
Asthma is a chronic inﬂammatory airway disease affecting 16million people in the United States alone and more than 300
million worldwide (1). It can range from a mild, intermittent
disease to one that is severe, persistent, and difﬁcult to treat (i.e.,
therapy-resistant) (2). Asthma-related deaths are uncommon,
but they appear to be increasing; currently there are approx-
imately 5,000 deaths per year in the United States and 100,000
throughout the world (3). New treatments are needed for ther-
apy-resistant, severe cases.
Bone marrow stromal cells (BMSCs) have recently been shown
to suppress harmful immune responses in patients with acute graft-
versus-host disease (4, 5) and in several animalmodels of allogeneic
rejection (6–8), a variety of autoimmune diseases (9–11), and lung
injury (12–15). The authors of many of these studies concluded that
BMSC-driven immunosuppression results from a shift in Th1/Th2
balance (8, 16, 17).DuringBMSC treatment, Th1 responses appear
to be decreasing while Th2 responses begin to dominate. In animals
with established allergies, Th2 responses are already dominant, and
we wondered how BMSCs would react to such an environment. In
this study we thus examined the effect of BMSCs on Th2-driven
allergic reactions in a mouse model of asthma (18, 19).
Results
Lung Pathology. Following ragweed (RW) challenge (for timing of
the events see Fig. 1), microscopic examination of the lungs showed
minimal or no inﬂammation in mice sensitized with PBS solution
and alum but no RW (Fig. 2A). Conversely, RW-sensitized mice
showed extensive inﬂammation with eosinophil and lymphocyte
invasion and severeperivascular andperibronchial cufﬁng (Fig. 2B).
Mice thatwere challengedwithRWbut treatedwith i.v. injectionsof
BMSCs had signiﬁcantly less lung pathology: few inﬂammatory cell
inﬁltrates were observed (Fig. 2C). Although no abnormal mucus-
ﬁlled cells were observed in controls as deﬁned by histological
staining using PAS (Fig. 2D), the amount of stainable mucus in the
airways was visibly increased following RW challenge (Fig. 2E).
BMSC treatment reduced the amount of mucus to near control
levels (Fig. 2F). In addition to improved lung scores (Fig. 3A), we
also observed a signiﬁcant decrease in both total inﬂammatory cell
numbers and eosinophils in the bronchoalveolar lavage (BAL) ﬂuid
(Fig. 3 B and C).
Cytokine Response. RW-challenged mice showed increased levels of
IL-4, IL-13, and IL-5 in BAL, all characteristic Th2 cytokines that
highlight allergic inﬂammation. IL-4 and IL-13 levels were sig-
niﬁcantly reduced when the animals were treated with i.v. BMSCs
(Fig. 3 D–F).
Ig Response. RW sensitization and subsequent antigen challenge is
known to affect Th2-speciﬁc Ig concentrations in blood (19).
Indeed, we found that both IgG1 and IgE serum levels were sig-
niﬁcantly increased following RW application, whereas IgG2a did
not change. BMSC treatment resulted in a signiﬁcant decrease of
RWinducedelevation of IgG1and IgE concentrations (Fig. 3G–I).
Use of Allogeneic BMSCs or Skin Fibroblasts Instead of Syngeneic
BMSCs. In a few groups ofmice, we determinedwhether therewas a
difference in effect when we use allogeneic BMSCs prepared from
Balb/C mice or syngeneic C57BL/6J dermal ﬁbroblasts instead of
syngeneic (C57/BL6) BMSCs. We measured total cell numbers
and the number of eosinophils (Fig. 4 A and B) as well as IL-4 and
IL-13 levels (Fig. 4C andD) fromBALand immunoglobulins from
serum (Fig. 4 E–G). We found that there was no signiﬁcant dif-
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ference between syngeneic versus allogeneic BMSCs (i.e., both
were equally effective), and skin ﬁbroblasts had only partial effect.
Although the number of total cells in BAL was reduced following
ﬁbroblast treatment, the number of eosinophils was not different
from the untreated group. Fibroblasts behaved similarly toBMSCs
in regulating cytokine levels, but they had no effect on serum IgE
concentrations. Interestingly, IgG2a levels were highly increased
following ﬁbroblast administration—an effect that we never
observed using BMSCs.
Searching for Mechanism of Action. One hour after i.v. injection of
BMSCs on d 14, the cells were found exclusively in the lung
whereas virtually no cells were seen in other organs as demon-
strated by bioluminescence measurements using luciferase
expressing stromal cells (Fig. 5A). To determine if the inﬂam-
matory environment seen in asthma could inﬂuence homing to
and/or survival of BMSCs in the lung, we injected luciferase-
expressing cells into animals on d 14, immediately after intra-
airway application of PBS solution or RW. Comparing emitted
luminescence at different time points we assessed the number of
stromal cells still present in the lungs. At 1, 12, and 24 h, the
number of BMSCs in control and asthmatic animals were com-
parable, whereas at 36 h—and more evidently after 48 h—we
detected considerably more BMSCs in the asthmatic lungs (Fig.
5A). To follow up on this observation, we injected Q-dot–labeled
BMSCs into control and RW-challenged animals and isolated
the Q-dot–positive BMSCs from the protease-digested lung cell
suspensions using FACS. At 6, 12, and 24 h after injection, the
number of Q-dot–positive cells did not differ between the two
groups. After 36 h, however, we detected a signiﬁcant increase in
the number of BMSCs retained in the asthmatic lungs, and this
difference remained detectable at 48, 72, and 96 h after BMSC
injection (Fig. 5 B and C). These observations suggest that the
developing allergic environment is capable to attract and retain
more BMSCs than unaffected lungs, indicating that asthmatic
lungs are likely to secrete factors that affect BMSC homing and
survival. We next continued to explore the nature of such factors.
Among the number of cytokines known to suppress allergic
responses the antiinﬂammatory actions of IL-10, TGFβ, and IFN-γ
are especially well established. To determine whether any of these
factors contributes to the beneﬁcial effect of BMSCs, we ﬁrst
examined their levels inBALﬂuid. Therewas a signiﬁcant increase
in the level of TGF-β in BAL ﬂuid collected from BMSC-treated
versus untreated mice, but no change in IFN-γ or IL-10 levels
(Fig. 6 A–C). As TGF-β was increased in BAL ﬂuid, and BMSCs
are reported to be able to secrete TGF-β (20), we next asked
whether serum or BAL ﬂuid from RW-challenged mice could
affect TGF-β production by BMSCs in vitro. TGF-β increased
in themediumwhenBMSCswere cultured in the presence ofRW-
challenged serum or BAL, suggesting that allergy-speciﬁc micro-
environment (i.e., serum or BAL) is capable of modulating
immunoregulatory functions of BMSCs. It has been reported that
stimulation of certain immune cells through the IL-4R pathway
results in up-regulated TGF-β expression (32). To ﬁnd out if
enhanced TGF-β production by BMSCs in the presence of allergic
Fig. 1. Timeline of the experiments showing the days of the interventions.
Fig. 2. Histological images of airways stained with PAS to show the mucin-
producing goblet cells (dark red in the lumen). Low-magniﬁcation images
depict a control lung (A), a lung following RWchallengewith no treatment (B),
and a lung with BMSC treatment (C). Note the signiﬁcant increase in lym-
phocytic inﬁltrates (arrows) in B and their decrease in C. The high magniﬁca-
tion images of the airways show a normal bronchus inD, a bronchus from RW-
challengedmousewithmucusbuildup (arrows) in the luminal surface (E), anda
treatedmousewith lessmucus in F. (Scale bar, 250 μm inA–C and50 μm inD–F.)
Fig. 3. Evaluation of the effect of BMSC treatment on the different
parameters of RW-induced asthma. Mice treated with BMSCs showed a
signiﬁcant reduction in lung histology scores (A), total number of BAL cells
(B), relative ratio of BAL eosinophils (C), and levels of allergy-speciﬁc Th2
cytokines IL-4 (D), IL-13 (E), and IL5 (F) in BAL. From the sera of challenged
mice we measured Ig concentrations, and in the BMSC-treated group we
found a signiﬁcant decrease in the level of Th2-speciﬁc Ig concentrations
IgG1 (G) and IgE (H), whereas there was no change in the level of IgG2a (I).
There were four to eight mice per group. *P < 0.05, **P < 0.01, and ***P <
0.001 in all graphs.
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serum or BAL could be triggered by activation through the IL-4R,
we repeated the aforementioned experiments using IL-4R–
deﬁcient BMSCs. We found that RW-challenged serum or BAL
could not enhance TGF-β production in IL-4R–KO BMSCs,
suggesting an important role for IL-4 (Fig. 6D).
As both IL-4 and IL-13 are able to bind to IL-4R, in another
series of experiments we examined the effect of blocking (using
speciﬁc antibodies) IL-4, IL-13, or both on the TGF-β production
byBMSCswhen they came in contactwithRW-sensitized serumor
BAL (Fig. 6E and F).When serum fromRW challengedmice was
added to the media, IL4 neutralization alone eliminated the
increased TGF-β production but blocking IL-13 did not have this
effect (Fig. 6E). Interestingly, when BAL from RW challenged
mice was added, the BMSCs increased their TGF-β production
even when either IL-4 or IL-13 was blocked; however, blocking
both cytokines simultaneously eliminated the effect (Fig. 6F). On
the other hand, neither recombinant IL-4 or IL-13 alone or in
combination increased TGF-β production (Fig. S1), suggesting a
possible role for other factors.
When treating mice with TGF-β– and IL-10–speciﬁc neutral-
izing antibodies beforeBMSC injection, we observed that blocking
TGF-β—but not IL-10—eliminated the beneﬁcial effect of
BMSCs demonstrated by the lack of reduction in BAL total cell
numbers and eosinophil counts (Fig. 7 A and B). Furthermore, in
mice injected with TGF-β1–KO BMSCs, the beneﬁcial effect was
no longer seen: treated animals showed no reduction in BAL cell
numbers, asthma-speciﬁc BAL cytokines, or serum Th2 immu-
noglobulins. Importantly TGF-β1–KO cells were unable to elicit
increase in BAL TGF-β concentrations, suggesting that BMSC-
derived TGF-β1 is responsible for the effect (Fig. 7C).
The IL-4 receptor is known to activate the STAT6 signaling
pathway (21). To see if the IL4Ra/STAT6 pathway is indeed
necessary for the BMSCs to act beneﬁcially in an allergic envi-
ronment—as suggested by the in vitro studies just described—we
injected STAT6-deﬁcient BMSCs instead of WT cells and
observed no TGF-β elevation in the BAL samples (Fig. 7C). In
accordancewith this result the elimination of STAT6 also reversed
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Fig. 4. Assessing the effect of allogeneic BMSCs or syngeneic skin ﬁbroblasts on RW-induced asthma. Allogeneic BMSCs exhibit a similar inhibitory effect as
syngeneic BMSCs on the total number of BAL cells (A), relative ratio of eosinophils (B), BAL inﬂammatory cytokines IL-4 (C) and IL-13 (D), and serum
immunoglobulins IgG1 (E), IgE (F), and IgG2a (G). There were four to eight mice per group. Skin ﬁbroblasts had a partial effect on the aforementioned
parameters (see same graphs).
Fig. 5. After i.v. delivery of BMSCs at the time of the ﬁrst challenge, stromal cells are concentrated in the lung. Asthmatic lungs seem to retain more BMSCs
than control unchallenged lungs at 48 h after administration, demonstrated by bioluminescence detection of luciferase-expressing stromal cells. Two rep-
resentative mice of three used are shown (A). To conﬁrm this observation, Q-dot–labeled BMSCs were injected at the time of the ﬁrst challenge, and lung cell
suspensions were analyzed using FACS at several time points after injection. After 6 h, the number of Q-dot–positive cells (BMSCs) are still comparable in the
two groups (each had four mice), but starting at 12 h there are signiﬁcantly more BMSCs retained in the asthmatic lungs compared with the controls at all
time points examined (B and C).
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the BMSC-derived attenuation of RW-induced asthma, pointing
to the importance of the IL4R/STAT6 pathway (Fig. 7 D–J).
As regulatory T cells (T-regs) are known to play a role in
alleviating asthma symptoms and TGF-β has been suggested to
play a role in T-reg differentiation, we wondered if the number
of T-regs in the lung tissue could also be affected by the BMSC
treatment in our model. Analyzing lung single cell suspensions
using FACS, we detected a steady increase in the number of
T-regs in challenged animals over time. Importantly, as early as
after 48 h, as well as after 72 and 96 h after challenge, we found
signiﬁcantly more T-regs in the BMSC-treated lungs than the
ones collected from challenged but untreated animals (Fig. 8).
Discussion
Asthma is an inﬂammatory disease of the airways. In asthma, the
lungs are invaded by a variety of inﬂammatory cells, including
eosinophils and lymphocytes. These cells, in addition to resident
mast cells, secrete cytokines and chemokines that trigger con-
striction of the bronchi and secretion of mucus.
The current working hypothesis is that asthma is caused by an
abnormal shift in the Th1/Th2 balance in favor of Th2 cells and
the production of IL-4, IL-5, and IL-13. Through these mediators,
Th2 lymphocytes are thought to recruit additional effector cells to
the lungs, and the cells recruited promote allergic inﬂammatory
events (22). BMSCs have been shown to have useful effects in a
number of diseases and disease models. In the majority of these
disorders, however, the T cell balance is shifted toward Th1
dominance. As BMSCs seem to “normalize” immune responses
and reestablish the physiological balance in a variety of auto-
immune and infectious diseases (23–27), we wondered whether
these cells might also be able to tip the balance back to normal in
an allergic environment with already-established Th2 dominance.
The rebalancing act would require that the cells detect an
imbalance and then take appropriate measures to correct it.
Our initial experiments showed that injecting BMSCs on d 14,
when ﬁrst challenging the sensitized animals signiﬁcantly
improved lung pathology, such as total cell number in BAL;
number of eosinophils in BAL and lung scores. Using luciferase-
expressing or Q-dot–labeled BMSCs, we demonstrated that
lungs are the primary site of BMSC accumulation following i.v.
injection, conﬁrming the known phenomenon of cell trapping in
the pulmonary microvasculature that is partially related to cell
size (28, 29). However, using Q-dot–labeled BMSCs we found
signiﬁcantly more BMSCs retained in the lungs when RW-
induced allergic inﬂammation was present compared with the
unchallenged state—a tendency also suggested by the bio-
luminescent measurements. As in our model, the primary site of
pathologic processes is the lung itself, and the enhanced pres-
ence of BMSCs could deliver a concentrated effort to modulate
pathological immune responses.
A D
B
E F
C
Fig. 6. Studying the mechanism of BMSC effect. In BAL BMSC treatment
resulted in elevated TGF-β levels (A). IFN-γ (B) and IL-10 (C) did not change.
Serum or BAL from RW challenged mice induced BMSCs to producemore
TGF-β in vitro, but this effect was eliminated when BMSCs lacked IL-4Ra (D).
Using neutralizing antibodies for IL-4 or IL-13 suggested both cytokines are
involved in stimulating BMSC’s TGF-β production when cocultured with
serum (E) or BAL (F) from RW challenged mice.
Fig. 7. In vivo demonstration of mechanism of action. The beneﬁcial effect of
BMSCs on inﬂammatory changes is eliminated in the presence of TGF-β neu-
tralizing antibodies, but spared when animals are treated with anti-IL-10 anti-
bodies (A and B). BMSCs from TGF-β or STAT6 deﬁcient animals did not induce
TGF-βproduction (C ) ordecreaseBALtotal cellnumbers (D), eosinophil numbers
(E), cytokine levels (F and G), or serum immunoglobulin concentrations (H–J).
Fig. 8. Quantiﬁcation of regulatory T cells in asthmatic lungs. With time
there is a gradual increase in the number of regulatory T cells in lungs
challenged with RW. BMSC-treated asthmatic lungs show a greater inﬂux of
T-regs starting at 36 h after challenge and further increasing up to 96 h.
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IL-10 and TGF-β, two well characterized antiinﬂammatory
cytokines, and IFN-γ, a key Th1 cytokine capable of down-
regulating Th2-mediated pathological responses, are all thought
to be capable of suppressing asthma (22, 30). As IL-10 has been
shown to play a signiﬁcant role in the beneﬁcial effect of BMSCs in
sepsis (27), we ﬁrst measured cytokines in serum and BAL in the
treated versus untreated RW-challenged mice. We found no
change in IL-10 or IFN-γ levels, but therewas a signiﬁcant increase
in the level of TGF-β, suggesting a different mechanism of action
than what was found in a septic environment. We then demon-
strated the importance of TGF-β in vivo by treating the mice with
TGF-β–speciﬁc neutralizing antibodies before BMSC injection.
Blocking TGF-β—but not IL-10—eliminated the beneﬁcial effect
of BMSC treatment. Next we looked for a possible source of
TGF-β. BMSCs themselves are capable of secreting TGF-β (31),
which has been implicated as one of the possible mediators of the
BMSCs’ immunosuppressive effect. We thus repeated the
experiment injecting BMSCs derived from TGF-β1–KOmice and
found no beneﬁcial effect, suggesting that the BMSC-derived
TGF-β is critical in suppressing the allergic responses. As TGF-β
synthesis can be enhanced through IL-4R in some immune cells
(32), we wondered if it is the IL-4 and IL-13 that “turns on” the
BMSCs to make TGF-β. We ﬁrst used BMSCs from mice lacking
the IL-4R (which is used by both IL-4 and IL-13) and found that
RW-challenged serum or BAL could no longer elicit increased
TGF-β production in these cells in vitro. In another set of
experiments using neutralizing antibodies against IL-4 or IL-13,
we could further demonstrate the importance of the IL4R. As the
IL-4R is known to activate the STAT6 pathway (21), we wanted to
conﬁrm our results by using BMSCs that genetically lacked
STAT6. As expected, STAT6-KO BMSCs were ineffective in
alleviating asthma pathology and could not trigger TGF-β ele-
vation in the BAL ﬂuids either. Based on these data, we suggest
that IL-4 and/or IL-13 bind to IL-4R receptors on BMSCs acti-
vating the STAT6 pathway. This, in turn, drives the cells to pro-
duce increased amounts of TGF-β. When this TGF-β is released
from the BMSCs in the allergic (i.e., Th2-dominant) environment,
TGF-β receptor activation on immune cells could result in a
decrease in IL-4 production (33) and ultimately leads to a shift
back toward immunological equilibrium (Fig. 9). Surprisingly,
neither recombinant IL-4 nor IL-13 alone or in combination was
able to elicit the elevation of TGF-β by BMSCs seen with RW-
conditioned BAL ﬂuid or blood serum in vitro. This indicates that
activation of the IL-4R/STAT6 pathway is necessary but not suf-
ﬁcient to cause TGF-β up-regulation in BMSCs. In addition to IL-
4 or IL-13, theremust be other important factors in vivo (present in
BAL ﬂuid or serum) that contribute to the production and sub-
sequent release of TGF-β by BMSCs.
We also demonstrated that BMSC-treated asthmatic animals
recruit signiﬁcantly more regulatory T cells to the lungs than
untreated mice. In animal models of allergic airways disease,
T-regs can suppress established airway inﬂammation and airway
hyperresponsiveness (34). Regulatory T cells are thought to sup-
press infection/inﬂammation by secreting antiinﬂammatory mol-
ecules (e.g., IL-10, TGF-β) (35, 36). It is possible that BMSCswork
together with regulatory T cells to suppress harmful allergic
responses in our model. BMSCs could initiate the suppressive
process by secreting TGF-β to block the proinﬂammatory Th2
responses and at the same time induce the differentiation and help
the survival of regulatory T cells (30) that will then continue to
improve asthma pathology after the BMSCs disappear.
It is worth mentioning that dermal ﬁbroblasts—cells frequently
used as control cells in studies of BMSCs—had beneﬁcial effects in
the model that we used when injected intravenously. The effect of
the ﬁbroblasts was not as strong as that of BMSCs. This suggests,
however, that ﬁbroblast-like cells, whether derived from the bone
marrow or other organs (including skin dermis), may also have
some immunomodulatory properties (37).
In the present study we demonstrated that i.v. injected BMSCs
are capable of suppressingTh2-driven allergic responses. It appears
that IL-4 and/or IL-13 induce production and secretionofTGF-β by
the BMSCs, which in turn effectively suppresses allergy speciﬁc
pathological changes in the asthma model we studied. These data
provide another example of the ability of BMSCs to “sense” their
immunological environment and respond accordingly. It is hard to
imagine a drug or combination of drugs that could act this way, and
furtherwork shouldbedone to determinewhether the cells couldbe
used to treat patients with therapy-resistant asthma.
Methods
Mice. C57BL/6J or Balb/C mice (6 to 8 weeks old) were obtained from Taconic
Farms. IL-4Rα–KO and STAT6-KO animals were purchased from Jackson
Laboratories. TGF-β1–KO mice have previously been produced and charac-
terized (38). The animals were housed and maintained in the National
Institute of Allergy and Infectious Diseases or National Institute of Dental
and Craniofacial Research animal facilities. All studies conformed to the
principles for laboratory animal research outlined by the Animal Welfare
Act, and were approved by the National Institute of Dental and Craniofacial
Research and/or National Institute of Allergy and Infectious Diseases Animal
Care and Use Committee. The groups for in vivo studies contained four to 10
mice, and each experiment was repeated two to three times.
Antigen Challenge. To elicit a bronchial allergic response, RW sensitization and
challenge were used (18, 19). C57BL/6J mice were sensitized on d 0 and 5
with 200 μL i.p. injections of 50 μg RW extract (Greer Laboratories), emul-
siﬁed in an equal volume (100 μL/antigen injection) of alum (Pierce) as
described earlier (39). Control animals were injected i.p. with the same
amount of alum mixed with PBS solution. Subsequently, as shown in Fig. 1,
the mice were challenged on d 14 and 15 with 50 μg RW extract in PBS
solution by intratracheal and intranasal inoculation (30 μL), respectively.
Control mice received an equal volume of PBS solution administered via the
same routes. In all cases, mice were killed by anesthetizing them with ket-
amine (Fort Dodge Animal Health) and xylazine (Phoenix Pharmaceuticals)
100 mg/kg and 10 mg/kg, respectively, followed by exsanguination.
Histology. Toassesspulmonaryinﬂammation,BALwasperformed72hafterthe
ﬁnal allergen challenge (as described later). Lungs were then immediately
placed in 10% neutral buffered formalin and sent to Histoserv (Germantown,
MD), where they were embedded in parafﬁn and stained. H&E was used to
evaluate cellular inﬂammationandperiodic acid–Schiff (PAS) stainwasused to
visualizemucus-containing goblet cells. Slides were coded and read “blind”; a
minimumof four lungs per groupwere given scores ranging from 0 to 2 based
on the level of peribronchial cufﬁng, perivascular cufﬁng, goblet cell hyper-
plasia, and interstitial inﬂammation (40).
Fig. 9. Schematic drawing shows the mechanism of effect based on data of
the present study. BMSCs “sense” the allergic environment, and as a result of
the increased levels of IL-4/IL-13, they respond by producing higher amounts
of TGF-β that, either alone or by recruiting regulatory T cells, will ultimately
lead to a decrease of lung eosinophil inﬁltration, as well as allergy-speciﬁc
cytokine and Ig production.
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BAL. Immediately after the mice were exsanguinated, the lungs were can-
nulated with a 20-gauge i.v. catheter and gently washed once with 500 μL 1%
FBS (HyClone) in PBS solution (for cytokine analysis) or twice with 750 μL 1%
FBS in PBS solution (for analysis of cellular inﬁltration). Samples for cytokine
analysis were stored at −80°C. Samples for cellular analysis were spun onto
glass slides in a cytospin instrument (Thermo-Shandon) and stained with
Kwik-Diff for differential cell analysis (Thermo-Shandon). A fraction was
used to determine total cell counts.
In Vivo Neutralization of Cytokines. IL-10– or TGF-β–neutralizing antibodies
(Clone 2A5 from Pierce Endogen or Clone 1D11 from R&D Systems, respec-
tively) were injected intraperitoneally (10 μg/g body weight in 200 μL PBS) on
two consecutive days at the approximate time of BMSC injection (d 14
and 15).
Measurement of Serum Antibody Isotypes. Antibody isotypes (IgG1, IgG2a, and
IgE) were assayed in sera collected 72 h after last RW challenge using ELISA kits
according to the manufacturer’s instructions (Immunology Consultants Labo-
ratory). All samples, including standards, were assayed in duplicate.
Preparation of Lung Cell Suspension. Lungs were removed, minced into small
pieces, and incubated in RPMI medium 1640 with 1% penicillin–streptomycin
and 1% glutamine for 30 min at 37 °C 5% CO2 in the presence of collagenase
type 1 (300 U mL−1) and DNase I (50 U mL−1; Worthington Biochemicals).
After the incubation, the cell suspension was ﬁltered through a 70-μm cell
strainer and then washed with complete RPMI medium.
Data Analysis. Data are summarized as mean ± SE. Student t test or two-way
ANOVA were performed using GraphPad Prism version 4.00 for Macintosh
(GraphPad Software). The statistical signiﬁcance value was set at P < 0.05.
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Summary
Background Mast cells (MCs) have a central role in the induction of allergic inflammation,
such as seen in asthma, and contribute to the severity of certain autoimmune diseases, such as
rheumatoid arthritis. The MC thus represents an important inflammatory cell, and one which
has resisted therapeutic attempts to alter its role in disease.
Objective Because bone marrow-derived stromal cells (BMSC, also known as mesenchymal
stem cells or MSCs) have been reported to alter allergic inflammation in vivo, we chose to
study the interaction between mouse BMSC and mouse bone marrow-derived MCs.
Methods MC degranulation, cytokine production and chemotaxis were evaluated in vitro
following co-culture with BMSCs either in cell contact or a transwell. In addition, MC
degranulation was assessed in vivo following administration of BMSCs in a model of passive
cutaneous anaphylaxis and a peritoneal degranulation assay. Mechanisms of MC suppression
by BMSCs were determined through use of inhibitors or antibodies to COX1, COX2, nitric
oxide, indoleamine 2, 3-dioxygenase, EP1–4 receptors, TGF-b and IL-10. Lastly, we utilized
either BMSCs or MCs deficient in COX1, COX2 or EP1-4 receptors to confirm the mechanisms
of inhibition of MC function by BMSCs.
Results We discovered that BMSCs will effectively suppress specific MC functions in vitro as
well as in vivo. When MCs are cocultured with BMSCs to allow cell-to-cell contact, BMSCs
suppressed MC degranulation, pro-inflammatory cytokine production, chemokinesis and
chemotaxis. Similarly, MC degranulation within mouse skin or the peritoneal cavity was
suppressed following in vivo administration of BMSCs. Further, we found that these inhibitory
effects were dependent on up-regulation of COX2 in BMSCs; and were facilitated through the
activation of EP4 receptors on MCs.
Conclusion and Clinical Relevance These observations support the concept that BMSCs have
the ability to suppress MC activation and therefore could be the basis for a novel cell based
therapeutic approach in the treatment of MC driven inflammatory diseases.
Keywords allergy, COX2, EP4 receptor, mesenchymal stem cell, stromal cell
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Introduction
Bone marrow-derived stromal cells (BMSCs, also known
as mesenchymal stem cells or MSCs) are multipotent
progenitor cells which may be isolated from the bone
marrow by adherence and culture expansion. These cells
have the natural ability to differentiate into bone, fat or
cartilage. Recently, there is a renewed interest in BMSCs
due to their immunomodulatory properties in vitro as well
as in vivo. Intravenously injected BMSCs have been shown
to have a beneficial effect in a variety of animal models of
disease with an inflammatory component; and to prevent
graft vs. host disease in humans [1–5]. We have success-
fully utilized BMSCs to therapeutically treat Th2-
mediated allergic responses in a mouse model of asthma
[6]. While clinical trials using BMSCs as cellular therapy
are currently ongoing for treatment of Th1 inflammatory
diseases, such as Crohn’s disease [7], our data suggests
that also targeting Th2-dominant allergic diseases with
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BMSC treatment has the potential to restore immune
balance and therefore may provide a novel therapeutic
approach for diseases with a Th2 bias.
The interactions between BMSCs and T cells [8–11] and
B cells [9, 12] have been well established. There is also
emerging data suggesting that BMSCs have the ability to
modulate cells of the macrophage/monocyte/dendritic cell
lineage, including their differentiation, maturation and
activation [11, 13–17]. Mast cells (MCs) represent an
important component of the immune system that are
involved many allergic and Th2-mediated inflammatory
diseases. MCs are derived from hematopoietic progenitor
cells and influence both innate and adaptive immunity.
They are well documented to be a critical effector cell in
acute allergic reactions and to release histamine as well as
cytokines and chemokines that influence innate and ac-
quired immune responses [18]. Since MCs are critical
effector cells in allergic inflammation, they represent an
important cell type to therapeutically target using the
immunomodulatory properties of BMSCs. Further, there
are currently no data in the literature regarding the
possible interactions between MCs and BMSCs; and how
these interactions might influence MC activation. We
therefore initiated in vitro and in vivo experiments to study
the immunomodulatory effects BMSCs on MC function.
Materials and methods
Mice
C57BL/6, B6.Cg-KitWsh, COX1/ and COX2/ mice
were obtained from Jackson Laboratories at 4–6 weeks of
age (Bar Harbor, ME, USA). Bone marrow from EP1–4/
mice were a generous gift of Dr Beverly H. Koller. Mice
were allowed food and water ad libitum; and were used
experimentally between 6 and 8 weeks of age. All animal
use procedures were in accordance with an institutional
Animal Care and Use Committee.
Cell culture
Bone marrow-derived MCs. Mouse bone marrow-derived
MCs (MC) were derived and cultured from femoral marrow
cells of C57Bl/6 mice (Jackson Laboratories). Cells were
cultured in RPMI-1640 medium supplemented with 10%
FBS, 100U/mL penicillin, 100 mg/mL streptomycin, 25mM
HEPES, 1.0mM sodium pyruvate, non-essential amino
acids (BioSource International, Camarillo, CA, USA),
0.0035% 2-ME and 300 ng/mL recombinant mouse IL-3
(PeproTech, Rocky Hill, NJ, USA). MCs were used follow-
ing 4–6 weeks of culture at 37 1C and 5% CO2.
Bone marrow stromal cells
Mouse BMSCs were collected from femora and tibiae
of mice under aseptic conditions. Cells were cultured in
a-MEM with 20% FBS, 1% glutamine and 1% penicillin/
streptomycin. Macrophages were depleted from cultures
using magnetic cell sorting with CD11b/CD45 beads
(Miltenyi Biotec, Auburn, CA, USA). All BMSCs were
shown to lack the hematopoietic lineage markers CD45,
CD11b and Gr-1 (BD Biosciences) by FACS analysis.
BMSCs were also shown to be able to differentiate into
osteogenic and adipogenic lineages in vitro.
Mast cell degranulation and cytokine production
IgE-mediated MC degranulation was determined by mea-
suring release of intracellular pre-formed b-hexosamini-
dase (b-hex) 30min following challenge with antigen. For
these experiments, MCs were seeded at 5104 cells/well in
96-well flat-bottom plates; and were sensitized with
100 ng/mL mouse IgE anti-dinitrophenyl (DNP) antibody
(Sigma-Aldrich, St Louis, MO, USA) for 24 h for degranu-
lation experiments. MC degranulation was induced by the
addition of 100 ng/mL dinitrophenylated human serum
albumin (DNP-HSA) (Sigma-Aldrich). Thirty minutes (at
37 1C) after addition of DNP, we measured b-hex release as
described [19], using p-nitrophenyl-N-acetyl-b-D-gluco-
pyranoside (8mM; Sigma-Aldrich) as a substrate for b-hex.
For experiments where MCs and BMSCs were co-cultured,
we added BMSCs at a ratio of 100 : 1, 10 : 1 or 1 : 1 24h
before stimulation of MC degranulation. The reaction be-
tween b-hex and p-nitrophenyl-N-acetyl-b-D-glucopyrano-
side was stopped after 90min with 0.2 M glycine. Optical
density (OD) was measured at 405nm using a GENios ELISA
plate reader (ReTirSoft Inc. Toronto, ON, Canada). b-Hex
release was expressed as the percentage of total cell content
after subtracting background release from unstimulated
cells. Cell content of b-hex from unstimulated and antigen
challenged cells was determined by lysing cells with 0.1%
Triton X-100.
For cytokine measurements, the cells were plated as
above, but the cytokines were measured in cell culture
supernatants 12 h following addition of 100 ng/mL DNP-
HSA; MCs alone were used as a positive control. Addi-
tionally, cytokines were measured in supernatants of
BMSCs exposed to IgE and DNP-HSA to account for any
cytokine production from the BMSC population in the co-
cultures. Ninety-six well transwell plates (Corning, Low-
ell, MA, USA) were utilized in cytokine measurement
experiments to determine the contribution of a contact-
dependent mechanism, and the contribution of soluble
mediators in the genesis of BMSC-mediated immunosup-
pression. For these experiments, BMSC were coated onto
the bottom chamber of the transwell system, while MCs
were added to the upper chamber. IgE sensitized MCs were
then stimulated by the addition of DNP-HSA followed by
collection of supernatants from the upper chamber 12 h
later. In addition, conditioned medium from BMSC cul-
tures was added to standard BMMC cultures followed by
c 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 41 : 526–534
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IgE sensitization and challenge 24 h following addition of
the conditioned medium in the MC cultures. For all
cytokine measurements, we used mouse TNF-a/TNFSF1A
Quantikine ELISA kits (R&D Systems, Minneapolis, MN,
USA). In addition to the co-culture experiments described
above, we utilized the following inhibitors and antibodies
within the co-cultures system to determine a mechanism
by which BMSCs suppress TNF-a production by MCs: 5 mM
indomethacin (Cayman Chemicals, Ann Arbor, MI, USA),
1 mM NS-398 (Sigma, Ann Arbor, MI, USA), 1 mM SC560
(Sigma), 1mM L-NAME (Sigma), 1mM methyl-D-trypto-
phane (Sigma), 10 mg/mL IL-10 neutralizing Ab (Pierce,
Ann Arbor, MI, USA), and 10 mg/mL TGF-b neutralizing
Ab (R&D Systems).
Passive cutaneous anaphylaxis and peritoneal
degranulation assay
The immunomodulatory effects of murine BMSCs on in
vivo MC degranulation were determined by monitoring
both the passive cutaneous anaphylaxis (PCA) reaction
and peritoneal degranulation. The PCA reaction measures
changes in vascular permeability, as determined by local
tissue extravasation of intravenously administered Evans
blue dye that is induced by release of vasodilatory
mediators following MC degranulation. For the PCA
experiments, C57BL/6 mice (6–8 weeks of age) (n= 6 mice
per group) received intradermal injections of 1 mg mouse
monoclonal IgE anti-DNP (Sigma-Aldrich) in 25 mL phos-
phate-buffered saline (PBS) in the right ear to sensitize
tissue MCs, followed by intradermal injection of 0.5106
BMSC in 25 mL PBS in the same ear 24 h later. The left ear
served as a negative control and received an intradermal
injection of PBS. Positive control mice received only an
injection of IgE anti-DNP in the right ear and PBS in the
left ear. Thirty minutes after BMSC injection, mice were
challenged with antigen by intravenous injection into the
tail vein with 0.5mg/mL DNP-HSA which was resus-
pended in 1% Evan’s blue in 100 mL saline. The mice were
euthanized by CO2 asphyxiation 30min after injection of
antigen and Evan’s blue, and the ears were excised and
incubated in 200 mL formamide at 55 1C for 24 h to extract
the Evan’s blue dye from the tissue. The total content of
Evan’s blue that was extracted from each ear was quanti-
tated by spectrophotometric analysis at 620 nm. The net
Evan’s blue was determined by subtraction of the amount
of Evan’s blue in the IgE positive ear or BMSC-treated ear
minus the PBS-treated ear. Comparison was made be-
tween IgE/antigen positive control mice and mice that
received IgE/antigen and a local administration of BMSCs.
A second method was used to measure MC degranula-
tion within the peritoneal cavity of mice. For the perito-
neal degranulation assay (PDA) experiments, the resident
peritoneal MCs in C57BL/6 mice (n= 6 mice/group) were
sensitized intraperitoneal (i.p.) with 1 mg monoclonal IgE
anti-DNP (Sigma) followed 24 h later by i.p. challenge
with DNP-HSA. To determine the degree of MC degranu-
lation following challenge, the peritoneal cavity was
irrigated with PBS and the irrigation fluid collected to
measure b-hex release as described above. The reaction
between b-hex in the peritoneal fluid and p-nitrophenyl-
N-acetyl-b-D-glucopyranoside was stopped after 90min
with 0.2 M glycine. OD was measured at 405 nm using a
GENios ELISA plate reader (ReTirSoft Inc.). For PDA
experiments, b-hex release is expressed as OD values. To
determine the effects of BMSCs on peritoneal MC degra-
nulation, an additional set of mice received 1106 BMSCs
1 h before challenge with DNP-HSA. We used B6.Cg-
KitWsh (MC-deficient) mice in these experiments to
establish that the observed response is MC specific; and
that the b-hex measured in the peritoneal cavity is a result
of MC degranulation.
To study EP receptor function in vivo, we used specific
receptor antagonists (Cayman Chemicals) at different
doses (EP1 antagonist SC-51322, 3mg/kg; EP2 antagonist
AH 6809, 1mg/kg; EP4 antagonist GW627368X, 1mg/
kg). All antagonists were administered as a single injec-
tion in 200 mL PBS at the time of BMSC injection.
Quantitative polymerase chain reaction
MCs were co-cultured with BMSC at a ratio of 100 : 1,
10 : 1 or 1 : 1. Following 24 h co-culture, MCs were stimu-
lated by aggregation of FceRI with antigen as described
above. The non-adherent MC population was washed off
(between 2% and 13% of MC were adherent and not
washed off as assessed by morphology), and thus sepa-
rated from the BMSC population. Total RNA fromMCs was
collected using a Qiagen Rneasy Mini Kit (Qiagen, Valen-
cia, CA, USA) following the manufacturer’s instructions.
RNA was reverse-transcribed using the Quantitect reverse
transcription kit (Qiagen). Quantitative real-time PCR was
performed using a Quantitech SYBR Green PCR Kit (Qia-
gen) and the ABI PRISM 7500 Detection system (Applied
Biosystems, Foster City, CA, USA) to obtain cycle thresh-
old (Ct) values for target and internal reference cDNA
levels. Gene specific primers for TNF-a were obtained
from Qiagen. Target cDNA levels were normalized to
GAPDH, an internal reference using the equation 2½DCt ,
where DCt is defined as Cttarget  Ctinternalreference . Values shown
were derived from the average of three independent
experiments.
Chemokinesis and chemotaxis
We cultured MCs in the presence of BMSCs for 24 h, after
which we placed only the MCs in a 96-well microchemo-
taxis plate with 8 mm pore size (Neuroprobes, Gaithers-
burg, MD, USA) as described [20]. The lower chamber
either contained only PBS (assay for spontaneous
c 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 41 : 526–534
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migration or chemokinesis) or contained stem cell factor
(SCF) as an attractant (chemotaxis). Cells from the lower
well were collected and counted by flow cytometry.
Chemotaxis of MC to SCF was examined either alone or
in the presence of BMSC. MC chemotaxis was measured
following a 24 h co-culture with BMSC. MCs were plated
on the chemotaxis filters at 30 000 cells/well and allowed
to settle for 10min. The filter was assembled with the
lower plate filled with PBS/0.1% bovine serum albumin
(BSA), with or without 100 ng/mL SCF and placed at 37 1C
for 60min. The lower well content (30 mL of PBS/0.1%
BSA with transmigrated cells) was collected, and the total
number of migrated cells was determined by counting the
total events of unlabeled MCs by allowing the total
volume of cells to flow through the flow cytometer (FACS
Caliber, Becton Dickinson, Franklin Lakes, NJ, USA). Each
condition was performed in triplicate and two experi-
ments were averaged.
Statistics
Data are summarized as meanSEM. Student’s t-test or
two-way ANOVA were performed using GraphPad Prism
version 4.00 for Macintosh (GraphPad Software, San
Diego, CA, USA). The statistical significance value was
set at Po0.05.
Results
Bone marrow-derived stromal cells suppress mast cell
degranulation and cytokine production
To determine if BMSCs could alter MC function, we first
co-cultured MCs with BMSCs at ratios from 1 : 1 to 1 : 100.
We found that BMSCs significantly decreased degranula-
tion of MCs as measured by release of b-hex, even at
culture ratios of 100 MCs to 1 BMSC (Fig. 1a). Similarly,
co-culture of MCs with BMSCs for 24 h significantly
reduced MC-derived TNF-a 12 h following challenge with
antigen in a dose-dependent manner (Fig. 1b). Since we
established a decrease in the protein level of TNF-a in the
medium of co-cultured MCs and BMSCs, we next verified
that this observation was associated with a concomitant
decrease in TNF-a mRNA synthesis within the MCs co-
cultured with BMSCs. Our data revealed that MCs tran-
scribed significantly less TNF-a mRNA when they were in
contact with BMSCs at both 30 and 120min following
challenge with antigen. Lastly, we measured TNF-a ex-
pression by BMSCs co-cultured with MCs in a transwell
Fig. 1. In vitro studies of the interactions between MCs and bone marrow-derived stromal cells (BMSCs). (a) Different ratios (1 : 1; 1 : 10 and 1 : 100) of
IgE sensitized MCs and BMSCs were cultured together for 24 h before IgE specific antigen challenge. b-hexosaminidase (b-hex) release was used as a
marker of MC degranulation. BMSCs attenuate MC degranulation in all ratios tested. (b) Different ratios (1 : 1; 1 : 10 and 1 : 100) of IgE sensitized MCs
and BMSCs were cultured together for 24 h before IgE specific antigen challenge for 12 h. TNF-a release was measured by ELISA. The BMSCs decreased
the amount of released TNF-a in a ratio-dependent manner. (c) The experiment in (b) was repeated to measure TNF-amRNA levels at two time-points (30
and 120min) following antigen challenge. Similar to the levels of TNF-a protein, mRNA synthesis also decreased in response to the presence of BMSCs
at both time-points in a ratio-dependent manner. (d) The migration of MCs was affected by the presence of BMSCs in the culture with increasing
numbers of BMSCs within the co-culture, the spontaneous (upper four columns) as well as stem cell factor (SCF)-induced migration (chemokinesis and
chemotaxis, respectively) of MCs were significantly reduced. Po0.05; Po0.01 and Po0.001
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system to exclude the possibility that BMSCs are not
indirectly activated by MC mediators; however, we did
not observe any TNF-a production by BMSCs (data not
shown). Thus, BMSCs do have the capacity to down-
regulate certain MC responses.
Bone marrow-derived stromal cells significantly reduce
mast cell chemotaxis
Once we observed that BMSCs affect the degranulation
and cytokine synthesis of MCs, we determined if BMSCs
might also influence the ability of MCs to migrate towards
a stimulus. Cells collected from the lower well of a
microchemotaxis plate were counted by flow cytometry.
When the lower chamber in the chemotaxis plate con-
tained only PBS, there was significantly less migration of
MCs (Fig. 1d). Similarly, when the lower chamber con-
tained SCF as an attractant, the number of MCs
that migrated was significantly decreased when the
MCs had been co-cultured with BMSCs, as compared to
MCs that had not been co-cultured with BMSCs (Fig. 1d).
Thus, MCs cultured in the presence of BMSCs for 24 h were
significantly impaired in their ability to migrate.
Mast cell activation in vivo is impaired following
administration of bone marrow-derived stromal cells
We next wanted to examine whether MC behaviour could
be altered by BMSCs in vivo. To assess this possibility, we
used two separate in vivo assays of MCs responsiveness.
Using a PCA model, when antigen-specific IgE was
injected intradermally into the ear followed by systemic
antigen challenge 24 h later, we found that the increased
vascular permeability resulting from MC activation was
significantly reduced when BMSCs were administered
(Fig. 2a). In the PDA assay, where MCs in the peritoneal
cavity are sensitized with antigen-specific IgE and then
challenged with antigen, we found a significant decrease
in the amount of b-hex in the peritoneal fluid when
BMSCs were present (Fig. 2b). To confirm that the change
in b-hex levels was due to MC degranulation, we repeated
the experiment using B6.Cg-KitWsh MC-deficient mice.
In these experiments, we did not observe any increase in
b-hex release within the peritoneal cavity following
challenge with antigen, consistent with the conclusion
that the b-hex measured in the C57BL/6 mice is indeed
derived from MCs (Fig. 2b).
Up-regulation of cyclooxygenase-2 by bone marrow-
derived stromal cells mediates the suppression of mast cell
activation via the EP4 receptor
Next we set out to identify a mechanism of action with
regard to the ability of BMSCs to suppress MC function.
For these experiments, we used MC-derived TNF-a pro-
duction as an end-point. Following the addition of a
variety of pharmacological inhibitors (COX1/2 inhibitors,
IDO inhibitor, NO inhibitor), blocking antibodies (anti-
TGF-b and anti-IL-10) to our co-cultures or use of BMSC
conditioned media or a transwell system, we measured
TNF-a release by MCs. We found that BMSCs were still
effective at suppressing MC derived TNF-a production in
transwell system or in the presence of COX1 inhibitor, NO
inhibitor, IDO inhibitor and blocking antibodies to IL-10
and TGF-b. Further, the BMSC conditioned media did not
have an effect on MC TNF-a production suggesting that
presence of MCs either in contact with BMSCs or in a
transwell system are required to elicit the suppressive
effect of BMSCs. When we added indomethacin (a COX1/
COX2 non-selective inhibitor) or a specific COX2 inhibitor
(NS-398), the suppressive effect mediated by BMSCs was
eliminated (Fig. 3a). To determine which cell population
was targeted by the COX2 inhibitors for suppression of
TNF-a release by MCs, we repeated the in vitro co-cultures
using either BMSCs or MCs that were deficient in COX2.
The suppressive effect was eliminated when COX2-defi-
cient BMSCs were used, but persisted when COX2-defi-
cient MCs were used in the co-culture system (Fig. 3b).
Fig. 2. Suppression of mast cell (MC) degranulation by bone marrow-
derived stromal cells (BMSCs) in vivo. (a) Passive cutaneous anaphylaxis
(PCA) was performed using systemically administered Evans blue as a
marker of tissue permeability within the mouse ear. Administration of
BMSCs to the IgE sensitized mouse ear before challenge with IgE-specific
antigen significantly decreased the amount of Evans blue leakage into
the tissues as quantified by optical density. (b) In vivo MC degranulation
was also examined by challenging IgE sensitized peritoneal MCs with
antigen (PDA) following intraperitoneal (i.p.) administration of either
PBS or BMSCs. MC degranulation was quantified by measuring an
increase in peritonealb-hexosaminidase ( b-hex) release following chal-
lenge as shown in the top two bars. In the bottom two bars, an increase in
b-hex release was not observed in MC-deficient mice, whereas i.p.
administration of BMSCs significantly decreased the amount of b-hex
release in C57Bl/6 mice which the MCs were sensitized and challenged
with antigen.
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Since COX2 will induce prostaglandin (PGE2) production,
which exerts its effects through binding to the EP1–4
receptors, we next examined the involvement of each of
these individual receptors in the MC population. Once
again, we used TNF-a production as a marker of MC
response. Data revealed that when MCs were derived from
EP1-, EP2- or EP3-deficient mice, they remained respon-
sive to the suppressive effects of the BMSCs. However,
when EP4-deficient MCs were used in the co-culture, the
BMSCs were unable to suppress TNF-a production by MCs
(Fig. 3c). Lastly, we confirmed that COX2 mRNA is up-
regulated upon co-culture of BMSCs and MCs. As shown
in Fig. 3d, we observed a significant up-regulation of
COX2 mRNA in BMSCs 4 h following co-culture. This up-
regulation was observed in both the contact and transwell
co-cultures; however, the expression of COX2 was much
greater when the cells were co-cultured in contact. Final-
ly, to test the mechanism of suppressive effect in vivo, we
repeated the PDA experiments and found that BMSCs
derived from COX2/ mice were unable to suppress
Fig. 3. Identifying a mechanism of mast cell (MC) suppression. (a) In the co-culture system, a variety of inhibitor and blocking antibodies were used to
test if they prevent the immunosuppressive effect of bone marrow-derived stromal cells (BMSCs) on MCs TNF-a production. The suppressive effect of
BMSCs was not altered when a COX1 inhibitor, IDO inhibitor, NO inhibitor or antibodies to TGF-b and IL-10 were applied to the co-culture. However,
when indomethacin (a COX1 and COX2 inhibitor) or a specific COX2 inhibitor (NS-398) were used the immuno-suppressive effect of the BMSCs was
eliminated. (b) Identifying the cellular source of COX2 in the system. Using COX1- and COX2-deficient cells (either MCs or BMSCs) in the co-culture
system, TNF-a production was measured following antigen stimulation of MCs. Exclusively, the use of COX2 knock-out (KO) BMSC in the co-culture
eliminated the effect suggesting that BMSC up-regulate COX2 synthesis. (c) Screening for the responsible receptor in the MC. MCs lacking the individual
EP receptors (EP1–4) was used to determine their effect on TNF-a production in the co-culture system with BMSCs. BMSCs were still able to suppress MC
derived TNF-a production when the EP13 receptors were absent. When EP4 KO MCs were used in the culture system, the immunosuppressive effect of
BMSCs was eliminated. (d) Up-regulation of COX2 in BMSC following co-culture with MCs. COX2 mRNA levels were measured by quantitative PCR at 2,
4 and 6 h following co-culture with MCs in either contact-dependent or a transwell system. COX2 mRNA was significantly up-regulated in BMSCs 4 h
following co-culture with MCs. While BMSC COX2 mRNA expression was increased in the transwell system, we observed a greater increase in COX2
expression when the cells were in contact.
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b-hex release by MCs in vivo (Fig. 4a). Surprisingly we
could not confirm the importance of EP4 receptor in vivo
using EP receptor antagonists (Fig. 4b). Pre-treating the
mice with different EP receptor antagonists before BMSC
injection and antigen challenge could not eliminate the
suppressive effect observed in vivo.
Discussion
There are now a number of studies which report that
BMSCs are capable of suppressing T and B cells, dendritic
cells and NK cells in vitro, and ameliorating inflammatory
responses in vivo [3–5, 21, 22]. The majority of these
studies explored how BMSCs could be used to treat graft
vs. host disease (GVHD) or inflammatory diseases
mediated by autoimmune pathology. More recent studies
have explored if BMSCs could influence innate immune
functions; and if these interactions could provide any
benefit in host defense [21, 23]. Indeed, we have demon-
strated that BMSCs provide protection against the devel-
opment of sepsis and more recently have reported that
BMSCs can modulate disease pathology in an allergic
model of ragweed-induced asthma [6, 24].
MCs have long been recognized for their role in the
genesis of allergic inflammation [18], thereby providing
an ideal cell target in which the immunomodulatory
effects of BMSCs may be beneficial. Despite the central
effector role of MCs in allergic inflammation, no studies
are yet available to address if BMSCs interact with MCs
and could thereby influence allergic inflammation.
In this study we address this question, and provide
evidence that mouse BMSCs co-cultured with MCs in vitro
effectively suppress MC activation, including FceRI-
mediated degranulation, TNF-a production and SCF-in-
duced migration. Using a classic PCA model and a model
of peritoneal MC degranulation, we found that in accor-
dance with our in vitro data, BMSCs also attenuate MC
activation in vivo. As such, these in vivo models demon-
strate the potential of BMSCs to reduce the severity of MC-
initiated allergic diseases.
The suppression of MC activation by BMSCs is greatest
when the cells are in contact as compared to when the
cells are co-cultured in a transwell system (Fig. 3a).
Further, BMSC conditioned media does not have the
ability to suppress MC activation. The lack of an effect
with conditioned media suggests that there is cross-talk
required between the MC and BMSC to initiate the
suppressive effect elicited by the BMSC. These findings
are similar to what is reported with the attenuation of MC
degranulation by bronchial epithelial cells [25]. Yang et al.
[25] demonstrated that after 16 h of co-culture with
bronchial epithelial cells, human lung MCs have signifi-
cantly attenuated response to IgE-mediated activation.
Similar to our data, the effect of bronchial epithelial cells
was contact dependent. In contrast, it has been reported
that several other cell types may promote MC survival and
proliferation. Hollins et al. [26] have shown that airway
smooth muscle promotes lung MC survival, proliferation
and activation primarily through a physical interaction
between membrane-bound SCF and its receptor on MCs.
In addition, it has been recently demonstrated that gen-
eration of cord blood-derived MCs can be enhance when
co-cultured with a bone marrow stomal cell line [27]. It
remains to be determined what effects BMSCs may have
on MC proliferation and maturation.
To identify the molecular pathways involved in such a
suppressive effect by BMSCs, we employed specific in-
hibitors as well as cells isolated from specific knock-out
mice. Based on our initial screening experiments using
inhibitors, we identified COX2 as a crucial intermediate in
the BMSC driven suppression of MCs. As both BMSCs and
MCs up-regulate COX2 in response to stimuli, we repeated
our experiments using co-culture systems where either
MCs or BMSCs lacked the COX2 gene. Based on these
studies, we identified that the up-regulation of COX2 is
Fig, 4. In vivo confirmation of COX2 mediated mechanism. (a) The
peritoneal assay depicted in Fig. 2 was repeated using COX2 knock-out
(KO) bone marrow-derived stromal cells (BMSCs) followed by challen-
ging the sensitized resident MCs with antigen. In contrast to wild-type
BMSCs, COX2-deficient BMSCs failed to suppress b-hexosaminidase (b-
hex) release by peritoneal MCs. (b) The peritoneal assay depicted in Fig. 2
was repeated using EP1–4 receptor antagonists delivered to the perito-
neal cavity at the same time as injection of BMSCs which was followed
24 h later by challenging the sensitized resident MCs with antigen and
measuring b-hex release. In contrast to injection of COX2-deficient
BMSCs as shown in Fig. 4a, addition of EP receptor antagonists did not
abrograte the suppressive effect of BMSCs. N= 4 mice/group and was
repeated two times.
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occurring within the BMSC population; and is critical
regulator of their suppressive action on MCs. Further, MC
derived COX2 did not prove essential.
Our next question was whether COX2 up-regulation
mediates the suppression of MCs by BMSC derived PGE2
by acting through EP receptors expressed on MCs. To
explore this hypothesis, we used MCs deficient for one of
the four known receptors for PGE2: EP1, EP2, EP3 or EP4.
Through the use of EP-deficient MCs, we demonstrate that
lack of EP4 in MCs abrogated the suppressive effect
elicited by BMSCs in vitro while the presence of EP1,
EP2, or EP3 was not critical. To determine whether EP4 is
critical to BMSC directed suppression of MC activation in
vivo, we used antagonists specific to EP1, EP2, EP3 and
EP4 receptors. However, when we probed the importance
of EP receptors in vivo using these receptor antagonists we
could not confirm our in vitro data. EP4 receptor antago-
nists did not prevent BMSCs from inhibiting MC degranu-
lation. In fact neither of the receptor antagonists could
hinder the BMSC suppressive phenotype. These seemingly
contradicting data between in vitro and in vivo findings
could be explained in several ways. First, in vitro we
utilized MCs deficient for EP receptors while in vivo we
pretreated wild-type mice with specific EP receptor an-
tagonists. It is possible that pharmacologic inhibition of
MC EP receptors is not as efficient as complete deletion of
the genes using transgenic technology. It is also possible
that in vivo, and in particular within the peritoneal cavity,
there are other cell types (macrophages, neutrophils, etc.)
that influence either direct interactions between BMSCs
and MCs or influence the pharmacological interven-
tion used to study the importance of EP receptors con-
sidering these cell types also express EP receptors. In fact,
we have shown that PGE2 released from BMSCs acting
through EP2 and EP4 receptors modulates macrophage
phenotype in a mouse model of sepsis [24] which in turn
could influence MC activation and pharmacological inter-
vention. Lastly, the fact that EP4 antagonists did not
prevent the suppression of MC degranulation in vivo
further highlights that ability of these cells to adjust to
their environment and lead to suppression of immune
responses.
The effect of PGE2 on MCs varies with the model system
employed. Several studies suggest that the presence of
PGE2 is inhibitory to MC activation [28–32]. Other data
reported that addition of PGE2 potentiates activation of
MCs stimulated with IgE and antigen [33–37]. In our
experiments, we examined the cellular interactions be-
tween MCs and BMSCs and our results are consistent with
the conclusion that PGE2 derived from a cellular source
(e.g. BMSCs) inhibits MC activation. In this regard they are
most consistent with published data showing that PGE2
inhibits lung MC degranulation and the resultant inflam-
mation and Th2 cytokine production [29, 31, 32].
When BMSCs are administered into the circulation they
will eventually end up in the microvascular bed of
different organs. Since MCs are primarily located in the
perivascular space of vessels BMSCs will inevitably inter-
act with them when leaving the vascular space during the
process of homing. It is also well described that BMSCs
preferentially home to sites of active inflammation, re-
sponding to a wide variety of inflammatory signals. In an
anaphylactic setting MCs predominate such an inflamma-
tory environment hence there is an increased chance for
them to communicate with and to be suppressed by
injected BMSCs. Based on our data, we suggest that BMSC
infusion (either systematic or local) could effectively
suppress immunologic responses mediated by MCs in the
setting of anaphylaxis. There is also an increasing amount
of data emphasizing the importance of MCs in the co-
ordination of autoimmune diseases [38]. In many cases,
the presence of MCs is critical to orchestrate autoimmune
inflammation as shown in animal models of multiple
sclerosis, rheumatoid arthritis or bullous pemphigoid
[38]. Since BMSCs are known to be able to attenuate
autoimmune inflammation [39], we hypothesize that
BMSC/MC interactions could – at least in part – explain
this suppressive phenotype and guide us in a better
understanding of BMSC immune biology.
In summary, we have shown that BMSCs have the
ability to influence the biology of MCs by limiting their
activation and migration. Our data additionally document
that these effects are mediated through prostaglandin
pathways. These observations support the conclusion that
BMSCs should be explored as a cell-based therapy in the
treatment of MC-directed allergic inflammation.
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